SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS

Abstract

The invention relates to substituted thiophenyl uracils of general formula (I)

##STR00001##

or the salts (I) thereof, wherein the groups in general formula (I) are as defined in the description, and to the use thereof as herbicides, in particular for controlling weeds and/or weed grasses in crops of cultivated plants and/or as plant growth regulators for influencing the growth of crops of cultivated plants.

Claims

1. A substituted thiophenyluracil of the general formula (I) or salt thereof ##STR00133## in which R.sup.1 is (C.sub.1-C.sub.8)-alkyl, amino, R.sup.17R.sup.18, R.sup.2 is hydrogen, (C.sub.1-C.sub.8)-alkyl, R.sup.3 is hydrogen, halogen, (C.sub.1-C.sub.8)-alkoxy, R.sup.4 is halogen, cyano, NO.sub.2, C(O)NH.sub.2, C(S)NH.sub.2, (C.sub.1-C.sub.8)-haloalkyl, (C.sub.2-C.sub.8)-alkynyl, R.sup.5 and R.sup.6 are independently hydrogen, halogen, (C.sub.1-C.sub.8)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl, (C.sub.3-C.sub.8)-cycloalkyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.2-C.sub.8)-alkenyl, (C.sub.2-C.sub.8)-alkynyl, (C.sub.1-C.sub.10)-haloalkyl, (C.sub.2-C.sub.8)-haloalkenyl, (C.sub.2-C.sub.8)-haloalkynyl, (C.sub.3-C.sub.10)-halocycloalkyl, (C.sub.4-C.sub.10)-cycloalkenyl, (C.sub.4-C.sub.10)-halocycloalkenyl, (C.sub.1-C.sub.8)-alkoxy, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-haloalkyl, (C.sub.1-C.sub.8)-haloalkoxy-(C.sub.1-C.sub.8)-haloalkyl, (C.sub.1-C.sub.8)-haloalkoxy-(C.sub.1-C.sub.8)-alkyl, aryl, aryl-(C.sub.1-C.sub.8)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.8)-alkyl, (C.sub.4-C.sub.10)-cycloalkenyl-(C.sub.1-C.sub.8)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-alkylthio-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-haloalkylthio-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-alkylcarbonyl-(C.sub.1-C.sub.8)-alkyl, C(O)OR.sup.19, C(O)NR.sup.17R.sup.18, C(O)R.sup.19, R.sup.19O(O)C—(C.sub.1-C.sub.8)-alkyl, R.sup.17R.sup.18N(O)C—(C.sub.1-C.sub.8)-alkyl, R.sup.17R.sup.18N—(C.sub.1-C.sub.8)-alkyl, or R.sup.5 and R.sup.6 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.5 and R.sup.6 together with the carbon atom to which they are bonded form a double bond optionally substituted by R.sup.22 and R.sup.23, according to formula (I′) below ##STR00134## R.sup.7 and R.sup.8 are independently hydrogen, halogen, (C.sub.1-C.sub.8)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl, (C.sub.3-C.sub.8)-cycloalkyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.2-C.sub.8)-alkenyl, (C.sub.2-C.sub.8)-alkynyl, (C.sub.1-C.sub.10)-haloalkyl, (C.sub.2-C.sub.8)-haloalkenyl, (C.sub.2-C.sub.8)-haloalkynyl, (C.sub.3-C.sub.10)-halocycloalkyl, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-haloalkyl, (C.sub.1-C.sub.8)-haloalkoxy-(C.sub.1-C.sub.8)-haloalkyl, (C.sub.1-C.sub.8)-haloalkoxy-(C.sub.1-C.sub.8)-alkyl, aryl, aryl-(C.sub.1-C.sub.8)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.8)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-alkylthio-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-haloalkylthio-(C.sub.1-C.sub.8)-alkyl, C(O)OR.sup.19, C(O)NR.sup.17R.sup.18, C(O)R.sup.19, R.sup.19O(O)C—(C.sub.1-C.sub.8)-alkyl, R.sup.17R.sup.18N(O)C—(C.sub.1-C.sub.8)-alkyl, R.sup.17R.sup.18N—(C.sub.1-C.sub.8)-alkyl, or R.sup.7 and R.sup.8 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.7 and R.sup.8 together with the carbon atom to which they are bonded form a double bond optionally substituted by R.sup.22 and R.sup.23, according to formula (I″) below ##STR00135## m is 0, 1, 2, n is 0, 1, 2, 3, 4, 5, 6, p is 1, 2, 3, X is O (oxygen), N (nitrogen) or the N—R.sup.15 or N—O—R.sup.16 moieties, and where R.sup.15 and R.sup.16 in the N—R.sup.15 and N—O—R.sup.16 moiety independently have the meanings according to the definitions below, Y is O (oxygen) or S (sulfur), SO, SO.sub.2, R.sup.10 and R.sup.11 are independently hydrogen, fluorine, cyano, (C.sub.1-C.sub.8-alkyl, (C.sub.3-C.sub.8)-cycloalkyl, (C.sub.3-C.sub.8)-cycloalkyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.2-C.sub.8)-alkenyl, (C.sub.2-C.sub.8)-alkynyl, (C.sub.1-C.sub.10)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.8)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.8)-alkyl, (C.sub.4-C.sub.10)-cycloalkenyl-(C.sub.1-C.sub.8)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.8)-alkyl, R.sup.19O—(C.sub.1-C.sub.8)-alkyl, R.sup.20S—(C.sub.1-C.sub.8)-alkyl, R.sup.20SO.sub.2—(C.sub.1-C.sub.8)-alkyl, or R.sup.10 and R.sup.11 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, R.sup.12 and R.sup.13 are independently hydrogen, fluorine, (C.sub.1-C.sub.8)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl, (C.sub.3-C.sub.8)-cycloalkyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.2-C.sub.8)-alkenyl, (C.sub.2-C.sub.8)-alkynyl, (C.sub.1-C.sub.10)-haloalkyl, (C.sub.2-C.sub.8)-haloalkenyl, (C.sub.2-C.sub.8)-haloalkynyl, (C.sub.3-C.sub.10)-halocycloalkyl, (C.sub.4-C.sub.10)-cycloalkenyl, (C.sub.4-C.sub.10)-halocycloalkenyl, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-haloalkyl, (C.sub.1-C.sub.8)-haloalkoxy-(C.sub.1-C.sub.8)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.8)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.8)-alkyl, (C.sub.4-C.sub.10)-cycloalkenyl-(C.sub.1-C.sub.8)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.8)-alkyl, R.sup.19O—(C.sub.1-C.sub.8)-alkyl, R.sup.20S—(C.sub.1-C.sub.8)-alkyl, R.sup.20SO.sub.2—(C.sub.1-C.sub.8)-alkyl, R.sup.17R.sup.18N—(C.sub.1-C.sub.8)-alkyl, or R.sup.10 and R.sup.14 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.14 is (C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-haloalkyl, (C.sub.3-C.sub.8)-cycloalkyl, (C.sub.3-C.sub.8)-cycloalkyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.2-C.sub.8)-alkenyl, (C.sub.2-C.sub.8)-alkynyl, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-haloalkoxy-(C.sub.1-C.sub.8)-alkyl, aryl, aryl-(C.sub.1-C.sub.8)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.8)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-alkylthio-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-haloalkylthio-(C.sub.1-C.sub.8)-alkyl, R.sup.17R.sup.18N—(C.sub.1-C.sub.8)-alkyl, cyano-(C.sub.1-C.sub.8)-alkyl, or R.sup.10 and R.sup.14 together with the carbon atoms to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.12 and R.sup.14 together with the carbon atoms to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, R.sup.15 is hydrogen, (C.sub.1-C.sub.8)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl, cyano-(C.sub.1-C.sub.8)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, (C.sub.3-C.sub.8)-cycloalkylsulfonyl, heterocyclylsulfonyl, aryl-(C.sub.1-C.sub.8)-alkylsulfonyl, (C.sub.1-C.sub.8)-alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, (C.sub.3-C.sub.8)-cycloalkylcarbonyl, heterocyclylcarbonyl, (C.sub.1-C.sub.8)-alkoxycarbonyl, (C.sub.1-C.sub.8)-alkoxy, (C.sub.2-C.sub.8)-alkenyloxy, aryl-(C.sub.1-C.sub.8)-alkoxycarbonyl, (C.sub.1-C.sub.8)-haloalkylcarbonyl, (C.sub.2-C.sub.8)-alkenyl, (C.sub.2-C.sub.8)-alkynyl, (C.sub.1-C.sub.8)-haloalkyl, halo-(C.sub.2-C.sub.8)-alkynyl, halo-(C.sub.2-C.sub.8)-alkenyl, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-alkyl, amino, (C.sub.1-C.sub.8)-alkylamino, bis[(C.sub.1-C.sub.8)-alkyl]amino, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-alkyl, heteroaryl-(C.sub.1-C.sub.8)-alkylsulfonyl, heterocyclyl-(C.sub.1-C.sub.8)-alkylsulfonyl, (C.sub.2-C.sub.8)-alkenyloxycarbonyl, (C.sub.2-C.sub.8)-alkynyloxycarbonyl, (C.sub.1-C.sub.8)-alkylaminocarbonyl, (C.sub.3-C.sub.8)-cycloalkylaminocarbonyl, bis-[(C.sub.1-C.sub.8)-alkyl]aminocarbonyl, R.sup.16 is hydrogen, (C.sub.1-C.sub.8)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.2-C.sub.8)-alkenyl, (C.sub.2-C.sub.8)-alkynyl, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-alkyl, aryl, aryl-(C.sub.1-C.sub.8)-alkyl, R.sup.19O(O)C—(C.sub.1-C.sub.8)-alkyl, R.sup.17R.sup.18N(O)C—(C.sub.1-C.sub.8)-alkyl, R.sup.17 and R.sup.18 are the same or different and are independently hydrogen, (C.sub.1-C.sub.8)-alkyl, (C.sub.2-C.sub.8)-alkenyl, (C.sub.2-C.sub.8)-alkynyl, (C.sub.1-C.sub.8)-cyanoalkyl, (C.sub.1-C.sub.10)-haloalkyl, (C.sub.2-C.sub.8)-haloalkenyl, (C.sub.2-C.sub.8)-haloalkynyl, (C.sub.3-C.sub.10)-cycloalkyl, (C.sub.3-C.sub.10)-halocycloalkyl, (C.sub.4-C.sub.10-cycloalkenyl, (C.sub.4-C.sub.10)-halocycloalkenyl, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-haloalkoxy-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-alkylthio-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-haloalkylthio-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.8)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.8)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.4-C.sub.10)-cycloalkenyl-(C.sub.1-C.sub.8)-alkyl, COR.sup.19, SO.sub.2R.sup.20, (C.sub.1-C.sub.8)-alkyl-HNO.sub.2S—, (C.sub.3-C.sub.8)-cycloalkyl-HNO.sub.2S—, heterocyclyl, (C.sub.1-C.sub.8)-alkoxycarbonyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-alkoxycarbonyl, aryl-(C.sub.1-C.sub.8)-alkoxycarbonyl-(C.sub.1-C.sub.8)-alkyl, aryl-(C.sub.1-C.sub.8)-alkoxycarbonyl, heteroaryl-(C.sub.1-C.sub.8)-alkoxycarbonyl, (C.sub.2-C.sub.8)-alkenyloxycarbonyl, (C.sub.2-C.sub.8)-alkynyloxycarbonyl, heterocyclyl-(C.sub.1-C.sub.8)-alkyl, R.sup.19 is hydrogen, (C.sub.1-C.sub.8)-alkyl, (C.sub.2-C.sub.8)-alkenyl, (C.sub.2-C.sub.8)-alkynyl, (C.sub.1-C.sub.8)-cyanoalkyl, (C.sub.1-C.sub.10)-haloalkyl, (C.sub.2-C.sub.8)-haloalkenyl, (C.sub.2-C.sub.8)-haloalkynyl, (C.sub.3-C.sub.10)-cycloalkyl, (C.sub.3-C.sub.10)-halocycloalkyl, (C.sub.4-C.sub.10)-cycloalkenyl, (C.sub.4-C.sub.10)-halocycloalkenyl, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.8)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.8)heteroaryl-(C.sub.1-C.sub.8)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.4-C.sub.10)-cycloalkenyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-alkoxycarbonyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.2-C.sub.8)-alkenyloxycarbonyl-(C.sub.1-C.sub.8)-alkyl, aryl-(C.sub.1-C.sub.8)-alkoxycarbonyl-(C.sub.1-C.sub.8)-alkyl, hydroxycarbonyl-(C.sub.1-C.sub.8)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.8)-alkyl, R.sup.20 is hydrogen, (C.sub.1-C.sub.8)-alkyl, (C.sub.2-C.sub.8)-alkenyl, (C.sub.2-C.sub.8)-alkynyl, (C.sub.1-C.sub.8)-cyanoalkyl, (C.sub.1-C.sub.10)-haloalkyl, (C.sub.2-C.sub.8)-haloalkenyl, (C.sub.2-C.sub.8)-haloalkynyl, (C.sub.3-C.sub.10)-cycloalkyl, (C.sub.3-C.sub.10)-halocycloalkyl, (C.sub.4-C.sub.10)-cycloalkenyl, (C.sub.4-C.sub.10)-halocycloalkenyl, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-alkyl, (C.sub.1-C.sub.8)-alkoxy-(C.sub.1-C.sub.8)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.8)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.8)-alkyl, heterocyclyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl-(C.sub.1-C.sub.8)-alkyl, (C.sub.4-C.sub.10)-cycloalkenyl-(C.sub.1-C.sub.8)-alkyl, NR.sup.17R.sup.18, R.sup.21 is hydrogen, fluorine, chlorine, bromine, trifluoromethyl, (C.sub.1-C.sub.8)-alkoxy and R.sup.22 and R.sup.23 are independently hydrogen, halogen, (C.sub.1-C.sub.8)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl, (C.sub.2-C.sub.8)-alkenyl, (C.sub.2-C.sub.8)-alkynyl, (C.sub.1-C.sub.8)-haloalkyl, aryl, or R.sup.22 and R.sup.23 together with the carbon atom to which they are bonded form a 3- to 10-membered monocyclic or bicyclic ring which is saturated or optionally interrupted by heteroatoms and optionally has further substitution.

2. A compound of the general formula (I) as claimed in claim 1 and/or salt thereof, wherein R.sup.1 is (C.sub.1-C.sub.7)-alkyl, amino, NR.sup.17R.sup.18, R.sup.2 is hydrogen, (C.sub.1-C.sub.7)-alkyl, R.sup.3 is hydrogen, halogen, (C.sub.1-C.sub.7)-alkoxy, R.sup.4 is halogen, cyano, NO.sub.2, C(O)NH.sub.2, C(S)NH.sub.2, (C.sub.1-C.sub.7)-haloalkyl, (C.sub.2-C.sub.7)-alkynyl, R.sup.5 and R.sup.6 are independently hydrogen, halogen, (C.sub.1-C.sub.7)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl, (C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.2-C.sub.7)-alkenyl, (C.sub.2-C.sub.7)-alkynyl, (C.sub.1-C.sub.7)-haloalkyl, (C.sub.2-C.sub.7)-haloalkenyl, (C.sub.2-C.sub.7)-haloalkynyl, (C.sub.3-C.sub.7)-halocycloalkyl, (C.sub.4-C.sub.7)-cycloalkenyl, (C.sub.4-C.sub.7)-halocycloalkenyl, (C.sub.1-C.sub.7)-alkoxy, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-haloalkyl, (C.sub.1-C.sub.7)-haloalkoxy-(C.sub.1-C.sub.7)-haloalkyl, (C.sub.1-C.sub.7)-haloalkoxy-(C.sub.1-C.sub.7)-alkyl, aryl, aryl-(C.sub.1-C.sub.7)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.7)-alkyl, (C.sub.4-C.sub.7)-cycloalkenyl-(C.sub.1-C.sub.7)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-alkylthio-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-haloalkylthio-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-alkylcarbonyl-(C.sub.1-C.sub.7)-alkyl, C(O)OR.sup.19, C(O)NR.sup.17R.sup.18, C(O)R.sup.19, R.sup.19O(O)C—(C.sub.1-C.sub.7)-alkyl, R.sup.17R.sup.18N(O)C—(C.sub.1-C.sub.7)-alkyl, R.sup.17R.sup.18N—(C.sub.1-C.sub.7)-alkyl, or R.sup.5 and R.sup.6 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.5 and R.sup.6 together with the carbon atom to which they are bonded form a double bond optionally substituted by R.sup.22 and R.sup.23, according to formula (I′) below ##STR00136## R.sup.7 and R.sup.8 are independently hydrogen, halogen, (C.sub.1-C.sub.7)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl, (C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.2-C.sub.7)-alkenyl, (C.sub.2-C.sub.7)-alkynyl, (C.sub.1-C.sub.7)-haloalkyl, (C.sub.2-C.sub.7)-haloalkenyl, (C.sub.2-C.sub.7)-haloalkynyl, (C.sub.3-C.sub.7)-halocycloalkyl, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-haloalkyl, (C.sub.1-C.sub.7)-haloalkoxy-(C.sub.1-C.sub.7)-haloalkyl, (C.sub.1-C.sub.7)-haloalkoxy-(C.sub.1-C.sub.7)-alkyl, aryl, aryl-(C.sub.1-C.sub.7)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.7)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-alkylthio-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-haloalkylthio-(C.sub.1-C.sub.7)-alkyl, C(O)OR.sup.19, C(O)NR.sup.17R.sup.18, C(O)R.sup.19, R.sup.19O (O)C—(C.sub.1-C.sub.7)-alkyl, R.sup.17R.sup.18N(O)C—(C.sub.1-C.sub.7)-alkyl, R.sup.17R.sup.18N—(C.sub.1-C.sub.7)-alkyl, or R.sup.7 and R.sup.8 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.7 and R.sup.8 together with the carbon atom to which they are bonded form a double bond optionally substituted by R.sup.22 and R.sup.23, according to formula (I″) below ##STR00137## m is 0, 1, 2, n is 0, 1, 2, 3, 4, 5, 6, p is 1, 2, 3, X is O (oxygen), N (nitrogen) or the N—R.sup.15 or N—O—R.sup.16 moieties, and where R.sup.15 and R.sup.16 in the N—R.sup.15 and N—O—R.sup.16 moiety independently have the meanings according to the definitions below, Y is O (oxygen) or S (sulfur), SO, SO.sub.2, R.sup.10 and R.sup.11 are independently hydrogen, fluorine, cyano, (C.sub.1-C.sub.7)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl, (C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.2-C.sub.7)-alkenyl, (C.sub.2-C.sub.7)-alkynyl, (C.sub.1-C.sub.7)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.7)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.7)-alkyl, (C.sub.4-C.sub.7)-cycloalkenyl-(C.sub.1-C.sub.7)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.7)-alkyl, R.sup.19O—(C.sub.1-C.sub.7)-alkyl, R.sup.20S—(C.sub.1-C.sub.7)-alkyl, R.sup.20SO.sub.2—(C.sub.1-C.sub.7)-alkyl, or R.sup.10 and R.sup.11 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, R.sup.12 and R.sup.13 are independently hydrogen, fluorine, (C.sub.1-C.sub.7)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl, (C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.2-C.sub.7)-alkenyl, (C.sub.2-C.sub.7)-alkynyl, (C.sub.1-C.sub.7)-haloalkyl, (C.sub.2-C.sub.7)-haloalkenyl, (C.sub.2-C.sub.7)-haloalkynyl, (C.sub.3-C.sub.7)-halocycloalkyl, (C.sub.4-C.sub.7)-cycloalkenyl, (C.sub.4-C.sub.7)-halocycloalkenyl, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-haloalkyl, (C.sub.1-C.sub.7)-haloalkoxy-(C.sub.1-C.sub.7)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.7)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.7)-alkyl, (C.sub.4-C.sub.10)-cycloalkenyl-(C.sub.1-C.sub.7)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.7)-alkyl, R.sup.19O—(C.sub.1-C.sub.7)-alkyl, R.sup.20S—(C.sub.1-C.sub.7)-alkyl, R.sup.20SO.sub.2—(C.sub.1-C.sub.7)-alkyl, R′R′N—(C.sub.1-C.sub.7)-alkyl, or R.sup.12 and R.sup.13 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.14 is (C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-haloalkyl, (C.sub.3-C.sub.7)-cycloalkyl, (C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.2-C.sub.7)-alkenyl, (C.sub.2-C.sub.7)-alkynyl, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-haloalkoxy-(C.sub.1-C.sub.7)-alkyl, aryl, aryl-(C.sub.1-C.sub.7)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.7)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-alkylthio-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-haloalkylthio-(C.sub.1-C.sub.7)-alkyl, R.sup.17R.sup.18N—(C.sub.1-C.sub.7)-alkyl, cyano-(C.sub.1-C.sub.7)-alkyl, or R.sup.10 and R.sup.14 together with the carbon atoms to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.12 and R.sup.14 together with the carbon atoms to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, R.sup.15 is hydrogen, (C.sub.1-C.sub.7)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl, cyano-(C.sub.1-C.sub.7)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, (C.sub.3-C.sub.7)-cycloalkylsulfonyl, heterocyclylsulfonyl, aryl-(C.sub.1-C.sub.7)-alkylsulfonyl, (C.sub.1-C.sub.7)-alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, (C.sub.3-C.sub.7)-cycloalkylcarbonyl, heterocyclylcarbonyl, (C.sub.1-C.sub.7)-alkoxycarbonyl, (C.sub.1-C.sub.7)-alkoxy, (C.sub.2-C.sub.7)-alkenyloxy, aryl-(C.sub.1-C.sub.7)-alkoxycarbonyl, (C.sub.1-C.sub.7)-haloalkylcarbonyl, (C.sub.2-C.sub.7)-alkenyl, (C.sub.2-C.sub.7)-alkynyl, (C.sub.1-C.sub.7)-haloalkyl, halo-(C.sub.2-C.sub.7)-alkynyl, halo-(C.sub.2-C.sub.7)-alkenyl, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-alkyl, amino, (C.sub.1-C.sub.7)-alkylamino, bis[(C.sub.1-C.sub.7)-alkyl]amino, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-alkyl, heteroaryl-(C.sub.1-C.sub.7)-alkylsulfonyl, heterocyclyl-(C.sub.1-C.sub.7)-alkylsulfonyl, (C.sub.2-C.sub.7)-alkenyloxycarbonyl, (C.sub.2-C.sub.7)-alkynyloxycarbonyl, (C.sub.1-C.sub.7)-alkylaminocarbonyl, (C.sub.3-C.sub.7)-cycloalkylaminocarbonyl, bis[(C.sub.1-C.sub.7)-alkyl]aminocarbonyl, R.sup.16 is hydrogen, (C.sub.1-C.sub.7)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.2-C.sub.7)-alkenyl, (C.sub.2-C.sub.7)-alkynyl, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-alkyl, aryl, aryl-(C.sub.1-C.sub.7)-alkyl, R.sup.19O(O)C—(C.sub.1-C.sub.7)-alkyl, R.sup.17R.sup.18N(O)C—(C.sub.1-C.sub.7)-alkyl, R.sup.17 and R.sup.18 are the same or different and are independently hydrogen, (C.sub.1-C.sub.7)-alkyl, (C.sub.2-C.sub.7)-alkenyl, (C.sub.2-C.sub.7)-alkynyl, (C.sub.1-C.sub.7)-cyanoalkyl, (C.sub.1-C.sub.7)-haloalkyl, (C.sub.2-C.sub.7)-haloalkenyl, (C.sub.2-C.sub.7)-haloalkynyl, (C.sub.3-C.sub.7)-cycloalkyl, (C.sub.3-C.sub.7)-halocycloalkyl, (C.sub.4-C.sub.10)-cycloalkenyl, (C.sub.4-C.sub.7)-halocycloalkenyl, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-haloalkoxy-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-alkylthio-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-haloalkylthio-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.7)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.7)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.4-C.sub.7)-cycloalkenyl-(C.sub.1-C.sub.7)-alkyl, COR.sup.19, SO.sub.2R.sup.20, (C.sub.1-C.sub.7)-alkyl-HNO.sub.2S—, (C.sub.3-C.sub.7)-cycloalkyl-HNO.sub.2S—, heterocyclyl, (C.sub.1-C.sub.7)-alkoxycarbonyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-alkoxycarbonyl, aryl-(C.sub.1-C.sub.7)-alkoxycarbonyl-(C.sub.1-C.sub.7)-alkyl, aryl-(C.sub.1-C.sub.7)-alkoxycarbonyl, heteroaryl-(C.sub.1-C.sub.7)-alkoxycarbonyl, (C.sub.2-C.sub.7)-alkenyloxycarbonyl, (C.sub.2-C.sub.7)-alkynyloxycarbonyl, heterocyclyl-(C.sub.1-C.sub.7)-alkyl, R.sup.19 is hydrogen, (C.sub.1-C.sub.7)-alkyl, (C.sub.2-C.sub.7)-alkenyl, (C.sub.2-C.sub.7)-alkynyl, (C.sub.1-C.sub.7)-cyanoalkyl, (C.sub.1-C.sub.10)-haloalkyl, (C.sub.2-C.sub.7)-haloalkenyl, (C.sub.2-C.sub.7)-haloalkynyl, (C.sub.3-C.sub.7)-cycloalkyl, (C.sub.3-C.sub.7)-halocycloalkyl, (C.sub.4-C.sub.7)-cycloalkenyl, (C.sub.4-C.sub.7)-halocycloalkenyl, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.7)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.7)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.4-C.sub.7)-cycloalkenyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-alkoxycarbonyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.2-C.sub.7)-alkenyloxycarbonyl-(C.sub.1-C.sub.7)-alkyl, aryl-(C.sub.1-C.sub.7)-alkoxycarbonyl-(C.sub.1-C.sub.7)-alkyl, hydroxycarbonyl-(C.sub.1-C.sub.7)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.7)-alkyl, R.sup.20 is hydrogen, (C.sub.1-C.sub.7)-alkyl, (C.sub.2-C.sub.7)-alkenyl, (C.sub.2-C.sub.7)-alkynyl, (C.sub.1-C.sub.7)-cyanoalkyl, (C.sub.1-C.sub.7)-haloalkyl, (C.sub.2-C.sub.7)-haloalkenyl, (C.sub.2-C.sub.7)-haloalkynyl, (C.sub.3-C.sub.7)-cycloalkyl, (C.sub.3-C.sub.7)-halocycloalkyl, (C.sub.4-C.sub.7)-cycloalkenyl, (C.sub.4-C.sub.7)-halocycloalkenyl, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-alkyl, (C.sub.1-C.sub.7)-alkoxy-(C.sub.1-C.sub.7)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.7)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.7)-alkyl, heterocyclyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.7)-alkyl, (C.sub.4-C.sub.7)-cycloalkenyl-(C.sub.1-C.sub.7)-alkyl, NR.sup.17R.sup.18 and R.sup.21 is hydrogen, fluorine, chlorine, bromine, trifluoromethyl, (C.sub.1-C.sub.7)-alkoxy and R.sup.22 and R.sup.23 are independently hydrogen, halogen, (C.sub.1-C.sub.7)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl, (C.sub.2-C.sub.7)-alkenyl, (C.sub.2-C.sub.7)-alkynyl, (C.sub.1-C.sub.7)-haloalkyl, aryl, or R.sup.22 and R.sup.23 together with the carbon atom to which they are bonded form a 3- to 10-membered monocyclic or bicyclic ring which is saturated or optionally interrupted by heteroatoms and optionally has further substitution.

3. A compound of the general formula (I) as claimed in claim 1 and/or salt thereof, wherein R.sup.1 is (C.sub.1-C.sub.6)-alkyl, amino, NR.sup.17R.sup.18, R.sup.2 is hydrogen, (C.sub.1-C.sub.6)-alkyl, R.sup.3 is hydrogen, halogen, (C.sub.1-C.sub.6)-alkoxy, R.sup.4 is halogen, cyano, NO.sub.2, C(O)NH.sub.2, C(S)NH.sub.2, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-alkynyl, R.sup.5 and R.sup.6 are independently hydrogen, halogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-halocycloalkyl, (C.sub.1-C.sub.6)-alkoxy, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-haloalkyl, (C.sub.1-C.sub.6)-haloalkoxy-(C.sub.1-C.sub.6)-haloalkyl, (C.sub.1-C.sub.6)-haloalkoxy-(C.sub.1-C.sub.6)-alkyl, aryl, aryl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.6)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkylthio-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkylthio-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkylcarbonyl-(C.sub.1-C.sub.6)-alkyl, C(O)OR.sup.19, C(O)NR.sup.17R.sup.18, C(O)R.sup.19, R.sup.19O(O)C—(C.sub.1-C.sub.6)-alkyl, R.sup.17R.sup.18N(O)C—(C.sub.1-C.sub.6)-alkyl, R.sup.17R.sup.18N—(C.sub.1-C.sub.6)-alkyl, or R.sup.5 and R.sup.6 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.5 and R.sup.6 together with the carbon atom to which they are bonded form a double bond optionally substituted by R.sup.22 and R.sup.23, according to formula (I′) below ##STR00138## R.sup.7 and R.sup.8 are independently hydrogen, halogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-halocycloalkyl, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-haloalkyl, (C.sub.1-C.sub.6)-haloalkoxy-(C.sub.1-C.sub.6)-haloalkyl, (C.sub.1-C.sub.6)-haloalkoxy-(C.sub.1-C.sub.6)-alkyl, aryl, aryl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.6)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkylthio-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkylthio-(C.sub.1-C.sub.6)-alkyl, C(O)OR.sup.19, C(O)NR.sup.17R.sup.18, C(O)R.sup.19, R.sup.19O(O)C—(C.sub.1-C.sub.6)-alkyl, R.sup.17R.sup.18N(O)C—(C.sub.1-C.sub.6)-alkyl, R.sup.17R.sup.18N—(C.sub.1-C.sub.6)-alkyl, or R.sup.7 and R.sup.8 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.7 and R.sup.8 together with the carbon atom to which they are bonded form a double bond optionally substituted by R.sup.22 and R.sup.23, according to formula (I″) below ##STR00139## m is 0, 1, 2, n is 0, 1, 2, 3, 4, 5, 6, p is 1, 2, 3, X is O (oxygen), N (nitrogen) or the N—R.sup.15 or N—O—R.sup.16 moieties, and where R.sup.15 and R.sup.16 in the N—R.sup.15 and N—O—R.sup.16 moiety independently have the meanings according to the definitions below, Y is O (oxygen) or S (sulfur), SO, SO.sub.2, R.sup.10 and R.sup.11 are independently hydrogen, fluorine, cyano, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.1-C.sub.6)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.6)-alkyl, (C.sub.4-C.sub.6)-cycloalkenyl-(C.sub.1-C.sub.6)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.6)-alkyl, R.sup.19O—(C.sub.1-C.sub.6)-alkyl, R.sup.20S—(C.sub.1-C.sub.6)-alkyl, R.sup.20SO.sub.2—(C.sub.1-C.sub.6)-alkyl, or R.sup.10 and R.sup.11 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, R.sup.12 and R.sup.13 are independently hydrogen, fluorine, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-halocycloalkyl, (C.sub.4-C.sub.6)-cycloalkenyl, (C.sub.4-C.sub.6)-halocycloalkenyl, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-haloalkyl, (C.sub.1-C.sub.6)-haloalkoxy-(C.sub.1-C.sub.6)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.6)-alkyl, (C.sub.4-C.sub.10)-cycloalkenyl-(C.sub.1-C.sub.6)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.6)-alkyl, R.sup.19O—(C.sub.1-C.sub.6)-alkyl, R.sup.20S—(C.sub.1-C.sub.6)-alkyl, R.sup.20SO.sub.2—(C.sub.1-C.sub.6)-alkyl, R.sup.17R.sup.18N—(C.sub.1-C.sub.6)-alkyl, or R.sup.12 and R.sup.13 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, R.sup.14 is (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkoxy-(C.sub.1-C.sub.6)-alkyl, aryl, aryl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.6)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkylthio-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkylthio-(C.sub.1-C.sub.6)-alkyl, R.sup.17R.sup.18N—(C.sub.1-C.sub.6)-alkyl, cyano-(C.sub.1-C.sub.6)-alkyl, or R.sup.10 and R.sup.14 together with the carbon atoms to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.12 and R.sup.14 together with the carbon atoms to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, R.sup.15 is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl, cyano-(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, (C.sub.3-C.sub.6)-cycloalkylsulfonyl, heterocyclylsulfonyl, aryl-(C.sub.1-C.sub.6)-alkylsulfonyl, (C.sub.1-C.sub.6)-alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, (C.sub.3-C.sub.6)-cycloalkylcarbonyl, heterocyclylcarbonyl, (C.sub.1-C.sub.6)-alkoxycarbonyl, (C.sub.1-C.sub.6)-alkoxy, (C.sub.2-C.sub.6)-alkenyloxy, aryl-(C.sub.1-C.sub.6)-alkoxycarbonyl, (C.sub.1-C.sub.6)-haloalkylcarbonyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.1-C.sub.6)-haloalkyl, halo-(C.sub.2-C.sub.6)-alkynyl, halo-(C.sub.2-C.sub.6)-alkenyl, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-alkyl, amino, (C.sub.1-C.sub.6)-alkylamino, bis[(C.sub.1-C.sub.6)-alkyl]amino, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-alkyl, heteroaryl-(C.sub.1-C.sub.6)-alkylsulfonyl, heterocyclyl-(C.sub.1-C.sub.6)-alkylsulfonyl, (C.sub.2-C.sub.6)-alkenyloxycarbonyl, (C.sub.2-C.sub.6)-alkynyloxycarbonyl, (C.sub.1-C.sub.6)-alkylaminocarbonyl, (C.sub.3-C.sub.6)-cycloalkylaminocarbonyl, bis[(C.sub.1-C.sub.6)-alkyl]aminocarbonyl, R.sup.16 is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-alkyl, aryl, aryl-(C.sub.1-C.sub.6)-alkyl, R.sup.19O(O)C—(C.sub.1-C.sub.6)-alkyl, R.sup.17R.sup.18N(O)C—(C.sub.1-C.sub.6)-alkyl, R.sup.17 and R.sup.18 are the same or different and are independently hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.1-C.sub.6)-cyanoalkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-halocycloalkyl, (C.sub.4-C.sub.10)-cycloalkenyl, (C.sub.4-C.sub.6)-halocycloalkenyl, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkoxy-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkylthio-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-haloalkylthio-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.4-C.sub.6)-cycloalkenyl-(C.sub.1-C.sub.6)-alkyl, COR.sup.19, SO.sub.2R.sup.20, (C.sub.1-C.sub.6)-alkyl-HNO.sub.2S—, (C.sub.3-C.sub.6)-cycloalkyl-HNO.sub.2S—, heterocyclyl, (C.sub.1-C.sub.6)-alkoxycarbonyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxycarbonyl, aryl-(C.sub.1-C.sub.6)-alkoxycarbonyl-(C.sub.1-C.sub.6)-alkyl, aryl-(C.sub.1-C.sub.6)-alkoxycarbonyl, heteroaryl-(C.sub.1-C.sub.6)-alkoxycarbonyl, (C.sub.2-C.sub.6)-alkenyloxycarbonyl, (C.sub.2-C.sub.6)-alkynyloxycarbonyl, heterocyclyl-(C.sub.1-C.sub.6)-alkyl, R.sup.19 is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.1-C.sub.6)-cyanoalkyl, (C.sub.1-C.sub.10)-haloalkyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-halocycloalkyl, (C.sub.4-C.sub.6)-cycloalkenyl, (C.sub.4-C.sub.6)-halocycloalkenyl, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.4-C.sub.6)-cycloalkenyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxycarbonyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyloxycarbonyl-(C.sub.1-C.sub.6)-alkyl, aryl-(C.sub.1-C.sub.6)-alkoxycarbonyl-(C.sub.1-C.sub.6)-alkyl, hydroxycarbonyl-(C.sub.1-C.sub.6)-alkyl, heterocyclyl, heterocyclyl-(C.sub.1-C.sub.6)-alkyl, R.sup.20 is hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.1-C.sub.6)-cyanoalkyl, (C.sub.1-C.sub.6)-haloalkyl, (C.sub.2-C.sub.6)-haloalkenyl, (C.sub.2-C.sub.6)-haloalkynyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.3-C.sub.6)-halocycloalkyl, (C.sub.4-C.sub.6)-cycloalkenyl, (C.sub.4-C.sub.6)-halocycloalkenyl, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkoxy-(C.sub.1-C.sub.6)-haloalkyl, aryl, aryl-(C.sub.1-C.sub.6)-alkyl, heteroaryl, heteroaryl-(C.sub.1-C.sub.6)-alkyl, heterocyclyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl-(C.sub.1-C.sub.6)-alkyl, (C.sub.4-C.sub.6)-cycloalkenyl-(C.sub.1-C.sub.6)-alkyl, NR.sup.17R.sup.18, R.sup.21 is hydrogen, fluorine, chlorine, bromine, trifluoromethyl, (C.sub.1-C.sub.6)-alkoxy and R.sup.22 and R.sup.23 are independently hydrogen, halogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl, (C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl, (C.sub.1-C.sub.6)-haloalkyl, aryl, or R.sup.22 and R.sup.23 together with the carbon atom to which they are bonded form a 3- to 10-membered monocyclic or bicyclic ring which is saturated or optionally interrupted by heteroatoms and optionally has further substitution.

4. A compound of the general formula (I) as claimed in claim 1 and/or salt thereof, wherein R.sup.1 is methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, amino, dimethylamino, diethylamino, methyl(ethyl)amino, methyl(n-propyl)amino, R.sup.2 is hydrogen, methyl, ethyl, n-propyl, isopropyl, R.sup.3 is hydrogen, fluorine, chlorine, bromine, methoxy, ethoxy, R.sup.4 is halogen, cyano, NO.sub.2, C(O)NH.sub.2, C(S)NH.sub.2, difluoromethyl, trifluoromethyl, ethynyl, propyn-1-yl, 1-butyn-1-yl, pentyn-1-yl, hexyn-1-yl, R.sup.5 and R.sup.6 are independently hydrogen, fluorine, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, spiro[2.2]pent-1-yl, spiro[2.3]hex-1-yl, spiro[2.3]hex-4-yl, 3-spiro[2.3]hex-5-yl, bicyclo[1.1.0]butan-1-yl, bicyclo[1.1.0]butan-2-yl, bicyclo[2.1.0]pentan-1-yl, bicyclo[1.1.1]pentan-1-yl, bicyclo[2.1.0]pentan-2-yl, bicyclo[2.1.0]pentan-5-yl, bicyclo[2.1.1]hexyl, 1-methylcyclopropyl, 2-methylcyclopropyl, 2,2-dimethylcyclopropyl, 2,3-dimethylcyclopropyl, 1,1′-bi(cyclopropyl)-1-yl, 1,1′-bi(cyclopropyl)-2-yl, 2′-methyl-1,1′-bi(cyclopropyl)-2-yl, 1-cyanocyclopropyl, 2-cyanocyclopropyl, 1-methylcyclobutyl, 2-methylcyclobutyl, 3-methylcyclobutyl, 3,3-dimethylcyclobut-1-yl, 1-cyanocyclobutyl, 2-cyanocyclobutyl, 3-cyanocyclobutyl, 3,3-difluorocyclobut-1-yl, 3-fluorocyclobut-1-yl, 2,2-difluorocycloprop-1-yl, 1-fluorocycloprop-1-yl, 2-fluorocycloprop-1-yl, 1-allylcyclopropyl, 1-vinylcyclobutyl, 1-vinylcyclopropyl, 1-ethylcyclopropyl, 1-methylcyclohexyl, 2-methylcyclohexyl, 3-methylcyclohexyl, 1-methoxycyclohexyl, 2-methoxycyclohexyl, 3-methoxycyclohexyl, 2-fluorocycloprop-1-yl, 4-fluorocyclohexyl, 4,4-difluorocyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-1-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methy 1-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-1-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-1-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-1-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-1-butenyl, 3,3-dimethyl-2-butenyl, 1-ethyl-1-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-1-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl, 1-ethyl-2-methyl-1-propenyl, 1-ethyl-2-methyl-2-propenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-2-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 3-methyl-1-butynyl, 1,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-1-pentynyl, 3-methyl-4-pentynyl, 4-methyl-1-pentynyl, 4-methyl-2-pentynyl, 1,1-dimethyl-2-butynyl, 1,1-dimethyl-3-butynyl, 1,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 3,3-dimethyl-1-butynyl, 1-ethyl-2-butynyl, 1-ethyl-3-butynyl, 2-ethyl-3-butynyl, 1-ethyl-1-methyl-2-propynyl, trifluoromethyl, pentafluoroethyl, 1,1,2,2-tetrafluoroethyl, heptafluoropropyl, nonafluorobutyl, chlorodifluoromethyl, bromodifluoromethyl, dichlorofluoromethyl, iododifluoromethyl, bromofluoromethyl, 1-fluoroethyl, 2-fluoroethyl, fluoromethyl, difluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, difluoro-tert-butyl, chloromethyl, bromomethyl, methoxy, ethoxy, n-propyloxy, isopropyloxy, n-butyloxy, tert-butyloxy, methoxymethyl, ethoxymethyl, n-propyloxymethyl, isopropyloxymethyl, methoxyethyl, ethoxyethyl, n-propyloxyethyl, isopropyloxyethyl, methoxy-n-propyl, methoxydifluoromethyl, ethoxydifluoromethyl, n-propyloxydifluoromethyl, n-butyloxydifluoromethyl, trifluoromethoxymethyl, trifluoromethoxyethyl, trifluoromethoxy-n-propyl, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,4,5-trifluorophenyl, 3,4,5-trifluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2,4,5-trichlorophenyl, 3,4,5-trichlorophenyl, 2,4,6-trichlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 2-bromo-4-fluorophenyl, 2-bromo-4-chlorophenyl, 3-bromo-4-fluorophenyl, 3-bromo-4-chlorophenyl, 3-bromo-5-fluorophenyl, 3-bromo-5-chlorophenyl, 2-fluoro-4-bromophenyl, 2-chloro-4-bromophenyl, 3-fluoro-4-bromophenyl, 3-chloro-4-bromophenyl, 2-chloro-4-fluorophenyl, 3-chloro-4-fluorophenyl, 2-fluoro-3-chlorophenyl, 2-fluoro-4-chlorophenyl, 2-fluoro-5-chlorophenyl, 3-fluoro-4-chlorophenyl, 3-fluoro-5-chlorophenyl, 2-fluoro-6-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 2,3-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2,4,5-trimethylphenyl, 3,4,5-trimethylphenyl, 2,4,6-trimethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 2,4,5-trimethoxyphenyl, 3,4,5-trimethoxyphenyl, 2,4,6-trimethoxyphenyl, 2-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 2-difluoromethoxyphenyl, 3-difluoromethoxyphenyl, 4-difluoromethoxyphenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-difluoromethylphenyl, 3-difluoromethylphenyl, 4-difluoromethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 3-trifluoromethyl-5-fluorophenyl, 3-trifluoromethyl-5-chlorophenyl, 3-methyl-5-fluorophenyl, 3-methyl-5-chlorophenyl, 3-methoxy-5-fluorophenyl, 3-methoxy-5-chlorophenyl, 3-trifluoromethoxy-5-chlorophenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl, 2-methylthiophenyl, 3-methylthiophenyl, 4-methylthiophenyl, 2-trifluoromethylthiophenyl, 3-trifluoromethylthiophenyl, 4-trifluoromethylthiophenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2-methoxycarbonylphenyl, 3-methoxycarbonylphenyl, 4-methoxycarbonylphenyl, 2-ethoxycarbonylphenyl, 3-ethoxycarbonylphenyl, 4-ethoxycarbonylphenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrazin-2-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2-yl, pyrimidin-5-yl, pyrimidin-4-yl, pyridazin-3-ylmethyl, pyridazin-4-ylmethyl, pyrimidin-2-ylmethyl, pyrimidin-5-ylmethyl, pyrimidin-4-ylmethyl, pyrazin-2-ylmethyl, 3-chloropyrazin-2-yl, 3-bromopyrazin-2-yl, 3-methoxypyrazin-2-yl, 3-ethoxypyrazin-2-yl, 3-trifluoromethylpyrazin-2-yl, 3-cyanopyrazin-2-yl, naphth-2-yl, naphth-1-yl, quinolin-4-yl, quinolin-6-yl, quinolin-8-yl, quinolin-2-yl, quinoxalin-2-yl, 2-naphthylmethyl, 1-naphthylmethyl, quinolin-4-ylmethyl, quinolin-6-ylmethyl, quinolin-8-ylmethyl, quinolin-2-ylmethyl, quinoxalin-2-ylmethyl, pyrazin-2-ylmethyl, 4-chloropyridin-2-yl, 3-chloropyridin-4-yl, 2-chloropyridin-3-yl, 2-chloropyridin-4-yl, 2-chloropyridin-5-yl, 2,6-dichloropyridin-4-yl, 3-chloropyridin-5-yl, 3,5-dichloropyridin-2-yl, 3-chloro-5-trifluoromethylpyridin-2-yl, (4-chloropyridin-2-yl)methyl, (3-chloropyridin-4-yl)methyl, (2-chloropyridin-3-yl)methyl, (2-chloropyridin-4-yl)methyl, (2-chloropyridin-5-yl)methyl, (2,6-dichloropyridin-4-yl)methyl, (3-chloropyridin-5-yl)methyl, (3,5-dichloropyridin-2-yl)methyl, thiophen-2-yl, thiophen-3-yl, 5-methylthiophen-2-yl, 5-ethylthiophen-2-yl, 5-chlorothiophen-2-yl, 5-bromothiophen-2-yl, 4-methylthiophen-2-yl, 3-methylthiophen-2-yl, 5-fluorothiophen-3-yl, 3,5-dimethylthiophen-2-yl, 3-ethylthiophen-2-yl, 4,5-dimethylthiophen-2-yl, 3,4-dimethylthiophen-2-yl, 4-chlorothiophen-2-yl, furan-2-yl, 5-methylfuran-2-yl, 5-ethylfuran-2-yl, 5-methoxycarbonylfuran-2-yl, 5-chlorofuran-2-yl, 5-bromofuran-2-yl, thiophan-2-yl, thiophan-3-yl, sulfolan-2-yl, sulfolan-3-yl, tetrahydrothiopyran-4-yl, tetrahydropyran-4-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, 1-(4-methylphenyl)ethyl, 1-(3-methylphenyl)ethyl, 1-(2-methylphenyl)ethyl, 1-(4-chlorophenyl)ethyl, 1-(3-chlorophenyl)ethyl, 1-(2-chlorophenyl)ethyl, benzyl, (4-fluorophenyl)methyl, (3-fluorophenyl)methyl, (2-fluorophenyl)methyl, (2,4-difluorophenyl)methyl, (3,5-difluorophenyl)methyl, (2,5-difluorophenyl)methyl, (2,6-difluorophenyl)methyl, (2,4,5-trifluorophenyl)methyl, (2,4,6-trifluorophenyl)methyl, (4-chlorophenyl)methyl, (3-chlorophenyl)methyl, (2-chlorophenyl)methyl, (2,4-dichlorophenyl)methyl, (3,5-dichlorophenyl)methyl, (2,5-dichlorophenyl)methyl, (2,6-dichlorophenyl)methyl, (2,4,5-trichlorophenyl)methyl, (2,4,6-trichlorophenyl)methyl, (4-bromophenyl)methyl, (3-bromophenyl)methyl, (2-bromophenyl)methyl, (4-iodophenyl)methyl, (3-iodophenyl)methyl, (2-iodophenyl)methyl, (3-chloro-5-trifluoromethylpyridin-2-yl)methyl, (2-bromo-4-fluorophenyl)methyl, (2-bromo-4-chlorophenyl)methyl, (3-bromo-4-fluorophenyl)methyl, (3-bromo-4-chlorophenyl)methyl, (3-bromo-5-fluorophenyl)methyl, (3-bromo-5-chlorophenyl)methyl, (2-fluoro-4-bromophenyl)methyl, (2-chloro-4-bromophenyl)methyl, (3-fluoro-4-bromophenyl)methyl, (3-chloro-4-bromophenyl)methyl, (2-chloro-4-fluorophenyl)methyl, (3-chloro-4-fluorophenyl)methyl, (2-fluoro-3-chlorophenyl)methyl, (2-fluoro-4-chlorophenyl)methyl, (2-fluoro-5-chlorophenyl)methyl, (3-fluoro-4-chlorophenyl)methyl, (3-fluoro-5-chlorophenyl)methyl, (2-fluoro-6-chlorophenyl)methyl, 2-phenyleth-1-yl, 3-trifluoromethyl-4-chlorophenyl, 3-chloro-4-trifluoromethylphenyl, 2-chloro-4-trifluoromethylphenyl, 3,5-difluoropyridin-2-yl, (3,6-dichloropyridin-2-yl)methyl, (4-trifluoromethylphenyl)methyl, (3-trifluoromethylphenyl)methyl, (2-trifluoromethylphenyl)methyl, (4-trifluoromethoxyphenyl)methyl, (3-trifluoromethoxyphenyl)methyl, (2-trifluoromethoxyphenyl)methyl, (4-methoxyphenyl)methyl, (3-methoxyphenyl)methyl, (2-methoxyphenyl)methyl, (4-methylphenyl)methyl, (3-methylphenyl)methyl, (2-methylphenyl)methyl, (4-cyanophenyl)methyl, (3-cyanophenyl)methyl, (2-cyanophenyl)methyl, (2,4-diethylphenyl)methyl, (3,5-diethylphenyl)methyl, (3,4-dimethylphenyl)methyl, (3,5-dimethoxyphenyl)methyl, 1-phenyleth-1-yl, 1-(o-chlorophenyl)eth-1-yl, 1,3-thiazol-2-yl, 4-methyl-1,3-thiazol-2-yl, 1,3-thiazol-2-yl, methylthiomethyl, ethylthiomethyl, ethylthioethyl, methylthioethyl, n-propylthiomethyl, isopropylthiomethyl, trifluoromethylthiomethyl, trifluoromethylthioethyl, R.sup.5 and R.sup.6 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.5 and R.sup.6 together with the carbon atom to which they are bonded form a double bond optionally substituted by R.sup.22 and R.sup.23, according to formula (I′) below ##STR00140## R.sup.7 and R.sup.8 are independently hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-methylcyclopropyl, 2-methylcyclopropyl, 2,2-dimethylcyclopropyl, 2,3-dimethylcyclopropyl, 1-methylcyclobutyl, 2-methylcyclobutyl, 3-methylcyclobutyl, 3,3-dimethylcyclobut-1-yl, 1-cyanocyclobutyl, 2-cyanocyclobutyl, 3-cyanocyclobutyl, 3,3-difluorocyclobut-1-yl, 3-fluorocyclobut-1-yl, 2,2-difluorocycloprop-1-yl, 1-fluorocycloprop-1-yl, 2-fluorocycloprop-1-yl, 1-allylcyclopropyl, 1-vinylcyclobutyl, 1-vinylcyclopropyl, 1-ethylcyclopropyl, 1-methylcyclohexyl, 2-methylcyclohexyl, 3-methylcyclohexyl, 1-methoxycyclohexyl, 2-methoxycyclohexyl, 3-methoxycyclohexyl, 2-fluorocycloprop-1-yl, 4-fluorocyclohexyl, 4,4-difluorocyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-1-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-1-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-1-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-1-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-1-butenyl, 3,3-dimethyl-2-butenyl, 1-ethyl-1-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-1-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl, 1-ethyl-2-methyl-1-propenyl, 1-ethyl-2-methyl-2-propenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-2-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 3-methyl-1-butynyl, 1,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-1-pentynyl, 3-methyl-4-pentynyl, 4-methyl-1-pentynyl, 4-methyl-2-pentynyl, 1,1-dimethyl-2-butynyl, 1,1-dimethyl-3-butynyl, 1,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 3,3-dimethyl-1-butynyl, 1-ethyl-2-butynyl, 1-ethyl-3-butynyl, 2-ethyl-3-butynyl, 1-ethyl-1-methyl-2-propynyl, trifluoromethyl, pentafluoroethyl, 1,1,2,2-tetrafluoroethyl, heptafluoropropyl, nonafluorobutyl, chlorodifluoromethyl, bromodifluoromethyl, dichlorofluoromethyl, iododifluoromethyl, bromofluoromethyl, 1-fluoroethyl, 2-fluoroethyl, fluoromethyl, difluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, difluoro-tert-butyl, chloromethyl, bromomethyl, methoxy, ethoxy, n-propyloxy, isopropyloxy, n-butyloxy, tert-butyloxy, methoxymethyl, ethoxymethyl, n-propyloxymethyl, isopropyloxymethyl, methoxyethyl, ethoxyethyl, n-propyloxyethyl, isopropyloxyethyl, methoxy-n-propyl, methoxydifluoromethyl, ethoxydifluoromethyl, n-propyloxydifluoromethyl, n-butyloxydifluoromethyl, trifluoromethoxymethyl, trifluoromethoxyethyl, trifluoromethoxy-n-propyl, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,4,5-trifluorophenyl, 3,4,5-trifluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2,4,5-trichlorophenyl, 3,4,5-trichlorophenyl, 2,4,6-trichlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 2-bromo-4-fluorophenyl, 2-bromo-4-chlorophenyl, 3-bromo-4-fluorophenyl, 3-bromo-4-chlorophenyl, 3-bromo-5-fluorophenyl, 3-bromo-5-chlorophenyl, 2-fluoro-4-bromophenyl, 2-chloro-4-bromophenyl, 3-fluoro-4-bromophenyl, 3-chloro-4-bromophenyl, 2-chloro-4-fluorophenyl, 3-chloro-4-fluorophenyl, 2-fluoro-3-chlorophenyl, 2-fluoro-4-chlorophenyl, 2-fluoro-5-chlorophenyl, 3-fluoro-4-chlorophenyl, 3-fluoro-5-chlorophenyl, 2-fluoro-6-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 2,3-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2,4,5-trimethylphenyl, 3,4,5-trimethylphenyl, 2,4,6-trimethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 2,4,5-trimethoxyphenyl, 3,4,5-trimethoxyphenyl, 2,4,6-trimethoxyphenyl, 2-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 2-difluoromethoxyphenyl, 3-difluoromethoxyphenyl, 4-difluoromethoxyphenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-difluoromethylphenyl, 3-difluoromethylphenyl, 4-difluoromethylphenyl, 3,5-bis(trifluoromethyl)phenyl, 3-trifluoromethyl-5-fluorophenyl, 3-trifluoromethyl-5-chlorophenyl, 3-methyl-5-fluorophenyl, 3-methyl-5-chlorophenyl, 3-methoxy-5-fluorophenyl, 3-methoxy-5-chlorophenyl, 3-trifluoromethoxy-5-chlorophenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl, 2-methylthiophenyl, 3-methylthiophenyl, 4-methylthiophenyl, 2-trifluoromethylthiophenyl, 3-trifluoromethylthiophenyl, 4-trifluoromethylthiophenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2-methoxycarbonylphenyl, 3-methoxycarbonylphenyl, 4-methoxycarbonylphenyl, 2-ethoxycarbonylphenyl, 3-ethoxycarbonylphenyl, 4-ethoxycarbonylphenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrazin-2-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-2-yl, pyrimidin-5-yl, pyrimidin-4-yl, pyridazin-3-ylmethyl, pyridazin-4-ylmethyl, pyrimidin-2-ylmethyl, pyrimidin-5-ylmethyl, pyrimidin-4-ylmethyl, pyrazin-2-ylmethyl, 3-chloropyrazin-2-yl, 3-bromopyrazin-2-yl, 3-methoxypyrazin-2-yl, 3-ethoxypyrazin-2-yl, 3-trifluoromethylpyrazin-2-yl, 3-cyanopyrazin-2-yl, naphth-2-yl, naphth-1-yl, quinolin-4-yl, quinolin-6-yl, quinolin-8-yl, quinolin-2-yl, quinoxalin-2-yl, 2-naphthylmethyl, 1-naphthylmethyl, quinolin-4-ylmethyl, quinolin-6-ylmethyl, quinolin-8-ylmethyl, quinolin-2-ylmethyl, quinoxalin-2-ylmethyl, pyrazin-2-ylmethyl, 4-chloropyridin-2-yl, 3-chloropyridin-4-yl, 2-chloropyridin-3-yl, 2-chloropyridin-4-yl, 2-chloropyridin-5-yl, 2,6-dichloropyridin-4-yl, 3-chloropyridin-5-yl, 3,5-dichloropyridin-2-yl, 3-chloro-5-trifluoromethylpyridin-2-yl, (4-chloropyridin-2-yl)methyl, (3-chloropyridin-4-yl)methyl, (2-chloropyridin-3-yl)methyl, (2-chloropyridin-4-yl)methyl, (2-chloropyridin-5-yl)methyl, (2,6-dichloropyridin-4-yl)methyl, (3-chloropyridin-5-yl)methyl, (3,5-dichloropyridin-2-yl)methyl, thiophen-2-yl, thiophen-3-yl, 5-methylthiophen-2-yl, 5-ethylthiophen-2-yl, 5-chlorothiophen-2-yl, 5-bromothiophen-2-yl, 4-methylthiophen-2-yl, 3-methylthiophen-2-yl, 5-fluorothiophen-3-yl, 3,5-dimethylthiophen-2-yl, 3-ethylthiophen-2-yl, 4,5-dimethylthiophen-2-yl, 3,4-dimethylthiophen-2-yl, 4-chlorothiophen-2-yl, furan-2-yl, 5-methylfuran-2-yl, 5-ethylfuran-2-yl, 5-methoxycarbonylfuran-2-yl, 5-chlorofuran-2-yl, 5-bromofuran-2-yl, thiophan-2-yl, thiophan-3-yl, sulfolan-2-yl, sulfolan-3-yl, tetrahydrothiopyran-4-yl, tetrahydropyran-4-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, 1-(4-methylphenyl)ethyl, 1-(3-methylphenyl)ethyl, 1-(2-methylphenyl)ethyl, 1-(4-chlorophenyl)ethyl, 1-(3-chlorophenyl)ethyl, 1-(2-chlorophenyl)ethyl, benzyl, (4-fluorophenyl)methyl, (3-fluorophenyl)methyl, (2-fluorophenyl)methyl, (2,4-difluorophenyl)methyl, (3,5-difluorophenyl)methyl, (2,5-difluorophenyl)methyl, (2,6-difluorophenyl)methyl, (2,4,5-trifluorophenyl)methyl, (2,4,6-trifluorophenyl)methyl, (4-chlorophenyl)methyl, (3-chlorophenyl)methyl, (2-chlorophenyl)methyl, (2,4-dichlorophenyl)methyl, (3,5-dichlorophenyl)methyl, (2,5-dichlorophenyl)methyl, (2,6-dichlorophenyl)methyl, (2,4,5-trichlorophenyl)methyl, (2,4,6-trichlorophenyl)methyl, (4-bromophenyl)methyl, (3-bromophenyl)methyl, (2-bromophenyl)methyl, (4-iodophenyl)methyl, (3-iodophenyl)methyl, (2-iodophenyl)methyl, (3-chloro-5-trifluoromethylpyridin-2-yl)methyl, (2-bromo-4-fluorophenyl)methyl, (2-bromo-4-chlorophenyl)methyl, (3-bromo-4-fluorophenyl)methyl, (3-bromo-4-chlorophenyl)methyl, (3-bromo-5-fluorophenyl)methyl, (3-bromo-5-chlorophenyl)methyl, (2-fluoro-4-bromophenyl)methyl, (2-chloro-4-bromophenyl)methyl, (3-fluoro-4-bromophenyl)methyl, (3-chloro-4-bromophenyl)methyl, (2-chloro-4-fluorophenyl)methyl, (3-chloro-4-fluorophenyl)methyl, (2-fluoro-3-chlorophenyl)methyl, (2-fluoro-4-chlorophenyl)methyl, (2-fluoro-5-chlorophenyl)methyl, (3-fluoro-4-chlorophenyl)methyl, (3-fluoro-5-chlorophenyl)methyl, (2-fluoro-6-chlorophenyl)methyl, 2-phenyleth-1-yl, 3-trifluoromethyl-4-chlorophenyl, 3-chloro-4-trifluoromethylphenyl, 2-chloro-4-trifluoromethylphenyl, 3,5-difluoropyridin-2-yl, (3,6-dichloropyridin-2-yl)methyl, (4-trifluoromethylphenyl)methyl, (3-trifluoromethylphenyl)methyl, (2-trifluoromethylphenyl)methyl, (4-trifluoromethoxyphenyl)methyl, (3-trifluoromethoxyphenyl)methyl, (2-trifluoromethoxyphenyl)methyl, (4-methoxyphenyl)methyl, (3-methoxyphenyl)methyl, (2-methoxyphenyl)methyl, (4-methylphenyl)methyl, (3-methylphenyl)methyl, (2-methylphenyl)methyl, (4-cyanophenyl)methyl, (3-cyanophenyl)methyl, (2-cyanophenyl)methyl, (2,4-diethylphenyl)methyl, (3,5-diethylphenyl)methyl, (3,4-dimethylphenyl)methyl, (3,5-dimethoxyphenyl)methyl, 1-phenyleth-1-yl, 1-(o-chlorophenyl)eth-1-yl, 1,3-thiazol-2-yl, 4-methyl-1,3-thiazol-2-yl, 1,3-thiazol-2-yl, methylthiomethyl, ethylthiomethyl, ethylthioethyl, methylthioethyl, n-propylthiomethyl, isopropylthiomethyl, trifluoromethylthiomethyl, trifluoromethylthioethyl, hydroxycarbonyl, methoxycarbonyl, ethoxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, tert-butyloxycarbonyl, allyloxycarbonyl, benzyloxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, isopropylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, methyl(ethyl)aminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, cyclohexylaminocarbonyl, allylaminocarbonyl, benzylaminocarbonyl, tert-butyloxycarbonylaminocarbonyl, hydroxycarbonylmethyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, n-propyloxycarbonylmethyl, isopropyloxycarbonylmethyl, n-butyloxycarbonylmethyl, tert-butyloxycarbonylmethyl, allyloxycarbonylmethyl, benzyloxycarbonylmethyl, aminocarbonylmethyl, methylaminocarbonylmethyl, ethylaminocarbonylmethyl, n-propylaminocarbonylmethyl, isopropylaminocarbonylmethyl, dimethylaminocarbonylmethyl, diethylaminocarbonylmethyl, methyl(ethyl)aminocarbonylmethyl, cyclopropylaminocarbonylmethyl, cyclobutylaminocarbonylmethyl, cyclopentylaminocarbonylmethyl, cyclohexylaminocarbonylmethyl, allylaminocarbonylmethyl, benzylaminocarbonylmethyl, aminomethyl, 2-aminoeth-1-yl, 1-aminoeth-1-yl, 1-aminoprop-1-yl, 3-aminoprop-1-yl, methylaminomethyl, dimethylaminomethyl, diethylaminomethyl, ethylaminomethyl, isopropylaminomethyl, cyclopropylaminomethyl, cyclobutylaminomethyl, cyclopentylaminomethyl, cyclohexylaminomethyl, methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl, tert-butyloxycarbonylaminomethyl, or R.sup.7 and R.sup.8 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.7 and R.sup.8 together with the carbon atom to which they are bonded form a double bond optionally substituted by R.sup.22 and R.sup.23, according to formula (I″) below ##STR00141## m is 0, 1, 2, n is 0, 1, 2, 3, 4, 5, 6, R.sup.21 is hydrogen, fluorine, chlorine, bromine, trifluoromethyl, methoxy, ethoxy, n-propyloxy, n-butyloxy, R.sup.22 and R.sup.23 are independently hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, trifluoromethyl, difluoromethyl, pentafluoroethyl, ethenyl, 1-propenyl, 1-methylethenyl, 1-butenyl, phenyl, or R.sup.22 and R.sup.23 together with the carbon atom to which they are bonded form a 3- to 10-membered monocyclic or bicyclic ring which is saturated or optionally interrupted by heteroatoms and optionally has further substitution and Q is one of the moieties Q-1 to Q-345 specified below: ##STR00142## ##STR00143## ##STR00144## ##STR00145## ##STR00146## ##STR00147## ##STR00148## ##STR00149## ##STR00150## ##STR00151## ##STR00152## ##STR00153## ##STR00154## ##STR00155## ##STR00156## ##STR00157## ##STR00158## ##STR00159## ##STR00160## ##STR00161## ##STR00162## ##STR00163## ##STR00164## ##STR00165## ##STR00166## ##STR00167## ##STR00168## ##STR00169## ##STR00170## ##STR00171## ##STR00172## ##STR00173## ##STR00174## ##STR00175##

5. A compound of the general formula (I) as claimed in claim 1 and/or salt thereof, wherein R.sup.1 is methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, amino, dimethylamino, diethylamino, R.sup.2 is hydrogen, methyl, ethyl, n-propyl, isopropyl, R.sup.3 is hydrogen, fluorine, chlorine, bromine, methoxy, ethoxy, R.sup.4 is halogen, cyano, C(O)NH.sub.2, C(S)NH.sub.2, difluoromethyl, trifluoromethyl, ethynyl, propyn-1-yl, R.sup.5 and R.sup.6 are independently hydrogen, fluorine, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, trifluoromethyl, pentafluoroethyl, 1,1,2,2-tetrafluoroethyl, heptafluoropropyl, nonafluorobutyl, difluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, methoxy, ethoxy, n-propyloxy, isopropyloxy, n-butyloxy, tert-butyloxy, methoxymethyl, ethoxymethyl, n-propyloxymethyl, isopropyloxymethyl, methoxyethyl, ethoxyethyl, n-propyloxyethyl, isopropyloxyethyl, methoxy-n-propyl, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, thiophen-2-yl, thiophen-3-yl, furan-2-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, phenylethyl, 1-(4-methylphenyl)ethyl, 1-(3-methylphenyl)ethyl, 1-(2-methylphenyl)ethyl, 1-(4-chlorophenyl)ethyl, 1-(3-chlorophenyl)ethyl, 1-(2-chlorophenyl)ethyl, benzyl, (4-fluorophenyl)methyl, (3-fluorophenyl)methyl, (2-fluorophenyl)methyl, (2,4-difluorophenyl)methyl, (3,5-difluorophenyl)methyl, (2,5-difluorophenyl)methyl, (2,6-difluorophenyl)methyl, (4-chlorophenyl)methyl, (3-chlorophenyl)methyl, (2-chlorophenyl)methyl, (2,4-dichlorophenyl)methyl, (3,5-dichlorophenyl)methyl, (2,5-dichlorophenyl)methyl, methylthiomethyl, ethylthiomethyl, ethylthioethyl, methylthioethyl, n-propylthiomethyl, isopropylthiomethyl, trifluoromethylthiomethyl, trifluoromethylthioethyl, or R.sup.5 and R.sup.6 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.5 and R.sup.6 together with the carbon atom to which they are bonded form a double bond optionally substituted by R.sup.22 and R.sup.23, according to formula (I′) below ##STR00176## R.sup.7 and R.sup.8 are independently hydrogen, fluorine, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-1-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-2-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 3-methyl-1-butynyl, 1,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, trifluoromethyl, pentafluoroethyl, 1,1,2,2-tetrafluoroethyl, heptafluoropropyl, difluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, difluoro-tert-butyl, methoxy, ethoxy, n-propyloxy, isopropyloxy, n-butyloxy, tert-butyloxy, methoxymethyl, ethoxymethyl, n-propyloxymethyl, isopropyloxymethyl, methoxyethyl, ethoxyethyl, n-propyloxyethyl, isopropyloxyethyl, methoxy-n-propyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,4,5-trifluorophenyl, 3,4,5-trifluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2,4,5-trichlorophenyl, 3,4,5-trichlorophenyl, 2,4,6-trichlorophenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, thiophen-2-yl, thiophen-3-yl, furan-2-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, 1-(4-methylphenyl)ethyl, 1-(3-methylphenyl)ethyl, 1-(2-methylphenyl)ethyl, 1-(4-chlorophenyl)ethyl, 1-(3-chlorophenyl)ethyl, 1-(2-chlorophenyl)ethyl, benzyl, (4-fluorophenyl)methyl, (3-fluorophenyl)methyl, (2-fluorophenyl)methyl, (2,4-difluorophenyl)methyl, (3,5-difluorophenyl)methyl, (2,5-difluorophenyl)methyl, (2,6-difluorophenyl)methyl, (2,4,5-trifluorophenyl)methyl, (2,4,6-trifluorophenyl)methyl, (4-chlorophenyl)methyl, (3-chlorophenyl)methyl, (2-chlorophenyl)methyl, (2,4-dichlorophenyl)methyl, (3,5-dichlorophenyl)methyl, (2,5-dichlorophenyl)methyl, (2,6-dichlorophenyl)methyl, (2,4,5-trichlorophenyl)methyl, (2,4,6-trichlorophenyl)methyl, methylthiomethyl, ethylthiomethyl, ethylthioethyl, methylthioethyl, n-propylthiomethyl, isopropylthiomethyl, trifluoromethylthiomethyl, trifluoromethylthioethyl, or R.sup.7 and R.sup.8 together with the carbon atom to which they are bonded form a fully saturated or partly saturated 3- to 10-membered monocyclic or bicyclic ring optionally interrupted by heteroatoms and optionally having further substitution, or R.sup.7 and R.sup.8 together with the carbon atom to which they are bonded form a double bond optionally substituted by R.sup.22 and R.sup.23, according to formula (I″) below ##STR00177## m is 0, 1, 2, n is 0, 1, 2, 3, R.sup.21 is hydrogen, fluorine, chlorine, bromine, trifluoromethyl, methoxy, ethoxy, n-propyloxy, n-butyloxy, R.sup.22 and R.sup.23 are independently hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, trifluoromethyl, difluoromethyl, pentafluoroethyl, ethenyl, 1-propenyl, 1-methylethenyl, 1-butenyl, phenyl, or R.sup.22 and R.sup.23 together with the carbon atom to which they are bonded form a 3- to 10-membered monocyclic or bicyclic ring which is saturated or optionally interrupted by heteroatoms and optionally has further substitution and Q is one of the moieties Q-1 to Q-345 specified in claim 4.

6. The use of one or more compounds of the general formula (I) and/or salts thereof as defined in claim 1 as herbicide and/or plant growth regulator, preferably in crops of useful plants and/or ornamentals.

7. A herbicidal and/or plant growth-regulating composition, wherein the composition contains one or more compounds of the formula (I) and/or salts thereof as defined in claim 1, and/or one or more further substances selected from groups (i) and/or (ii): (i) one or more further active agrochemical ingredients, preferably selected from the group consisting of insecticides, acaricides, nematicides, further herbicides, fungicides, safeners, fertilizers and further growth regulators, (ii) one or more formulation auxiliaries customary in crop protection.

8. A method of controlling harmful plants or of regulating the growth of plants, wherein an effective amount of one or more compounds of the formula (I) and/or salts thereof as defined in claim 1 or is applied to the plants, plant seeds, the soil in or on which the plants grow, or the cultivation area.

Description

SYNTHESIS EXAMPLES

No. I.2-72: Tetrahydrofuran-3-ylmethyl 2-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)butanoate

[0221] ##STR00055##

[0222] 2-Fluoro-4-chloroaniline (145 g, 996 mmol) and triethylamine (202 g, 2000 mmol) were successively added cautiously to a solution of triphosgene (119 g, 401 mmol) in abs. dichloromethane (1000 mL), in such a way that the temperature of the resulting reaction mixture remained below 20° C. After the end of the addition, the reaction mixture was stirred at room temperature overnight and then washed with water (3×500 mL) and 1N hydrochloric acid (500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The 2-fluoro-4-chlorophenyl isocyanate was used in the next step without further purification. Sodium hydride (5.60 g, 140 mmol, 60% dispersion in mineral oil) was suspended in abs. N,N-dimethylformamide, and ethyl (2E)-3-amino-4,4,4-trifluorobut-2-enoate (14.2 g, 77.5 mmol) was added. The reaction mixture was stirred at room temperature for 1 h, then cooled down to a temperature of −30° C., and 2-fluoro-4-chlorophenyl isocyanate (12.0 g, 70.0 mmol) was added. On completion of addition, the resulting reaction mixture was stirred at room temperature for a further 4 h and then added to ice-water. After the addition of ethyl acetate and acidification with 1N hydrochloric acid, the aqueous phase was extracted thoroughly with ethyl acetate. The combined organic phases were washed with water, dried over sodium sulfate, filtered and concentrated under reduced pressure. In this way, 3-(4-chloro-2-fluorophenyl)-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (15.2 g, 50.2 mmol, 65%) was obtained, which was used in the next step without further purification. It was also possible to repeat this reaction step successfully on a larger scale. To a solution of 3-(4-chloro-2-fluorophenyl)-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (238 g, 770 mmol) in abs. N,N-dimethylformamide (800 mL) was added potassium carbonate (117 g, 850 mmol). Thereafter, a solution of methyl iodide (120 g, 850 mmol) in abs. N,N-dimethylformamide (100 mL) was added and the resulting reaction mixture was stirred at room temperature for a further 1 h. On completion of conversion, the reaction mixture was cooled to a temperature of 0° C., water (2000 mL) was added cautiously, and then the mixture was extracted thoroughly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. In this way, 3-(4-chloro-2-fluorophenyl)-1-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (241 g, 747 mmol, 97% of theory) was obtained, which was converted in the next step without further purification. 3-(4-Chloro-2-fluorophenyl)-1-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (100 g, 310 mmol) was then added stepwise to chlorosulfonic acid in a baked-out round-bottom flask. The resulting reaction mixture was then stirred at a temperature of 110° C. for 20 h and, after cooling to room temperature, added to ice-water and extracted repeatedly with ethyl acetate (3×300 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. This gave 2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]benzenesulfonyl chloride (75.0 g, 178 mmol, 57% of theory), which was used in the next step without further purification. To an initial charge of 2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]sulfonyl chloride (100.0 g, 237 mmol) in a round-bottom flask were successively added hydrochloric acid (500 mL), acetic acid (500 mL) and tin dichloride dihydrate (270 g, 1197 mmol). The resulting reaction mixture was stirred at a temperature of 100° C. for 10 h, after cooling to room temperature added to ice-water, and extracted thoroughly with dichloromethane (3×400 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. Final column chromatography purification afforded 3-(4-chloro-2-fluoro-5-sulfanylphenyl)-1-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (73.0 g, 206 mmol, 83% of theory) in the form of a colorless solid. 2-Chlorobutanecarboxylic acid (691 mg, 5.64 mmol) was dissolved in abs. acetonitrile under argon in a baked-out round-bottom flask, and then cesium carbonate (3.67 g, 11.28 mmol) and 3-(4-chloro-2-fluoro-5-sulfanylphenyl)-1-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (2.0 g, 5.64 mmol) were added. The resulting reaction mixture was stirred at a temperature of 50° C. for 1 h and, after cooling to room temperature, admixed with water and dichloromethane and extracted thoroughly. The aqueous phase was then acidified with 10% hydrochloric acid and again extracted repeatedly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and 2-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)butanoic acid (2.0 g, 80% of theory) was obtained in the form of a colorless solid.

[0223] .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.53 (d, 1H), 7.38 (d, 1H), 6.36 (d, 1H), 3.68 (m, 1H), 3.55 (s, 3H), 2.05-1.95 (m, 1H), 1.93-1.82 (m, 1H), 1.09 (t, 3H). 2-({2-Chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)butanoic acid (90 mg, 0.20 mmol), 1-hydroxy-1H-benzotriazole (36 mg, 0.27 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (51 mg, 0.27 mmol) were dissolved in abs. dichloromethane in a baked-out round-bottom flask under argon and, after stirring at room temperature for 5 minutes, tetrahydro-3-furanmethanol (27 mg, 0.28 mmol) and triethylamine (0.04 mL, 0.27 mmol) were added. The resulting reaction mixture was stirred at room temperature for 6 h, then admixed with water and dichloromethane and extracted thoroughly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and tetrahydrofuran-3-ylmethyl 2-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)butanoate (83 mg, 77% of theory) was obtained in the form of a highly viscous, colorless oil. .sup.1H-NMR (CDCl.sub.3 δ, ppm) 7.47 (m, 1H), 7.37 (d, 1H), 6.35 (d, 1H), 4.13-3.89 (m, 2H), 3.83-3.67 (m, 4H), 3.55 (s, 3H), 3.47-3.43 (m, 1H), 2.53-2.40 (m, 1H), 2.02-1.90 (m, 2H), 1.89-1.79 (m, 1H), 1.59-1.49 (m, 1H), 1.07 (t, 3H).

No. I.2-91: Tetrahydro-2H-pyran-2-ylmethyl 2-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)butanoate

[0224] ##STR00056##

[0225] 2-({2-Chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)butanoic acid (100 mg, 0.23 mmol), 1-hydroxy-1H-benzotriazole (40 mg, 0.29 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (57 mg, 0.29 mmol) were dissolved in abs. dichloromethane in a baked-out round-bottom flask under argon and, after stirring at room temperature for 5 minutes, 2-(hydroxymethyl)tetrahydropyran (34 mg, 0.29 mmol) and triethylamine (0.04 mL, 0.29 mmol) were added. The resulting reaction mixture was stirred at room temperature for 2 h, then admixed with water and dichloromethane and extracted thoroughly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and tetrahydro-2H-pyran-2-ylmethyl 2-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)butanoate (38 mg, 31% of theory) was obtained in the form of a highly viscous, colorless oil. .sup.1H-NMR (CDCl.sub.3 δ, ppm) 7.53 (m, 1H), 7.35 (m, 1H), 6.35 (m, 1H), 4.12-3.88 (m, 3H), 3.76-3.71 (m, 1H), 3.55 (s, 3H), 3.47-3.32 (m, 2H), 2.03-1.92 (m, 1H), 1.89-1.78 (m, 2H), 1.62-1.42 (m, 5H), 1.08 (t, 3H).

No. I.2-92: Tetrahydro-2H-pyran-3-ylmethyl 2-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)butanoate

[0226] ##STR00057##

[0227] 2-({2-Chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)butanoic acid (100 mg, 0.23 mmol), 1-hydroxy-1H-benzotriazole (40 mg, 0.29 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (57 mg, 0.29 mmol) were dissolved in abs. dichloromethane in a baked-out round-bottom flask under argon and, after stirring at room temperature for 5 minutes, 3-(hydroxymethyl)tetrahydropyran (34 mg, 0.29 mmol) and triethylamine (0.04 ml, 0.29 mmol) were added. The resulting reaction mixture was stirred at room temperature for 2 h, then admixed with water and dichloromethane and extracted thoroughly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and tetrahydro-2H-pyran-3-ylmethyl 2-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)butanoate (25 mg, 20% of theory) was obtained in the form of a highly viscous, colorless oil. .sup.1H-NMR (CDCl.sub.3 δ, ppm) 7.52 (m, 1H), 7.37 (m, 1H), 6.35 (m, 1H), 4.03-3.97 (m, 1H), 3.96-3.87 (m, 1H), 3.85-3.77 (m, 1H), 3.72-3.68 (m, 1H), 3.55 (s, 3H), 3.41-3.34 (m, 1H), 3.17-3.10 (m, 1H), 2.03-1.92 (m, 1H), 1.89-1.78 (m, 2H), 1.62-1.42 (m, 5H), 1.08 (t, 3H).

No. I.4-91: Tetrahydro-2H-pyran-2-ylmethyl 2-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)-4-methylpentanoate

[0228] ##STR00058##

[0229] 2-Chloro-4-methylpentanecarboxylic acid (849 mg, 5.64 mmol) was dissolved in abs. acetonitrile under argon in a baked-out round-bottom flask, and then cesium carbonate (3.67 g, 11.28 mmol) and 3-(4-chloro-2-fluoro-5-sulfanylphenyl)-1-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (2.0 g, 5.64 mmol) were added. The resulting reaction mixture was stirred at a temperature of 50° C. for 1 h and, after cooling to room temperature, admixed with water and dichloromethane and extracted thoroughly. The aqueous phase was then acidified with 10% hydrochloric acid and again extracted repeatedly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and 2-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)-4-methylpentanoic acid (1.62 g, 61% of theory) was obtained in the form of a colorless solid. .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.53 (d, 1H), 7.37 (d, 1H), 6.37 (m, 1H), 3.82-3.78 (m, 1H), 3.55 (s, 3H), 1.90-1.78 (m, 2H), 1.73-1.65 (m, 1H), 0.99-0.92 (m, 6H). 2-({2-Chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)-4-methylpentanoic acid (120 mg, 0.26 mmol), 1-hydroxy-1H-benzotriazole (45 mg, 0.33 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (66 mg, 0.33 mmol) were dissolved in abs. dichloromethane in a baked-out round-bottom flask under argon and, after stirring at room temperature for 5 minutes, 2-(hydroxymethyl)tetrahydropyran (39 mg, 0.33 mmol) and triethylamine (0.05 mL, 0.33 mmol) were added. The resulting reaction mixture was stirred at room temperature for 2 h, then admixed with water and dichloromethane and extracted thoroughly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and tetrahydro-2H-pyran-2-ylmethyl 2-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)-4-methylpentanoate (81 mg, 56% of theory) was obtained in the form of a highly viscous, colorless oil. .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.53 (m, 1H), 7.35 (m, 1H), 6.35 (d, 1H), 4.08-3.98 (m, 1H), 3.94-3.84 (m, 3H), 3.55 (s, 3H), 3.48-3.33 (m, 2H), 1.90-1.76 (m, 3H) 1.71-1.63 (m, 1H), 1.57-1.43 (m, 5H), 1.28-1.17 (m, 1H), 0.96-0.93 (m, 6H), 0.90-0.84 (m, 1H).

No. I.6-221: 2-({2-Chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)-3-methyl-N-(tetrahydrofuran-2-ylmethyl)butanamide

[0230] ##STR00059##

[0231] 2-Chloro-3-methylbutanecarboxylic acid (770 mg, 5.64 mmol) was dissolved in abs. acetonitrile under argon in a baked-out round-bottom flask, and then cesium carbonate (3.67 g, 11.28 mmol) and 3-(4-chloro-2-fluoro-5-sulfanylphenyl)-1-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (2.0 g, 5.64 mmol) were added. The resulting reaction mixture was stirred at a temperature of 50° C. for 1 h and, after cooling to room temperature, admixed with water and dichloromethane and extracted thoroughly. The aqueous phase was then acidified with 10% hydrochloric acid and again extracted repeatedly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and 2-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)-3-methylbutanoic acid (0.47 g, 21% of theory) was obtained in the form of a colorless solid. .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.49 (d, 1H), 7.37 (d, 1H), 6.33 (m, 1H), 3.58-3.48 (m, 1H), 3.53 (s, 3H), 2.25-2.17 (m, 1H), 1.18 (d, 3H), 1.11 (d, 3H). 2-({2-Chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)-3-methylbutanoic acid (100 mg, 0.22 mmol), 1-hydroxy-1H-benzotriazole (39 mg, 0.29 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (65 mg, 0.29 mmol) were dissolved in abs. dichloromethane in a baked-out round-bottom flask under argon and, after stirring at room temperature for 5 minutes, 2-(aminomethyl)tetrahydrofuran (29 mg, 0.29 mmol) and triethylamine (0.04 ml, 0.29 mmol) were added. The resulting reaction mixture was stirred at room temperature for 2 h, then admixed with water and dichloromethane and extracted thoroughly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and 2-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)-3-methyl-N-(tetrahydrofuran-2-ylmethyl)butanamide (44 mg, 37% of theory) was obtained in the form of a highly viscous, colorless oil. .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.36 (m, 1H), 7.28 (m, 1H), 6.91-6.81 (m, 1H, NH), 6.34 (m, 1H), 3.90-3.61 (m, 3H), 3.58-3.56 (m, 1H), 3.54 (s, 3H), 3.50-3.42 (m, 1H), 3.20-3.06 (m, 1H), 2.42-2.33 (m, 1H), 1.92-1.68 (m, 3H), 1.48-1.42/1.33-1.28 (m, 1H), 1.15 (d, 3H), 1.11 (d, 3H).

No. I.12-72: Tetrahydrofuran-3-ylmethyl 2-({2-chloro-4-fluoro-5-[3,5-dimethyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)butanoate

[0232] ##STR00060##

[0233] A solution of n-butyllithium in hexane (2.5M, 240 mL) was added to a solution, cooled to −10° C., of diisopropylamine (61.0 g, 603 mmol) in abs. tetrahydrofuran (300 mL). The resulting reaction mixture was stirred at a temperature of −10° C. for 30 minutes and then cooled further to −78° C. This was followed by cautious addition of ethyl propionate (51.0 g, 499 mmol). The reaction mixture was stirred at −78° C. for 1 h, 2,2,2-trifluoroethyl trifluoroacetate (147 g, 750 mmol) was added and, finally, the mixture was stirred at room temperature overnight. On completion of conversion, the mixture was acidified with dil. hydrochloric acid (1M) and repeatedly extracted thoroughly with ethyl acetate. These combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure, and the ethyl 4,4,4-trifluoro-2-methyl-3-oxobutanoate (62.0 g, 63% of theory) obtained in this way was, as a portion (49.5 g, 250 mmol), without further purification, dissolved in toluene (400 mL) in a round-bottom flask and admixed with ammonium acetate (96.0 g, 1245 mmol) and acetic acid (15 mL). The resulting reaction mixture was stirred under reflux conditions with use of a water separator for several hours until no further water was separated out. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure and then the residue was taken up with ethyl acetate and water. The water phase was then extracted thoroughly with ethyl acetate, and the combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. Distillative purification of the residue obtained afforded ethyl (2Z)-3-amino-4,4,4-trifluoro-2-methylbut-2-enoate (31.0 g, 62% of theory). 2-Fluoro-4-chloroaniline (145 g, 996 mmol) and triethylamine (202 g, 2000 mmol) were successively added cautiously to a solution of triphosgene (119 g, 401 mmol) in abs. dichloromethane (1000 mL), in such a way that the temperature of the resulting reaction mixture remained below 20° C. After the end of the addition, the reaction mixture was stirred at room temperature overnight and then washed with water (3×500 mL) and 1N hydrochloric acid (500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The 2-fluoro-4-chlorophenyl isocyanate obtained was used in the next step without further purification. Sodium hydride (5.60 g, 140 mmol, 60% dispersion in mineral oil) was suspended in abs. N,N-dimethylformamide, and ethyl (2Z)-3-amino-4,4,4-trifluoro-2-methylbut-2-enoate (14.2 g, 72.1 mmol) was added. The reaction mixture was stirred at room temperature for 1 h, then cooled down to a temperature of −30° C., and 2-fluoro-4-chlorophenyl isocyanate (12.0 g, 70.0 mmol) was added. On completion of addition, the resulting reaction mixture was stirred at room temperature for a further 4 h and then added to ice-water. After the addition of ethyl acetate and acidification with 1N hydrochloric acid, the aqueous phase was extracted thoroughly with ethyl acetate. The combined organic phases were washed with water, dried over sodium sulfate, filtered and concentrated under reduced pressure. In this way, 3-(4-chloro-2-fluorophenyl) 5-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (15.5 g, 48.1 mmol, 66%) was obtained, which was used in the next step without further purification. To a solution of 3-(4-chloro-2-fluorophenyl)-5-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (23.8 g, 73.8 mmol) in abs. N,N-dimethylformamide (80 mL) was added potassium carbonate (11.7 g, 84.7 mmol). Thereafter, a solution of methyl iodide (12.0 g, 84.5 mmol) in abs. N,N-dimethylformamide (10 mL) was added and the resulting reaction mixture was stirred at room temperature for a further 1 h. On completion of conversion, the reaction mixture was cooled to a temperature of 0° C., water (200 mL) was added cautiously, and then the mixture was extracted thoroughly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. In this way, 3-(4-chloro-2-fluorophenyl)-1,5-dimethyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (24.1 g, 71.6 mmol, 97% of theory) was obtained, which was converted in the next step without further purification. 3-(4-Chloro-2-fluorophenyl)-1,5-dimethyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (10.0 g, 29.7 mmol) was then added stepwise to chlorosulfonic acid (200 mL) in a baked-out round-bottom flask. The resulting reaction mixture was then stirred at a temperature of 110° C. for 20 h and, after cooling to room temperature, added to ice-water and extracted repeatedly with ethyl acetate (3×300 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. This gave 2-chloro-4-fluoro-5-[3,5-dimethyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]benzenesulfonyl chloride (7.74 g, 17.8 mmol, 60% of theory), which was used in the next step without further purification. To an initial charge of 2-chloro-4-fluoro-5-[3,5-dimethyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]sulfonyl chloride (10.0 g, 23.0 mmol) in a round-bottom flask were successively added hydrochloric acid (50 mL), acetic acid (50 mL) and tin dichloride dihydrate (27.0 g, 120 mmol). The resulting reaction mixture was stirred at a temperature of 100° C. for 10 h, after cooling to room temperature added to ice-water, and extracted thoroughly with dichloromethane (3×400 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. Final column chromatography purification afforded 3-(4-chloro-2-fluoro-5-sulfanylphenyl)-1,5-dimethyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (7.6 g, 20.6 mmol, 89% of theory) in the form of a colorless solid. 2-Chlorobutanecarboxylic acid (332 mg, 2.71 mmol) was dissolved in abs. acetonitrile under argon in a baked-out round-bottom flask, and then cesium carbonate (1.77 g, 5.42 mmol) and 3-(4-chloro-2-fluoro-5-sulfanylphenyl)-1,5-dimethyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (1.0 g, 2.71 mmol) were added. The resulting reaction mixture was stirred at a temperature of 50° C. for 1 h and, after cooling to room temperature, admixed with water and dichloromethane and extracted thoroughly. The aqueous phase was then acidified with 10% hydrochloric acid and again extracted repeatedly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and 2-({2-chloro-5-[3,5-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]-4-fluorophenyl}sulfanyl)butanoic acid (1.42 g, 80% of theory) was obtained in the form of a colorless solid. .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.55 (d, 1H), 7.37 (d, 1H), 3.68 (m, 1H), 3.55 (s, 3H), 2.28-2.21 (m, 3H), 2.05-1.91 (m, 1H), 1.90-1.78 (m, 1H), 1.10 (t, 3H). 2-({2-Chloro-5-[3,5-dimethyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]-4-fluorophenyl}sulfanyl)butanoic acid (160 mg, 0.35 mmol), 1-hydroxy-1H-benzotriazole (62 mg, 0.46 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (88 mg, 0.46 mmol) were dissolved in abs. dichloromethane in a baked-out round-bottom flask under argon and, after stirring at room temperature for 5 minutes, 3-(hydroxymethyl)tetrahydrofuran (47 mg, 0.46 mmol) and triethylamine (0.12 mL, 0.84 mmol) were added. The resulting reaction mixture was stirred at room temperature for 6 h, then admixed with water and dichloromethane and extracted thoroughly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and tetrahydrofuran-3-ylmethyl 2-({2-chloro-4-fluoro-5-[3,5-dimethyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)butanoate (171 mg, 75% of theory) was obtained in the form of a highly viscous, colorless oil. .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.47 (m, 1H), 7.37 (d, 1H), 4.13-3.89 (m, 2H), 3.83-3.67 (m, 4H), 3.55 (s, 3H), 3.49-3.43 (m, 1H), 2.53-2.44 (m, 1H), 2.26-2.21 (m, 3H), 2.02-1.92 (m, 2H), 1.90-1.82 (m, 1H), 1.59-1.49 (m, 1H), 1.07 (t, 3H).

No. I.44-71: Tetrahydrofuran-2-ylmethyl ({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1 (2H)-yl]phenyl}sulfanyl)(cyclopropyl)acetate

[0234] ##STR00061##

[0235] Ethyl chloro(cyclopropyl)acetate (409 mg, 1.97 mmol) was dissolved in abs. acetonitrile under argon in a baked-out round-bottom flask, and then cesium carbonate (273 mg, 1.97 mmol) and 3-(4-chloro-2-fluoro-5-sulfanylphenyl)-1-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (700 mg, 1.97 mmol) were added. The resulting reaction mixture was stirred at a temperature of 50° C. for 2 h and, after cooling to room temperature, admixed with water and dichloromethane and extracted thoroughly. The aqueous phase was then acidified with 10% hydrochloric acid and again extracted repeatedly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and ethyl ({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)(cyclopropyl)acetate (940 mg, 99% of theory) was obtained in the form of a colorless solid. .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.51 (d, 1H), 7.35 (d, 1H), 6.34 (s, 1H), 4.18-4.05 (m, 2H), 3.53 (s, 3H), 3.13-3.10 (m, 1H), 1.33-1.26 (m, 1H), 1.15 (t, 3H), 0.75-0.66 (m, 2H), 0.48-0.44 (m, 1H), 0.42-0.36 (m, 1H). Ethyl ({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)(cyclopropyl)acetate (160 mg, 0.33 mmol) was then dissolved in ethyl acetate, and 6N HCl was added. The reaction mixture obtained was stirred at a temperature of 100° C. for 3 h, after cooling to room temperature admixed with water, and extracted thoroughly with abs. dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and ({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)(cyclopropyl)acetic acid (120 mg, 79% of theory) was obtained in the form of a colorless solid. .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.54 (dd, 1H), 7.36 (d, 1H), 6.34 (m, 1H), 3.55 (s, 3H), 3.11-3.08 (m, 1H), 1.32-1.24 (m, 1H), 0.77-0.69 (m, 2H), 0.52-0.38 (m, 2H).2-({2-Chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)(cyclopropyl)acetic acid (120 mg, 0.27 mmol), 1-hydroxy-1H-benzotriazole (47 mg, 0.35 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (66 mg, 0.35 mmol) were dissolved in abs. dichloromethane in a baked-out round-bottom flask under argon and, after stirring at room temperature for 5 minutes, 2-(hydroxymethyl)tetrahydrofuran (35 mg, 0.35 mmol) and triethylamine (0.09 mL, 0.64 mmol) were added. The resulting reaction mixture was stirred at room temperature for 2 h, then admixed with water and dichloromethane and extracted thoroughly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and tetrahydrofuran-2-ylmethyl ({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)(cyclopropyl)acetate (81 mg, 54% of theory) was obtained in the form of a highly viscous, colorless oil. .sup.1H-NMR (d.sub.6δ, ppm) 7.83 (d, 1H), 7.72/7.68 (m, 1H), 6.62 (m, 1H), 4.06-3.99 (m, 1H), 3.97-3.85 (m, 2H), 3.70-3.64 (m, 1H), 3.62-3.56 (m, 1H), 3.48-3.34 (m, 4H), 1.90-1.68 (m, 3H) 1.53-1.40 (m, 1H), 1.30-1.13 (m, 1H), 0.69-0.58 (m, 2H), 0.48-0.35 (m, 2H).

No. I.48-82: Tetrahydrothiophen-3-ylmethyl 3-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1 (2H)-yl]phenyl}sulfanyl)-2,2-dimethylpropanoate

[0236] ##STR00062##

[0237] 3-Chloropivalic acid (778 mg, 5.64 mmol) was dissolved in abs. acetonitrile (30 mL) under argon in a baked-out round-bottom flask, and then potassium carbonate (1.64 g, 11.28 mmol) and 3-(4-chloro-2-fluoro-5-sulfanylphenyl)-1-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (2.0 g, 5.64 mmol) were added. The resulting reaction mixture was stirred at a temperature of 45° C. for 2 h and, after cooling to room temperature, admixed with water and dichloromethane and extracted thoroughly. The aqueous phase was then acidified with 10% hydrochloric acid and again extracted repeatedly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and 3-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)-2,2-dimethylpropanoic acid (2.35 g, 87% of theory) was obtained in the form of a colorless solid. .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.49 (d, 1H), 7.37 (d, 1H), 6.39 (s, 1H), 3.57 (s, 3H), 3.02 (s, 2H), 1.29 (s, 6H). 3-({2-Chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)-2,2-dimethylpropanoic acid (200 mg, 0.44 mmol), 1-hydroxy-1H-benzotriazole (77 mg, 0.57 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (110 mg, 0.57 mmol) were dissolved in abs. dichloromethane in a baked-out round-bottom flask under argon and, after stirring at room temperature for 5 minutes, tetrahydrothiophen-3-ylmethanol (68 mg, 0.57 mmol) and triethylamine (0.15 mL, 1.06 mmol) were added. The resulting reaction mixture was stirred at room temperature for 3 h, then admixed with water and dichloromethane and extracted thoroughly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and tetrahydrothiophen-3-ylmethyl 3-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)-2,2-dimethylpropanoate (128 mg, 52% of theory) was obtained in the form of a highly viscous, colorless oil. .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.34 (d, 1H), 7.30 (d, 1H), 6.36 (m, 1H), 4.12-4.08 (m, 1H), 4.06-4.00 (m, 1H), 3.56 (s, 3H), 3.12 (s, 2H), 2.93-2.85 (m, 3H) 2.64-2.58 (m, 1H), 2.56-2.48 (m, 1H), 2.13-2.09 (m, 1H), 1.78-1.69 (m, 1H), 1.32 (s, 6H).

No. I.48-92: Tetrahydro-2H-pyran-3-ylmethyl 3-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)-2,2-dimethylpropanoate

[0238] ##STR00063##

[0239] 3-({2-Chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)-2,2-dimethylpropanoic acid (200 mg, 0.44 mmol), 1-hydroxy-1H-benzotriazole (77 mg, 0.57 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (110 mg, 0.57 mmol) were dissolved in abs. dichloromethane in a baked-out round-bottom flask under argon and, after stirring at room temperature for 5 minutes, tetrahydro-2H-pyran-3-ylmethanol (66 mg, 0.57 mmol) and triethylamine (0.15 mL, 1.06 mmol) were added. The resulting reaction mixture was stirred at room temperature for 3 h, then admixed with water and dichloromethane and extracted thoroughly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and tetrahydro-2H-pyran-3-ylmethyl 3-({2-chloro-4-fluoro-5-[3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]phenyl}sulfanyl)-2,2-dimethylpropanoate (149 mg, 61% of theory) was obtained in the form of a highly viscous, colorless oil.

[0240] .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.34 (d, 1H), 7.31 (m, 1H), 6.36 (m, 1H), 4.02-3.95 (m, 1H), 3.92-3.70 (m, 3H), 3.56 (s, 3H), 3.43-3.37 (m, 1H), 3.27-3.19 (m, 1H), 3.11 (s, 2H), 1.99-1.91 (m, 1H), 1.84-1.77 (m, 1H), 1.66-1.59 (m, 2H), 1.33-1.27 (m, 1H), 1.31 (s, 6H).

No. I.60-71: Tetrahydrofuran-2-ylmethyl 2-({2-chloro-5-[5-ethyl-3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]-4-fluorophenyl}sulfanyl)propanoate

[0241] ##STR00064##

[0242] Analogously to the synthesis of example No. I.12-72, a solution of n-butyllithium in hexane was added to a solution, cooled to −10° C., of diisopropylamine in abs. tetrahydrofuran. The resulting reaction mixture was stirred at a temperature of −10° C. for 40 minutes and then cooled further to −78° C. Then ethyl butanoate was added cautiously. The reaction mixture was stirred at −78° C. for 1 h, a suitable amount of 2,2,2-trifluoroethyl trifluoroacetate was added and, finally, the mixture was stirred at room temperature overnight. On completion of conversion, the mixture was acidified with dil. hydrochloric acid (1M) and repeatedly extracted thoroughly with ethyl acetate. These combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure, and the ethyl 4,4,4-trifluoro-2-ethyl-3-oxobutanoate (67% of theory) obtained in this way, without further purification, was dissolved in toluene in a round-bottom flask and admixed with ammonium acetate and acetic acid. The resulting reaction mixture was stirred under reflux conditions with use of a water separator for several hours until no further water was separated out. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure and then the residue was taken up with ethyl acetate and water. The water phase was then extracted thoroughly with ethyl acetate, and the combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. Distillative purification of the residue obtained afforded ethyl (2Z)-3-amino-4,4,4-trifluoro-2-ethylbut-2-enoate (58% of theory). 2-Fluoro-4-chloroaniline and triethylamine were successively added cautiously to a solution of triphosgene in abs. dichloromethane, in such a way that the temperature of the resulting reaction mixture remained below 20° C. After the end of the addition, the reaction mixture was stirred at room temperature overnight and then washed with water and 1N hydrochloric acid, dried over sodium sulfate, filtered and concentrated under reduced pressure. The 2-fluoro-4-chlorophenyl isocyanate was used in the next step without further purification. Sodium hydride (60% dispersion in mineral oil) was suspended in abs. N,N-dimethylformamide, and ethyl (2Z)-3-amino-4,4,4-trifluoro-2-ethylbut-2-enoate was added. The reaction mixture was stirred at room temperature for 1 h, then cooled down to a temperature of −30° C., and 2-fluoro-4-chlorophenyl isocyanate was added. On completion of addition, the resulting reaction mixture was stirred at room temperature for a further 4 h and then added to ice-water. After the addition of ethyl acetate and acidification with 1N hydrochloric acid, the aqueous phase was extracted thoroughly with ethyl acetate. The combined organic phases were washed with water, dried over sodium sulfate, filtered and concentrated under reduced pressure. In this way, 3-(4-chloro-2-fluorophenyl)-5-ethyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (66%) was obtained, which was used in the next step without further purification. To a solution of 3-(4-chloro-2-fluorophenyl)-5-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (1 equiv.) in abs. N,N-dimethylformamide was added potassium carbonate (1.2 equiv). Thereafter, a solution of methyl iodide (1.2 equiv.) in abs. N,N-dimethylformamide was added and the resulting reaction mixture was stirred at room temperature for a further 1 h. On completion of conversion, the reaction mixture was cooled to a temperature of 0° C., water was added cautiously, and then the mixture was extracted thoroughly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. In this way, 3-(4-chloro-2-fluorophenyl)-5-ethyl-1-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (97% of theory) was obtained, which was converted in the next step without further purification. 3-(4-Chloro-2-fluorophenyl)-5-ethyl-1-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione was then added stepwise to chlorosulfonic acid in a baked-out round-bottom flask. The resulting reaction mixture was then stirred at a temperature of 110° C. for 20 h and, after cooling to room temperature, added to ice-water and extracted repeatedly with ethyl acetate. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. This gave 2-chloro-4-fluoro-5-[5-ethyl-3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]benzenesulfonyl chloride (54% of theory), which was used in the next step without further purification. To an initial charge of 2-chloro-4-fluoro-5-[5-ethyl-3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]sulfonyl chloride (1 equiv.) in a round-bottom flask were successively added hydrochloric acid (2 mL/mmol), acetic acid (2.5 mL/mmol) and tin dichloride dihydrate (3 equiv). The resulting reaction mixture was stirred at a temperature of 100° C. for 10 h, after cooling to room temperature added to ice-water, and extracted thoroughly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. Final column chromatography purification afforded 3-(4-chloro-2-fluoro-5-sulfanylphenyl)-5-ethyl-1-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (84% of theory) in the form of a colorless solid. 2-Chloropropanecarboxylic acid (567 mg, 5.23 mmol) was dissolved in abs. acetonitrile under argon in a baked-out round-bottom flask, and then cesium carbonate (3.41 g, 10.45 mmol) and 3-(4-chloro-2-fluoro-5-sulfanylphenyl)-5-ethyl-1-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione (2.0 g, 5.23 mmol) were added. The resulting reaction mixture was stirred at a temperature of 50° C. for 1 h and, after cooling to room temperature, admixed with water and dichloromethane and extracted thoroughly. The aqueous phase was then acidified with 10% hydrochloric acid and again extracted repeatedly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and 2-({2-chloro-5-[5-ethyl-3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]-4-fluorophenyl}sulfanyl)propanoic acid (1.30 g, 54% of theory) was obtained in the form of a colorless solid. .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.54 (d, 1H), 7.39 (d, 1H), 3.90-3.83 (m, 1H), 3.54 (s, 3H), 2.72-2.69 (m, 2H), 1.55 (d, 3H), 1.13 (t, 3H). 2-({2-Chloro-5-[5-ethyl-3-dimethyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]-4-fluorophenyl}sulfanyl)propanoic acid (110 mg, 0.24 mmol), 1-hydroxy-1H-benzotriazole (42 mg, 0.31 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (60 mg, 0.31 mmol) were dissolved in abs. dichloromethane in a baked-out round-bottom flask under argon and, after stirring at room temperature for 5 minutes, 2-(hydroxymethyl)tetrahydrofuran (32 mg, 0.31 mmol) and triethylamine (0.08 mL, 0.61 mmol) were added. The resulting reaction mixture was stirred at room temperature for 6 h, then admixed with water and dichloromethane and extracted thoroughly with dichloromethane. The combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography (ethyl acetate/heptane gradient), and tetrahydrofuran-2-ylmethyl 2-({2-chloro-5-[5-ethyl-3-methyl-2,6-dioxo-4-(trifluoromethyl)-3,6-dihydropyrimidin-1(2H)-yl]-4-fluorophenyl}sulfanyl)propanoate (58 mg, 43% of theory) was obtained in the form of a highly viscous, colorless oil. .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.56-7.52 (m, 1H), 7.38-7.33 (m, 1H), 4.18-3.88 (m, 4H), 3.83-3.68 (m, 2H), 3.54 (s, 3H), 2.74-2.68 (m, 2H), 2.01-1.82 (m, 3H), 1.64-1.50 (m, 4H), 1.13 (t, 3H).

[0243] In analogy to the above-cited preparation examples that have been recited at the corresponding point, and taking account of the general details of the preparation of substituted N-heterocyclyl- and N-heteroaryltetrahydropyrimidinones, the compounds cited below are obtained. When a structural element in table 1 is defined by a structural formula containing a dotted line, this dotted line means that the group in question is connected to the rest of the molecule at that position. When a structural element in table 1 is defined by a structural formula containing an arrow, the arrow represents a bond of the respective Q group to the carbonyl group in the general formula (I).

##STR00065##

[0244] Table I.1: Preferred compounds of the formula (I.1) are the compounds I.1-1 to I.1-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.1-1 to I.1-345 from table I.1 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

TABLE-US-00001 TABLE 1 No. Q 1 Q-1 2 Q-2 3 Q-3 4 Q-4 5 Q-5 6 Q-6 7 Q-7 8 Q-8 9 Q-9 10 Q-10 11 Q-11 12 Q-12 13 Q-13 14 Q-14 15 Q-15 16 Q-16 17 Q-17 18 Q-18 19 Q-19 20 Q-20 21 Q-21 22 Q-22 23 Q-23 24 Q-24 25 Q-25 26 Q-26 27 Q-27 28 Q-28 29 Q-29 30 Q-30 31 Q-31 32 Q-32 33 Q-33 34 Q-34 35 Q-35 36 Q-36 37 Q-37 38 Q-38 39 Q-39 40 Q-40 41 Q-41 42 Q-42 43 Q-43 44 Q-44 45 Q-45 46 Q-46 47 Q-47 48 Q-48 49 Q-49 50 Q-50 51 Q-51 52 Q-52 53 Q-53 54 Q-54 55 Q-55 56 Q-56 57 Q-57 58 Q-58 59 Q-59 60 Q-60 61 Q-61 62 Q-62 63 Q-63 64 Q-64 65 Q-65 66 Q-66 67 Q-67 68 Q-68 69 Q-69 70 Q-70 71 Q-71 72 Q-72 73 Q-73 74 Q-74 75 Q-75 76 Q-76 77 Q-77 78 Q-78 79 Q-79 80 Q-80 81 Q-81 82 Q-82 83 Q-83 84 Q-84 85 Q-85 86 Q-86 87 Q-87 88 Q-88 89 Q-89 90 Q-90 91 Q-91 92 Q-92 93 Q-93 94 Q-94 95 Q-95 96 Q-96 97 Q-97 98 Q-98 99 Q-99 100 Q-100 101 Q-101 102 Q-102 103 Q-103 104 Q-104 105 Q-105 106 Q-106 107 Q-107 108 Q-108 109 Q-109 110 Q-110 111 Q-111 112 Q-112 113 Q-113 114 Q-114 115 Q-115 116 Q-116 117 Q-117 118 Q-118 119 Q-119 120 Q-120 121 Q-121 122 Q-122 123 Q-123 124 Q-124 125 Q-125 126 Q-126 127 Q-127 128 Q-128 129 Q-129 130 Q-130 131 Q-131 132 Q-132 133 Q-133 134 Q-134 135 Q-135 136 Q-136 137 Q-137 138 Q-138 139 Q-139 140 Q-140 141 Q-141 142 Q-142 143 Q-143 144 Q-144 145 Q-145 146 Q-146 147 Q-147 148 Q-148 149 Q-149 150 Q-150 151 Q-151 152 Q-152 153 Q-153 154 Q-154 155 Q-155 156 Q-156 157 Q-157 158 Q-158 159 Q-159 160 Q-160 161 Q-161 162 Q-162 163 Q-163 164 Q-164 165 Q-165 166 Q-166 167 Q-167 168 Q-168 169 Q-169 170 Q-170 171 Q-171 172 Q-172 173 Q-173 174 Q-174 175 Q-175 176 Q-176 177 Q-177 178 Q-178 179 Q-179 180 Q-180 181 Q-181 182 Q-182 183 Q-183 184 Q-184 185 Q-185 186 Q-186 187 Q-187 188 Q-188 189 Q-189 190 Q-190 191 Q-191 192 Q-192 193 Q-193 194 Q-194 195 Q-195 196 Q-196 197 Q-197 198 Q-198 199 Q-199 200 Q-200 201 Q-201 202 Q-202 203 Q-203 204 Q-204 205 Q-205 206 Q-206 207 Q-207 208 Q-208 209 Q-209 210 Q-210 211 Q-211 212 Q-212 213 Q-213 214 Q-214 215 Q-215 216 Q-216 217 Q-217 218 Q-218 219 Q-219 220 Q-220 221 Q-221 222 Q-222 223 Q-223 224 Q-224 225 Q-225 226 Q-226 227 Q-227 228 Q-228 229 Q-229 230 Q-230 231 Q-231 232 Q-232 233 Q-233 234 Q-234 235 Q-235 236 Q-236 237 Q-237 238 Q-238 239 Q-239 240 Q-240 241 Q-241 242 Q-242 243 Q-243 244 Q-244 245 Q-245 246 Q-246 247 Q-247 248 Q-248 249 Q-249 250 Q-250 251 Q-251 252 Q-252 253 Q-253 254 Q-254 255 Q-255 256 Q-256 257 Q-257 258 Q-258 259 Q-259 260 Q-260 261 Q-261 262 Q-262 263 Q-263 264 Q-264 265 Q-265 266 Q-266 267 Q-267 268 Q-268 269 Q-269 270 Q-270 271 Q-271 272 Q-272 273 Q-273 274 Q-274 275 Q-275 276 Q-276 277 Q-277 278 Q-278 279 Q-279 280 Q-280 281 Q-281 282 Q-282 283 Q-283 284 Q-284 285 Q-285 286 Q-286 287 Q-287 288 Q-288 289 Q-289 290 Q-290 291 Q-291 292 Q-292 293 Q-293 294 Q-294 295 Q-295 296 Q-296 297 Q-297 298 Q-298 299 Q-299 300 Q-300 301 Q-301 302 Q-302 303 Q-303 304 Q-304 305 Q-305 306 Q-306 307 Q-307 308 Q-308 309 Q-309 310 Q-310 311 Q-311 312 Q-312 313 Q-313 314 Q-314 315 Q-315 316 Q-316 317 Q-317 318 Q-318 319 Q-319 320 Q-320 321 Q-321 322 Q-322 323 Q-323 324 Q-324 325 Q-325 326 Q-326 327 Q-327 328 Q-328 329 Q-329 330 Q-330 331 Q-331 332 Q-332 333 Q-333 334 Q-334 335 Q-335 336 Q-336 337 Q-337 338 Q-338 339 Q-339 340 Q-340 341 Q-341 342 Q-342 343 Q-343 344 Q-344 345 Q-345

##STR00066##

[0245] Table I.2: Preferred compounds of the formula (I.2) are the compounds I.2-1 to I.2-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.2-1 to I.2-345 from table I.2 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00067##

[0246] Table I.3: Preferred compounds of the formula (I.3) are the compounds I.3-1 to I.3-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.3-1 to I.3-345 from table I.3 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00068##

[0247] Table I.4: Preferred compounds of the formula (I.4) are the compounds I.4-1 to I.4-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.4-1 to I.4-345 from table I.4 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00069##

[0248] Table I.5: Preferred compounds of the formula (I.5) are the compounds I.5-1 to I.5-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.5-1 to I.5-345 from table I.5 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00070##

[0249] Table I.6: Preferred compounds of the formula (I.6) are the compounds I.6-1 to I.6-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.6-1 to I.6-345 from table I.6 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00071##

[0250] Table I.7: Preferred compounds of the formula (I.7) are the compounds I.7-1 to I.7-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.7-1 to I.7-345 from table I.7 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00072##

[0251] Table I.8: Preferred compounds of the formula (I.8) are the compounds I.8-1 to I.8-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.8-1 to I.8-345 from table I.8 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00073##

[0252] Table I.9: Preferred compounds of the formula (I.9) are the compounds I.9-1 to I.9-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.9-1 to I.9-345 from table I.9 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00074##

[0253] Table I.10: Preferred compounds of the formula (I.10) are the compounds I.10-1 to I.10-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.10-1 to I.10-345 from table I.10 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00075##

[0254] Table I.11: Preferred compounds of the formula (I.11) are the compounds I.11-1 to I.11-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.11-1 to I.11-345 from table I.11 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00076##

[0255] Table I.12: Preferred compounds of the formula (I.12) are the compounds I.12-1 to I.12-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.12-1 to I.12-345 from table I.12 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00077##

[0256] Table I.13: Preferred compounds of the formula (I.13) are the compounds I.13-1 to I.13-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.13-1 to I.13-345 from table I.13 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00078##

[0257] Table I.14: Preferred compounds of the formula (I.14) are the compounds I.14-1 to I.14-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.14-1 to I.14-345 from table I.14 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00079##

[0258] Table I.15: Preferred compounds of the formula (I.15) are the compounds I.15-1 to I.15-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.15-1 to I.15-345 from table I.15 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00080##

[0259] Table I.16: Preferred compounds of the formula (I.16) are the compounds I.16-1 to I.16-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.16-1 to I.16-345 from table I.16 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00081##

[0260] Table I.17: Preferred compounds of the formula (I.17) are the compounds I.17-1 to I.17-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.17-1 to I.17-345 from table I.17 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00082##

[0261] Table I.18: Preferred compounds of the formula (I.18) are the compounds I.18-1 to I.18-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.18-1 to I.18-345 from table I.18 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00083##

[0262] Table I.19: Preferred compounds of the formula (I.19) are the compounds I.19-1 to I.19-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.19-1 to I.19-345 from table I.19 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table I.

##STR00084##

[0263] Table I.20: Preferred compounds of the formula (I.20) are the compounds I.20-1 to I.20-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.20-1 to I.20-345 from table I.20 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00085##

[0264] Table I.21: Preferred compounds of the formula (I.21) are the compounds I.21-1 to I.21-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.21-1 to I.21-345 from table I.21 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00086##

[0265] Table I.22: Preferred compounds of the formula (I.22) are the compounds I.22-1 to I.22-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.22-1 to I.22-345 from table I.22 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table I.

##STR00087##

[0266] Table I.23: Preferred compounds of the formula (I.23) are the compounds I.23-1 to I.23-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.23-1 to I.23-345 from table I.23 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00088##

[0267] Table I.24: Preferred compounds of the formula (I.24) are the compounds I.24-1 to I.24-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.24-1 to I.24-345 from table I.24 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table I.

##STR00089##

[0268] Table I.25: Preferred compounds of the formula (I.25) are the compounds I.25-1 to I.25-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.25-1 to I.25-345 from table I.25 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00090##

[0269] Table I.26: Preferred compounds of the formula (I.26) are the compounds I.26-1 to I.26-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.26-1 to I.26-345 from table I.26 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00091##

[0270] Table I.27: Preferred compounds of the formula (I.27) are the compounds I.27-1 to I.27-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.27-1 to I.27-345 from table I.27 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00092##

[0271] Table I.28: Preferred compounds of the formula (I.28) are the compounds I.28-1 to I.28-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.28-1 to I.28-345 from table I.28 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table I.

##STR00093##

[0272] Table I.29: Preferred compounds of the formula (I.29) are the compounds I.29-1 to I.29-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.29-1 to I.29-345 from table I.29 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00094##

[0273] Table I.30: Preferred compounds of the formula (I.30) are the compounds I.30-1 to I.30-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.30-1 to I.30-345 from table I.30 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00095##

[0274] Table I.31: Preferred compounds of the formula (I.31) are the compounds I.31-1 to I.31-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.31-1 to I.31-345 from table I.31 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00096##

[0275] Table I.32: Preferred compounds of the formula (I.32) are the compounds I.32-1 to I.32-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.32-1 to I.32-345 from table I.32 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table I.

##STR00097##

[0276] Table I.33: Preferred compounds of the formula (I.33) are the compounds I.33-1 to I.33-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.33-1 to I.33-345 from table I.33 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00098##

[0277] Table I.34: Preferred compounds of the formula (I.34) are the compounds I.34-1 to I.34-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.34-1 to I.34-345 from table I.34 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00099##

[0278] Table I.35: Preferred compounds of the formula (I.35) are the compounds I.35-1 to I.35-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.35-1 to I.35-345 from table I.35 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00100##

[0279] Table I.36: Preferred compounds of the formula (I.36) are the compounds I.36-1 to I.36-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.36-1 to I.36-345 from table I.36 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table I.

##STR00101##

[0280] Table I.37: Preferred compounds of the formula (I.37) are the compounds I.37-1 to I.37-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.37-1 to I.37-345 from table I.37 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00102##

[0281] Table I.38: Preferred compounds of the formula (I.38) are the compounds I.38-1 to I.38-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.38-1 to I.38-345 from table I.38 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00103##

[0282] Table I.39: Preferred compounds of the formula (I.39) are the compounds I.39-1 to I.39-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.39-1 to I.39-345 from table I.39 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00104##

[0283] Table I.40: Preferred compounds of the formula (I.40) are the compounds I.40-1 to I.40-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.40-1 to I.40-345 from table I.40 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table I.

##STR00105##

[0284] Table I.41: Preferred compounds of the formula (I.41) are the compounds I.41-1 to I.41-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.41-1 to I.41-345 from table I.41 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00106##

[0285] Table I.42: Preferred compounds of the formula (I.42) are the compounds I.42-1 to I.42-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.42-1 to I.42-345 from table I.42 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00107##

[0286] Table I.43: Preferred compounds of the formula (I.43) are the compounds I.43-1 to I.43-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.43-1 to I.43-345 from table I.43 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00108##

[0287] Table I.44: Preferred compounds of the formula (I.44) are the compounds I.44-1 to I.44-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.44-1 to I.44-345 from table I.44 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00109##

[0288] Table I.45: Preferred compounds of the formula (I.45) are the compounds I.45-1 to I.45-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.45-1 to I.45-345 from table I.45 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00110##

[0289] Table I.46: Preferred compounds of the formula (I.46) are the compounds I.46-1 to I.46-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.46-1 to I.46-345 from table I.46 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00111##

[0290] Table I.47: Preferred compounds of the formula (I.47) are the compounds I.47-1 to I.47-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.47-1 to I.47-345 from table I.47 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00112##

[0291] Table I.48: Preferred compounds of the formula (I.48) are the compounds I.48-1 to I.48-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.48-1 to I.48-345 from table I.48 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table I.

##STR00113##

[0292] Table I.49: Preferred compounds of the formula (I.49) are the compounds I.49-1 to I.49-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.49-1 to I.49-345 from table I.49 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00114##

[0293] Table I.50: Preferred compounds of the formula (I.50) are the compounds I.50-1 to I.50-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.50-1 to I.50-345 from table I.50 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00115##

[0294] Table I.51: Preferred compounds of the formula (I.51) are the compounds I.51-1 to I.51-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.51-1 to I.51-345 from table I.51 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00116##

[0295] Table I.52: Preferred compounds of the formula (I.52) are the compounds I.52-1 to I.52-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.52-1 to I.52-345 from table I.52 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table I.

##STR00117##

[0296] Table I.53: Preferred compounds of the formula (I.53) are the compounds I.53-1 to I.53-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.53-1 to I.53-345 from table I.53 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00118##

[0297] Table I.54: Preferred compounds of the formula (I.54) are the compounds I.54-1 to I.54-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.54-1 to I.54-345 from table I.54 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00119##

[0298] Table I.55: Preferred compounds of the formula (I.55) are the compounds I.55-1 to I.55-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.55-1 to I.55-345 from table I.55 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00120##

[0299] Table I.56: Preferred compounds of the formula (I.56) are the compounds I.56-1 to I.56-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.56-1 to I.56-345 from table I.56 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table I.

##STR00121##

[0300] Table I.57: Preferred compounds of the formula (I.57) are the compounds I.57-1 to I.57-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.57-1 to I.57-345 from table I.57 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00122##

[0301] Table I.58: Preferred compounds of the formula (I.58) are the compounds I.58-1 to I.58-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.58-1 to I.58-345 from table I.58 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00123##

[0302] Table I.59: Preferred compounds of the formula (I.59) are the compounds I.59-1 to I.59-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.59-1 to I.59-345 from table I.59 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

##STR00124##

[0303] Table I.60: Preferred compounds of the formula (I.60) are the compounds I.60-1 to I.60-345 in which Q has the definitions from table 1 that are given in the respective line. The compounds I.60-1 to I.60-345 from table I.60 are thus defined by the meaning of the respective entries No. 1 to 345 for Q from table 1.

[0304] NMR data of selected examples:

[0305] a) Conventional NMR interpretation

Example No. I.12-91

[0306] .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.52 (m, 1H), 7.34 (m, 1H), 4.12-4.08 (m, 1H), 4.06-3.89 (m, 2H), 3.77-3.72 (m, 1H), 3.54 (s, 3H), 3.51-3.34 (m, 2H), 2.24-2.20 (m, 3H), 2.03-1.93 (m, 1H), 1.90-1.79 (m, 2H), 1.58-1.47 (m, 3H), 1.31-1.23 (m, 2H), 1.07 (t, 3H).

Example No. I.12-221

[0307] .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.33 (m, 1H), 7.19 (m, 1H), 6.72 (br. m, 1H, NH), 3.91-3.77 (m, 1H), 3.75-3.69 (m, 1H), 3.67-3.62 (m, 2H), 3.55 (s, 3H), 3.51-3.40 (m, 1H), 3.21-3.08 (m, 1H), 2.24-2.20 (m, 3H), 2.09-2.02 (m, 1H), 1.96-1.70 (m, 4H), 1.49/1.33 (m, 1H), 1.12 (t, 3H).

Example No. I.14-71

[0308] .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.51 (m, 1H), 7.34 (m, 1H), 4.16-4.10 (m, 1H), 4.07-3.85 (m, 3H), 3.81-3.67 (m, 2H), 3.54 (s, 3H), 2.24-2.21 (m, 3H), 1.96-1.80 (m, 4H), 1.78-1.74 (m, 1H), 1.69-1.65 (m, 1H), 1.53-1.48 (m, 1H), 0.97-0.93 (m, 6H).

Example No. I.48-127

[0309] .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.48 (m, 1H), 7.32 (m, 1H), 6.29 (m, 1H), 4.19-4.14 (m, 1H), 3.92-3.70 (m, 3H), 3.59-3.54 (m, 1H), 3.53 (s, 3H), 3.11 (s, 2H), 1.84-1.75 (m, 2H), 1.66-1.59 (m, 2H), 1.31 (s, 6H).

Example No. I.54-241

[0310] .sup.1H-NMR (CDCl.sub.3δ, ppm) 7.33-7.27 (m, 2H), 6.73 (br. m, 1H, NH), 4.07-4.03 (m, 2H), 3.98-3.94 (m, 1H), 3.54 (s, 3H), 3.52-3.48 (m, 1H), 3.43-3.38 (m, 1H), 3.13 (s, 2H), 2.26-2.23 (m, 2H), 1.88-1.82 (m, 1H), 1.63-1.48 (m, 4H), 1.39-1.31 (m, 2H), 1.30 (s, 6H).

[0311] b) NMR Peak List Method

[0312] The .sup.1H NMR data of selected examples are stated in the form of .sup.1H NMR peak lists. For each signal peak, first the δ value in ppm and then the signal intensity in round brackets are listed. The δ value/signal intensity number pairs for different signal peaks are listed with separation from one another by semicolons. The peak list for an example therefore takes the following form:

δ.sub.1(intensity.sub.1); δ.sub.2(intensity.sub.2); . . . ; δ.sub.i(intensity.sub.i); . . . ; δ.sub.n(intensity.sub.n)

[0313] The intensity of sharp signals correlates with the height of the signals in a printed example of an NMR spectrum in cm and shows the true ratios of the signal intensities. In the case of broad signals, several peaks or the middle of the signal and the relative intensity thereof may be shown in comparison to the most intense signal in the spectrum. For calibration of the chemical shifts of .sup.1H NMR spectra we use tetramethylsilane and/or the chemical shift of the solvent, particularly in the case of spectra that are measured in DMSO. Therefore, the tetramethylsilane peak may, but need not, occur in NMR peak lists. The lists of the .sup.1H NMR peaks are similar to the conventional .sup.1H NMR printouts and thus usually contain all peaks listed in a conventional NMR interpretation. In addition, like conventional .sup.1H NMR printouts, they may show solvent signals, signals of stereoisomers of the target compounds which are likewise provided by the invention, and/or peaks of impurities. In the reporting of compound signals in the delta range of solvents and/or water, our lists of .sup.1H NMR peaks show the standard solvent peaks, for example peaks of DMSO in DMSO-D.sub.6 and the peak of water, which usually have a high intensity on average. The peaks of stereoisomers of the target compounds and/or peaks of impurities usually have a lower intensity on average than the peaks of the target compounds (for example with a purity of >90%). Such stereoisomers and/or impurities may be typical of the particular preparation process. Their peaks can thus help in identifying reproduction of our preparation process with reference to “by-product fingerprints”. An expert calculating the peaks of the target compounds by known methods (MestreC, ACD simulation, or using empirically evaluated expected values) can, if required, isolate the peaks of the target compounds, optionally using additional intensity filters. This isolation would be similar to the peak picking in question in conventional .sup.1H NMR interpretation. Further details of .sup.1H NMR peak lists can be found in Research Disclosure Database Number 564025.

Example No. I.1-1

[0314] .sup.1H-NMR (400.0 MHz, d.sub.6-DMSO): δ=7.8581 (5.0); 7.8343 (5.1); 7.7555 (4.4); 7.7521 (4.6); 7.7365 (4.4); 7.7330 (4.5); 6.6090 (7.8); 6.6018 (7.3); 4.1623 (1.3); 4.1529 (1.4); 4.1477 (1.6); 4.1380 (1.6); 4.1326 (3.0); 4.1234 (3.1); 4.1174 (3.8); 4.1082 (3.2); 4.0965 (2.2); 4.0861 (5.0); 4.0805 (6.1); 4.0760 (2.8); 4.0679 (4.8); 4.0629 (4.0); 4.0503 (2.0); 4.0461 (1.8); 4.0371 (0.7); 3.4700 (0.7); 3.4611 (1.1); 3.4410 (4.1); 3.4218 (22.0); 3.4092 (3.6); 3.4059 (2.9); 3.3896 (0.9); 3.3861 (0.9); 3.3670 (0.6); 3.3580 (1.4); 3.3420 (1.3); 3.3090 (340.3); 3.2586 (0.6); 3.1931 (66.1); 2.6739 (1.5); 2.6692 (2.1); 2.6648 (1.5); 2.5225 (11.0); 2.5092 (126.4); 2.5047 (249.2); 2.5002 (330.8); 2.4956 (234.6); 2.4912 (107.9); 2.3315 (1.5); 2.3270 (2.0); 2.3225 (1.4); 2.0719 (0.6); 1.4280 (16.0); 1.4108 (15.6); 1.2356 (1.4); 0.0079 (1.2);−0.0002 (23.5); −0.0086 (0.8).

Example No. I.1-2

[0315] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5397 (3.3); 7.5341 (3.2); 7.5209 (3.4); 7.5153 (3.2); 7.3790 (3.7); 7.3772 (3.6); 7.3563 (3.7); 7.3545 (3.6); 7.2715 (0.6); 7.2691 (0.8); 7.2601 (121.6); 6.9961 (0.7); 6.3470 (6.9); 4.2477 (0.6); 4.2422 (0.6); 4.2387 (0.7); 4.2330 (0.7); 4.2315 (0.8); 4.2259 (0.7); 4.2223 (0.7); 4.2179 (1.4); 4.2125 (1.4); 4.2091 (1.3); 4.2035 (1.5); 4.2017 (1.7); 4.1961 (1.6); 4.1926 (1.3); 4.1871 (1.3); 4.1659 (2.0); 4.1570 (2.4); 4.1520 (2.2); 4.1432 (2.2); 4.1363 (1.0); 4.1272 (1.0); 4.1225 (1.1); 4.1135 (1.0); 3.9568 (0.8); 3.9541 (0.8); 3.9390 (2.9); 3.9362 (3.0); 3.9211 (3.0); 3.9184 (3.0); 3.9033 (0.8); 3.9006 (0.8); 3.5776 (0.6); 3.5754 (0.6); 3.5685 (0.8); 3.5663 (0.9); 3.5638 (0.9); 3.5615 (1.0); 3.5525 (14.7); 3.5493 (16.0); 3.5466 (7.3); 3.5400 (2.0); 3.5377 (2.0); 3.5352 (2.1); 3.5330 (2.0); 3.5240 (3.9); 3.5150 (2.9); 3.5075 (2.5); 3.4986 (2.5); 3.4955 (1.2); 3.4916 (2.0); 3.4883 (2.3); 3.4789 (1.2); 3.4741 (6.2); 3.4708 (7.4); 3.4566 (6.5); 3.4533 (7.1); 3.4391 (2.2); 3.4358 (2.3); 1.5468 (4.2); 1.5375 (11.9); 1.5344 (11.9); 1.5196 (10.7); 1.5165 (11.0); 1.1773 (6.8); 1.1744 (7.2); 1.1598 (13.9); 1.1569 (14.6); 1.1422 (6.7); 1.1394 (6.9); 0.0080 (1.5); 0.0063 (0.6); 0.0055 (0.6); 0.0046 (0.7); −0.0002 (45.4); −0.0051 (0.8); −0.0059 (0.6); −0.0068 (0.5); −0.0085 (1.3)

Example No. I.1-6

[0316] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5328 (0.9); 7.5276 (0.9); 7.5181 (0.6); 7.5140 (0.9); 7.5088 (0.8); 7.3395 (0.9); 7.3367 (0.9); 7.3198 (2.1); 7.3173 (2.5); 7.3063 (2.3); 7.2982 (1.1); 7.2942 (2.2); 7.2800 (0.7); 7.2592 (78.8); 6.3060 (1.7); 4.4956 (2.9); 4.1932 (0.6); 4.1876 (0.6); 4.1792 (0.5); 3.9513 (0.6); 3.9463 (0.7); 3.9334 (0.7); 3.9284 (0.8); 3.6000 (0.6); 3.5914 (0.6); 3.5860 (0.6); 3.5774 (0.5); 3.5692 (0.6); 3.5607 (0.7); 3.5527 (0.6); 3.5442 (0.6); 3.5181 (3.4); 3.5148 (2.7); 1.5387 (3.1); 1.5363 (3.9); 1.5328 (16.0); 1.5209 (2.8); 1.5187 (2.8); 0.0080 (0.9); −0.0002 (28.4); −0.0085 (1.0)

Example No. I.1-23

[0317] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5409 (1.6); 7.5320 (1.5); 7.5220 (1.6); 7.5197 (0.5); 7.5132 (1.5); 7.3815 (1.8); 7.3797 (1.7); 7.3587 (1.8); 7.3569 (1.7); 7.2606 (50.8); 6.3467 (2.5); 6.3433 (2.6); 4.2511 (0.5); 4.2372 (0.6); 4.2307 (0.6); 4.2284 (0.6); 4.2212 (1.0); 4.2144 (0.8); 4.2119 (0.6); 4.2053 (0.6); 4.1845 (0.7); 4.1756 (0.8); 4.1745 (0.9); 4.1706 (0.8); 4.1616 (0.8); 3.9293 (1.3); 3.9244 (1.4); 3.9114 (1.3); 3.9065 (1.4); 3.6225 (0.7); 3.6192 (0.8); 3.6135 (0.7); 3.6100 (0.9); 3.6087 (0.9); 3.6052 (0.8); 3.5994 (0.7); 3.5962 (0.7); 3.5904 (1.1); 3.5861 (1.0); 3.5817 (2.0); 3.5794 (1.3); 3.5758 (2.1); 3.5720 (2.5); 3.5687 (2.6); 3.5644 (2.6); 3.5622 (3.1); 3.5579 (3.1); 3.5522 (7.2); 3.5492 (7.2); 3.5460 (3.2); 3.5093 (2.8); 3.5079 (2.9); 3.5019 (1.6); 3.4986 (1.4); 3.4952 (2.2); 3.4860 (1.3); 3.3571 (15.3); 3.3552 (16.0); 1.5520 (13.3); 1.5348 (5.1); 1.5322 (5.3); 1.5169 (5.0); 1.5143 (5.2); 0.0080 (0.6); −0.0002 (19.0); −0.0085 (0.6)

Example No. I.1-26

[0318] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.4990 (1.2); 7.4958 (1.2); 7.4803 (1.2); 7.4771 (1.2); 7.3772 (2.2); 7.3545 (2.2); 7.2599 (53.8); 6.3496 (3.4); 4.1628 (0.9); 4.1463 (1.9); 4.1422 (0.6); 4.1298 (1.7); 4.1261 (1.0); 4.1135 (0.5); 3.8961 (1.1); 3.8940 (1.1); 3.8783 (1.1); 3.8761 (1.1); 3.5553 (5.0); 3.5522 (5.2); 3.5491 (2.1); 3.3709 (2.2); 3.3551 (4.7); 3.3394 (2.2); 3.2888 (16.0); 1.8226 (1.1); 1.8197 (0.7); 1.8179 (0.7); 1.8067 (1.7); 1.8035 (1.0); 1.7909 (1.1); 1.7873 (0.7); 1.5428 (2.4); 1.5304 (4.5); 1.5290 (4.6); 1.5125 (4.4); 1.5112 (4.4); 0.0080 (0.7); −0.0002 (21.3); −0.0085 (0.6)

Example No. I.1-27

[0319] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5187 (1.0); 7.4987 (2.9); 7.4955 (2.9); 7.4799 (3.0); 7.4767 (2.9); 7.3753 (5.5); 7.3525 (5.4); 7.2598 (178.1); 6.9958 (1.0); 6.3486 (8.0); 4.2021 (0.6); 4.1857 (1.3); 4.1749 (2.0); 4.1694 (0.8); 4.1585 (3.8); 4.1521 (1.3); 4.1490 (1.2); 4.1422 (2.1); 4.1361 (2.4); 4.1329 (2.3); 4.1200 (1.3); 4.1168 (1.2); 4.1089 (0.8); 4.1057 (0.8); 3.9141 (0.7); 3.9104 (0.7); 3.8963 (2.4); 3.8924 (2.4); 3.8784 (2.4); 3.8746 (2.4); 3.8605 (0.7); 3.8567 (0.7); 3.5549 (12.8); 3.5519 (13.0); 3.4574 (3.1); 3.4399 (9.7); 3.4223 (10.0); 3.4127 (5.1); 3.4048 (3.6); 3.3969 (10.8); 3.3811 (5.2); 1.8436 (0.7); 1.8277 (2.5); 1.8247 (1.8); 1.8118 (3.6); 1.8086 (2.6); 1.7959 (2.4); 1.7923 (1.7); 1.7798 (0.6); 1.5391 (48.0); 1.5282 (11.1); 1.5271 (11.2); 1.5104 (10.8); 1.5093 (10.8); 1.1833 (8.1); 1.1657 (16.0); 1.1483 (7.7); 0.0080 (2.6); −0.0002 (68.8); −0.0085 (1.9)

Example No. I.1-30

[0320] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.4874 (2.6); 7.4843 (2.6); 7.4687 (2.6); 7.4656 (2.6); 7.3539 (0.9); 7.3482 (5.1); 7.3367 (1.8); 7.3324 (3.3); 7.3297 (3.5); 7.3254 (5.4); 7.3144 (8.6); 7.3083 (7.4); 7.2897 (2.2); 7.2858 (1.7); 7.2828 (1.2); 7.2753 (1.1); 7.2679 (2.5); 7.2589 (80.3); 6.3305 (4.0); 6.3262 (4.0); 4.4641 (13.0); 4.2120 (0.7); 4.2013 (1.0); 4.1992 (1.0); 4.1846 (2.0); 4.1775 (1.0); 4.1731 (1.0); 4.1687 (1.2); 4.1615 (1.9); 4.1571 (1.8); 4.1455 (1.2); 4.1410 (0.9); 4.1343 (0.6); 4.1299 (0.6); 3.8943 (0.5); 3.8880 (0.5); 3.8765 (1.8); 3.8701 (1.9); 3.8586 (1.9); 3.8523 (2.0); 3.8409 (0.6); 3.8345 (0.5); 3.5320 (5.7); 3.5290 (5.9); 3.5252 (3.6); 3.5209 (5.8); 3.5179 (5.8); 3.4740 (3.5); 3.4584 (7.6); 3.4428 (3.7); 1.8671 (1.3); 1.8640 (1.5); 1.8588 (1.2); 1.8513 (1.9); 1.8482 (2.1); 1.8429 (1.7); 1.8355 (1.3); 1.8325 (1.4); 1.8266 (1.1); 1.5396 (16.0); 1.5037 (9.4); 1.4858 (9.2); 0.0080 (0.9); −0.0002 (28.4); −0.0085 (1.1)

Example No. I.1-41

[0321] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5027 (2.8); 7.4969 (2.7); 7.4839 (2.8); 7.4781 (2.6); 7.3968 (4.7); 7.3741 (4.7); 7.2601 (75.4); 6.3476 (4.2); 6.3359 (4.5); 4.2864 (0.5); 4.2768 (0.5); 4.2691 (0.6); 4.2625 (1.2); 4.2552 (1.3); 4.2456 (1.4); 4.2380 (1.4); 4.2290 (0.7); 4.2205 (1.2); 4.2074 (1.4); 4.1987 (0.9); 4.1762 (0.5); 4.0936 (0.6); 4.0891 (0.7); 4.0858 (0.7); 4.0806 (0.8); 4.0758 (0.6); 4.0721 (0.5); 4.0648 (1.2); 4.0602 (1.4); 4.0571 (1.3); 4.0518 (1.7); 4.0462 (1.1); 4.0433 (1.1); 4.0392 (1.0); 4.0184 (1.3); 4.0158 (1.3); 4.0114 (1.2); 4.0080 (1.3); 4.0012 (1.3); 3.9991 (1.3); 3.9936 (2.0); 3.9819 (0.8); 3.9746 (3.3); 3.9569 (3.0); 3.9393 (1.0); 3.5485 (9.6); 3.5456 (13.2); 3.5424 (9.5); 1.5641 (16.0); 1.5510 (10.5); 1.5489 (10.7); 1.5331 (9.8); 1.5311 (10.0); 0.0080 (1.0); −0.0002 (28.5); −0.0084 (1.1)

Example No. I.1-48

[0322] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.4827 (3.6); 7.4756 (3.6); 7.4640 (3.7); 7.4569 (3.6); 7.3941 (6.3); 7.3714 (6.3); 7.2601 (69.5); 6.3516 (6.0); 6.3465 (6.1); 4.1836 (0.6); 4.1683 (0.9); 4.1641 (0.9); 4.1556 (1.4); 4.1514 (1.6); 4.1401 (2.1); 4.1361 (2.3); 4.1247 (2.4); 4.1206 (1.8); 4.1188 (1.7); 4.1091 (2.3); 4.1033 (2.1); 4.0938 (1.6); 4.0881 (1.4); 4.0810 (0.9); 4.0753 (0.9); 4.0600 (0.5); 3.9536 (0.9); 3.9482 (0.9); 3.9357 (3.1); 3.9304 (3.2); 3.9179 (3.2); 3.9126 (3.3); 3.9001 (0.9); 3.8948 (0.9); 3.5521 (16.0); 2.8422 (2.3); 2.8233 (4.3); 2.8052 (2.6); 1.9510 (0.9); 1.9339 (2.6); 1.9170 (3.7); 1.9006 (2.5); 1.8826 (0.7); 1.5430 (9.4); 1.5355 (14.1); 1.5333 (14.2); 1.5177 (13.0); 1.5155 (13.3); 0.0080 (1.4); −0.0002 (41.0); −0.0085 (1.3)

Example No. I.1-51

[0323] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5376 (1.7); 7.5324 (1.7); 7.5189 (1.8); 7.5132 (3.6); 7.4940 (2.3); 7.3769 (3.6); 7.3724 (2.8); 7.3541 (3.6); 7.3496 (2.8); 7.2609 (45.7); 6.3468 (6.2); 4.1354 (0.6); 4.1307 (0.7); 4.1257 (0.7); 4.1207 (0.6); 4.1067 (0.9); 4.1020 (0.9); 4.0969 (0.9); 4.0920 (0.9); 4.0259 (2.8); 4.0221 (3.5); 4.0150 (1.9); 4.0108 (2.8); 4.0085 (2.3); 3.9867 (1.0); 3.9839 (1.1); 3.9722 (1.1); 3.9693 (1.6); 3.9581 (0.8); 3.9552 (0.9); 3.9512 (2.2); 3.9428 (2.0); 3.9333 (2.2); 3.9267 (1.6); 3.9246 (1.6); 3.9155 (0.7); 3.5506 (12.7); 3.4955 (0.6); 3.4856 (0.6); 3.4804 (0.8); 3.4702 (0.8); 3.4648 (0.7); 3.4548 (0.6); 3.4459 (0.6); 3.4315 (0.9); 3.4301 (0.9); 3.4179 (0.8); 3.4157 (0.9); 3.4020 (0.5); 3.3119 (11.2); 3.3079 (11.9); 3.2969 (16.0); 3.2954 (15.9); 3.2888 (1.2); 1.5673 (3.6); 1.5440 (12.3); 1.5261 (12.0); 1.0981 (9.4); 1.0819 (11.4); 1.0685 (4.4); 1.0647 (4.6); 0.0080 (0.5); −0.0002 (18.6); −0.0085 (0.6)

Example No. I.1-71

[0324] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5648 (2.1); 7.5583 (2.1); 7.5460 (2.2); 7.5394 (2.2); 7.5304 (3.9); 7.5195 (0.7); 7.5116 (3.9); 7.3735 (5.1); 7.3507 (5.1); 7.3107 (0.6); 7.2687 (0.6); 7.2679 (0.6); 7.2671 (0.7); 7.2663 (0.9); 7.2654 (1.1); 7.2646 (1.4); 7.2606 (89.1); 7.2542 (1.4); 7.2533 (1.2); 7.2525 (1.0); 7.2517 (0.9); 7.2509 (0.9); 7.2501 (0.8); 7.2493 (0.7); 7.2485 (0.7); 7.2477 (0.6); 7.2469 (0.6); 7.2461 (0.6); 7.2453 (0.6); 7.2445 (0.5); 7.2437 (0.5); 6.9965 (0.5); 6.3436 (7.1); 4.1548 (1.0); 4.1460 (1.3); 4.1445 (1.2); 4.1358 (1.2); 4.1270 (1.3); 4.1180 (1.8); 4.1082 (1.5); 4.0605 (0.9); 4.0522 (1.6); 4.0444 (1.5); 4.0346 (2.2); 4.0286 (2.3); 4.0216 (2.0); 4.0178 (2.8); 4.0117 (2.3); 4.0080 (2.6); 4.0015 (2.7); 3.9908 (3.0); 3.9877 (3.0); 3.9805 (1.7); 3.9784 (1.9); 3.9755 (2.6); 3.9722 (1.7); 3.9676 (0.9); 3.9632 (1.9); 3.9593 (3.6); 3.9476 (1.2); 3.9441 (1.5); 3.9412 (3.5); 3.9235 (3.8); 3.9057 (3.1); 3.8879 (0.9); 3.8365 (0.5); 3.8324 (0.5); 3.8292 (0.5); 3.8274 (0.6); 3.8196 (0.8); 3.8154 (1.6); 3.8117 (1.7); 3.8063 (1.2); 3.8033 (0.7); 3.7989 (1.6); 3.7946 (1.8); 3.7912 (1.9); 3.7892 (1.7); 3.7826 (0.8); 3.7783 (0.7); 3.7748 (0.9); 3.7571 (0.6); 3.7533 (0.7); 3.7421 (1.2); 3.7372 (1.5); 3.7242 (1.6); 3.7214 (1.9); 3.7194 (1.9); 3.7086 (0.7); 3.7033 (1.4); 3.6985 (0.8); 3.5505 (14.1); 3.5475 (16.0); 3.5442 (9.5); 1.9589 (0.6); 1.9549 (0.6); 1.9512 (0.6); 1.9468 (0.8); 1.9422 (0.9); 1.9390 (0.8); 1.9294 (1.1); 1.9257 (1.2); 1.9212 (1.1); 1.9124 (0.8); 1.9085 (1.6); 1.9018 (1.3); 1.8974 (1.1); 1.8883 (1.6); 1.8853 (1.4); 1.8821 (1.6); 1.8801 (1.6); 1.8729 (1.5); 1.8701 (2.0); 1.8665 (2.0); 1.8622 (1.6); 1.8578 (1.6); 1.8534 (2.0); 1.8497 (2.3); 1.8459 (1.6); 1.8368 (1.8); 1.8323 (1.6); 1.8281 (1.0); 1.8237 (0.9); 1.8190 (1.1); 1.8110 (0.7); 1.8023 (0.7); 1.5444 (7.3); 1.5401 (14.1); 1.5367 (8.6); 1.5265 (8.0); 1.5222 (14.2); 1.5189 (8.9); 1.5093 (1.5); 1.5068 (1.5); 1.5008 (1.4); 1.4894 (1.1); 1.4827 (0.8); 1.4718 (0.6); 0.0079 (1.0); −0.0002 (34.7);−0.0051 (0.8); −0.0060 (0.7); −0.0068 (0.6); −0.0085 (1.3)

Example No. I.1-72

[0325] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5183 (2.8); 7.4878 (2.2); 7.4839 (4.0); 7.4690 (2.2); 7.4652 (4.0); 7.3851 (4.2); 7.3789 (0.5); 7.3624 (4.3); 7.3095 (0.6); 7.2780 (0.8); 7.2772 (0.8); 7.2755 (1.0); 7.2748 (1.1); 7.2740 (1.1); 7.2731 (1.3); 7.2724 (1.4); 7.2715 (1.6); 7.2707 (1.9); 7.2699 (2.3); 7.2692 (2.6); 7.2684 (2.9); 7.2675 (3.4); 7.2667 (4.1); 7.2659 (5.1); 7.2651 (6.2); 7.2594 (494.5); 7.2481 (1.6); 7.2474 (1.5); 7.2466 (1.3); 7.2458 (1.0); 7.2450 (1.0); 7.2442 (0.9); 7.2434 (0.8); 7.2426 (0.8); 7.2418 (0.7); 7.2402 (0.6); 7.2379 (0.7); 7.2313 (0.5); 7.2290 (0.6); 7.2100 (1.2); 6.9954 (2.9); 6.3491 (8.5); 4.1065 (0.7); 4.0954 (0.7); 4.0900 (0.8); 4.0790 (1.4); 4.0684 (1.0); 4.0629 (1.1); 4.0584 (0.7); 4.0516 (1.1); 4.0423 (0.6); 4.0379 (0.6); 4.0315 (1.2); 4.0271 (1.3); 4.0153 (1.2); 4.0108 (1.2); 3.9912 (1.8); 3.9716 (1.8); 3.9643 (0.9); 3.9524 (1.2); 3.9496 (1.3); 3.9452 (1.3); 3.9331 (1.4); 3.9280 (2.1); 3.9250 (2.5); 3.9191 (2.7); 3.9100 (1.8); 3.9068 (2.3); 3.9014 (2.9); 3.8890 (0.6); 3.8833 (0.7); 3.8324 (0.7); 3.8116 (1.8); 3.7979 (1.8); 3.7776 (1.1); 3.7698 (1.4); 3.7521 (1.9); 3.7476 (1.7); 3.7351 (2.1); 3.7304 (2.9); 3.7165 (2.2); 3.7129 (2.3); 3.6993 (1.3); 3.6927 (1.3); 3.6723 (0.5); 3.5527 (15.6); 3.5498 (16.0); 3.4694 (1.4); 3.4561 (2.8); 3.4470 (1.4); 3.4425 (1.8); 3.4340 (2.5); 3.4205 (1.3); 2.4781 (0.7); 2.4607 (1.1); 2.4446 (1.1); 2.4253 (0.8); 2.0052 (0.5); 1.9926 (0.6); 1.9854 (0.6); 1.9719 (1.1); 1.9592 (1.0); 1.9530 (1.0); 1.9404 (1.1); 1.9271 (0.6); 1.9206 (0.6); 1.7155 (0.6); 1.5875 (4.4); 1.5610 (2.2); 1.5356 (17.2); 1.5178 (16.6); 1.4932 (0.5); 0.1462 (0.6); 0.0080 (6.1); 0.0064 (2.8); −0.0002 (180.8); −0.0067 (2.5);−0.0085 (5.4); −0.1495 (0.6)

Example No. I.1-73

[0326] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5193 (0.8); 7.4895 (0.9); 7.4869 (1.1); 7.4844 (1.8); 7.4795 (3.2); 7.4708 (1.0); 7.4682 (1.1); 7.4657 (1.8); 7.4607 (3.2); 7.3851 (4.5); 7.3814 (1.9); 7.3624 (4.4); 7.3585 (1.9); 7.2750 (0.5); 7.2742 (0.6); 7.2734 (0.6); 7.2726 (0.7); 7.2718 (0.8); 7.2710 (0.8); 7.2702 (0.9); 7.2694 (1.0); 7.2686 (1.1); 7.2677 (1.3); 7.2670 (1.5); 7.2661 (1.8); 7.2603 (139.3); 6.9964 (0.8); 6.3486 (9.3); 4.1031 (0.5); 4.0985 (0.5); 4.0877 (0.8); 4.0760 (0.9); 4.0713 (0.8); 4.0590 (1.0); 4.0521 (0.6); 4.0406 (0.6); 4.0361 (0.7); 4.0325 (0.5); 4.0250 (1.7); 4.0092 (2.1); 3.9949 (2.6); 3.9840 (0.8); 3.9767 (2.3); 3.9683 (0.7); 3.9637 (1.1); 3.9579 (1.5); 3.9530 (1.1); 3.9498 (1.2); 3.9450 (0.9); 3.9362 (2.8); 3.9314 (2.1); 3.9271 (1.5); 3.9245 (1.8); 3.9225 (2.5); 3.9182 (3.5); 3.9094 (1.8); 3.9066 (2.2); 3.9046 (2.8); 3.9004 (3.4); 3.8940 (1.0); 3.8896 (1.2); 3.8857 (1.9); 3.8828 (1.4); 3.8679 (0.6); 3.6971 (0.6); 3.6843 (0.6); 3.6787 (0.8); 3.5981 (0.8); 3.5911 (0.7); 3.5848 (0.9); 3.5765 (1.0); 3.5686 (0.7); 3.5534 (15.6); 3.5505 (16.0); 3.3818 (0.6); 3.3786 (0.6); 3.3674 (1.0); 3.3627 (0.7); 3.3595 (0.6); 3.3543 (0.8); 3.3448 (0.8); 3.3404 (0.6); 3.3313 (0.6); 2.5282 (0.5); 2.5223 (0.6); 2.5073 (0.7); 2.4890 (0.6); 1.7064 (0.7); 1.6903 (0.8); 1.6868 (0.7); 1.6746 (1.1); 1.6702 (0.6); 1.6580 (0.6); 1.5762 (0.9); 1.5595 (7.6); 1.5442 (1.5); 1.5322 (15.1); 1.5144 (14.7); 1.2426 (6.2); 1.2399 (3.3); 1.2275 (6.1); 1.2248 (3.3); 1.2021 (8.5); 1.1992 (5.0); 1.1869 (8.4); 1.1839 (4.9); 1.0629 (0.6); 1.0432 (0.6); 1.0403 (0.5); 0.0079 (1.6);−0.0002 (54.8); −0.0085 (1.6)

Example No. I.1-81

[0327] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5311 (2.7); 7.5180 (2.7); 7.5118 (4.1); 7.4916 (1.8); 7.3745 (5.4); 7.3517 (5.4); 7.3093 (1.6); 7.2594 (297.8); 7.2136 (0.9); 6.9955 (1.6); 6.3558 (5.1); 6.3475 (5.4); 4.1135 (1.2); 4.0857 (2.7); 4.0666 (2.5); 4.0176 (2.3); 4.0013 (2.4); 3.9901 (2.4); 3.9772 (1.4); 3.9613 (0.9); 3.9427 (0.6); 3.9253 (1.6); 3.9068 (2.0); 3.8960 (1.8); 3.8879 (2.1); 3.8777 (1.6); 3.8699 (1.8); 3.5557 (16.0); 3.5111 (1.5); 3.4935 (2.1); 3.4817 (1.6); 2.8256 (2.4); 2.8090 (2.1); 2.7901 (2.6); 1.9569 (5.4); 1.9482 (5.7); 1.6795 (1.9); 1.6640 (1.8); 1.6533 (1.6); 1.5497 (49.4); 1.5290 (13.9); 0.1467 (0.6);−0.0002 (129.8); −0.1494 (0.7)

Example No. I.1-82

[0328] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5179 (1.1); 7.4941 (2.9); 7.4756 (3.0); 7.3892 (3.7); 7.3666 (3.6); 7.2595 (165.1); 6.9954 (0.9); 6.3516 (6.1); 4.1319 (0.5); 4.1180 (0.8); 4.1045 (1.1); 4.0908 (1.3); 4.0744 (0.8); 4.0547 (1.6); 4.0419 (2.1); 4.0245 (2.2); 3.9976 (1.4); 3.9690 (0.6); 3.9377 (1.6); 3.9213 (2.5); 3.9036 (1.9); 3.8870 (0.5); 3.5556 (16.0); 2.8500 (3.8); 2.8339 (6.8); 2.8171 (5.2); 2.5355 (1.4); 2.5181 (1.8); 2.4916 (1.3); 2.4363 (0.9); 2.4180 (1.5); 2.4008 (1.3); 2.3827 (0.9); 2.0651 (1.0); 2.0502 (1.3); 2.0365 (1.4); 2.0204 (1.1); 1.6453 (1.4); 1.5544 (27.5); 1.5408 (13.6); 1.5226 (10.6); −0.0002 (71.3)

Example No. I.1-89

[0329] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5182 (2.0); 7.5134 (2.7); 7.5047 (2.6); 7.4945 (2.7); 7.4861 (2.6); 7.3909 (5.0); 7.3682 (4.8); 7.3098 (0.6); 7.2595 (347.3); 7.2263 (0.5); 7.2100 (0.7); 6.9954 (1.8); 6.3503 (4.3); 6.3446 (4.4); 4.7259 (1.4); 4.7202 (1.6); 4.7104 (2.8); 4.7062 (3.1); 4.6949 (1.7); 4.6906 (2.9); 4.6866 (1.8); 4.6753 (1.4); 4.3843 (2.1); 4.3689 (4.1); 4.3591 (1.5); 4.3534 (2.2); 4.3467 (2.7); 4.3435 (2.6); 4.3281 (1.4); 4.3121 (0.9); 4.3031 (0.8); 4.2948 (0.8); 4.2837 (1.6); 4.2749 (1.8); 4.2674 (1.7); 4.2584 (1.8); 4.2433 (1.7); 4.2392 (1.7); 4.2276 (1.8); 4.2236 (1.8); 4.2153 (0.8); 4.1956 (0.8); 3.9493 (0.6); 3.9346 (2.0); 3.9311 (2.4); 3.9168 (2.2); 3.9132 (2.2); 3.8990 (0.7); 3.5515 (12.5); 3.5487 (12.5); 3.1880 (1.0); 3.1724 (1.5); 3.1563 (0.9); 1.5667 (5.0); 1.5452 (16.0); 1.5274 (14.7); 1.2669 (0.8); 0.8820 (1.0); 0.1460 (0.6); 0.0080 (4.0); −0.0002 (126.5); −0.0084 (3.8); −0.1496 (0.6)

Example No. I.1-91

[0330] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5528 (1.1); 7.5434 (1.2); 7.5330 (2.3); 7.5265 (2.1); 7.5181 (1.8); 7.5083 (1.4); 7.3756 (1.9); 7.3656 (2.5); 7.3526 (2.2); 7.3431 (2.1); 7.3130 (0.8); 7.2595 (197.6); 7.2135 (1.0); 6.9954 (1.1); 6.3487 (7.2); 4.0925 (0.8); 4.0837 (0.9); 4.0641 (1.5); 4.0550 (1.8); 4.0285 (0.9); 4.0203 (0.9); 4.0092 (0.9); 3.9982 (1.5); 3.9819 (1.4); 3.9662 (2.0); 3.9615 (2.1); 3.9529 (2.9); 3.9434 (3.2); 3.9258 (3.2); 3.9072 (2.1); 3.5538 (16.0); 3.4639 (0.8); 3.4354 (0.8); 3.3991 (1.7); 3.3722 (2.0); 3.3463 (0.9); 1.8363 (1.4); 1.5449 (26.8); 1.5223 (8.9); 1.5142 (7.9); 1.4866 (6.0); 1.4542 (2.1); 1.2517 (1.0); 1.2373 (1.0); −0.0002 (85.0)

Example No. I.1-92

[0331] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5181 (1.6); 7.4892 (2.8); 7.4703 (2.8); 7.3852 (4.0); 7.3621 (3.6); 7.2594 (272.3); 7.2084 (0.7); 7.1515 (0.6); 6.9953 (1.5); 6.3492 (7.7); 4.0194 (0.7); 4.0045 (0.7); 3.9914 (1.0); 3.9773 (1.1); 3.9379 (1.5); 3.9261 (2.0); 3.9099 (3.0); 3.8903 (3.0); 3.8588 (1.2); 3.8120 (3.2); 3.7833 (3.1); 3.5527 (16.0); 3.3939 (1.0); 3.3671 (1.5); 3.1633 (1.2); 3.1414 (2.0); 3.1126 (1.0); 1.8568 (1.1); 1.7483 (1.2); 1.7243 (1.3); 1.5854 (4.1); 1.5751 (4.6); 1.5470 (45.8); 1.5325 (14.5); 1.5145 (11.1); 1.2355 (1.0); 0.1470 (0.6); −0.0002 (115.4); −0.1493 (0.5)

Example No. I.1-94

[0332] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5301 (1.6); 7.5254 (1.6); 7.5186 (1.7); 7.5162 (1.8); 7.5114 (1.7); 7.5067 (1.7); 7.4975 (1.7); 7.3653 (3.8); 7.3425 (3.8); 7.3095 (0.6); 7.2783 (0.5); 7.2759 (0.6); 7.2751 (0.7); 7.2743 (0.7); 7.2735 (0.8); 7.2727 (0.8); 7.2719 (1.0); 7.2711 (1.0); 7.2703 (1.2); 7.2695 (1.3); 7.2687 (1.5); 7.2679 (1.7); 7.2671 (1.9); 7.2663 (2.1); 7.2655 (2.5); 7.2647 (3.0); 7.2639 (4.0); 7.2630 (5.6); 7.2598 (228.0); 7.2549 (3.3); 7.2541 (2.4); 7.2533 (1.7); 7.2525 (1.2); 7.2517 (0.8); 7.2509 (0.6); 7.2501 (0.6); 7.2493 (0.6); 7.2485 (0.6); 6.9957 (1.3); 6.3491 (5.8); 5.0568 (0.6); 5.0518 (1.1); 5.0464 (0.7); 5.0407 (0.9); 5.0358 (1.2); 5.0297 (0.7); 5.0255 (0.9); 3.9219 (0.9); 3.9155 (0.9); 3.9040 (1.0); 3.8976 (1.1); 3.8943 (0.7); 3.8761 (2.1); 3.8581 (2.2); 3.8401 (0.6); 3.5522 (10.4); 3.4128 (0.6); 3.3966 (2.0); 3.3869 (1.3); 3.3813 (1.3); 3.3698 (3.4); 3.3545 (2.0); 3.3453 (0.6); 3.3407 (1.3); 3.3370 (1.8); 3.3297 (1.0); 3.3273 (1.0); 3.3063 (10.9); 3.3039 (11.5); 3.2975 (16.0); 3.2950 (15.8); 3.2905 (1.5); 3.2856 (1.3); 3.2800 (1.1); 3.2755 (1.2); 3.2635 (0.7); 3.2589 (0.8); 3.2534 (0.7); 3.2486 (0.8); 2.0223 (0.6); 1.5634 (6.4); 1.5379 (5.7); 1.5356 (6.0); 1.5319 (4.4); 1.5296 (4.3); 1.5200 (5.6); 1.5177 (5.8); 1.5140 (4.2); 1.5118 (4.0); 1.2572 (0.5); 1.2408 (0.8); 1.2244 (0.6); 1.1974 (5.6); 1.1937 (5.8); 1.1812 (5.5); 1.1775 (5.7); 1.1180 (7.3); 1.1018 (7.3); 0.2376 (0.6); 0.1262 (0.8); 0.0079 (2.9); 0.0063 (1.0); 0.0054 (1.1); 0.0046 (1.3); −0.0002 (93.0); −0.0052 (1.4); −0.0060 (1.1); −0.0068 (0.9); −0.0085 (2.6)

Example No. I.1-115

[0333] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.8084 (0.6); 7.5230 (4.8); 7.5183 (2.4); 7.5153 (4.8); 7.5092 (0.9); 7.5042 (4.8); 7.4965 (4.6); 7.4017 (9.3); 7.3790 (9.4); 7.3597 (0.9); 7.3085 (1.1); 7.2595 (339.3); 6.9955 (1.9); 6.3673 (0.7); 6.3552 (7.8); 6.3496 (7.6); 5.3758 (0.6); 5.3679 (1.4); 5.3647 (1.7); 5.3599 (1.6); 5.3519 (2.9); 5.3471 (3.1); 5.3389 (1.6); 5.3345 (1.9); 5.3313 (1.6); 5.3233 (0.8); 4.8455 (2.8); 4.8293 (4.9); 4.8127 (4.3); 4.7994 (1.6); 4.5397 (1.6); 4.5271 (3.1); 4.5249 (3.1); 4.5204 (1.6); 4.5147 (1.8); 4.5077 (2.9); 4.4915 (3.0); 4.4811 (2.9); 4.4713 (2.2); 4.4591 (1.4); 3.9656 (1.2); 3.9558 (1.1); 3.9476 (3.7); 3.9380 (3.9); 3.9298 (3.8); 3.9201 (4.0); 3.9121 (1.1); 3.9023 (1.2); 3.5543 (16.0); 3.5495 (13.0); 2.0790 (0.9); 2.0688 (1.2); 2.0047 (3.4); 1.5836 (3.5); 1.5508 (25.8); 1.5329 (25.1); 0.3306 (0.6); 0.1573 (0.6); 0.0080 (3.5); −0.0002 (134.8); −0.0085 (4.5)

Example No. I.1-117

[0334] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5259 (0.6); 7.5186 (0.6); 7.5072 (0.6); 7.4956 (0.6); 7.4870 (0.6); 7.4826 (0.6); 7.4769 (0.6); 7.4684 (0.6); 7.4640 (0.6); 7.4392 (1.1); 7.4329 (0.7); 7.4163 (1.0); 7.4104 (0.7); 7.2597 (104.1); 6.9957 (0.6); 6.3581 (1.0); 6.3453 (1.6); 6.3306 (1.0); 5.2985 (8.4); 3.9819 (0.6); 3.9787 (0.6); 3.9687 (0.6); 3.9641 (0.7); 3.9613 (0.9); 3.9508 (0.6); 3.9441 (1.0); 3.9357 (1.0); 3.9211 (0.8); 3.5511 (5.3); 3.5487 (5.1); 2.8421 (0.5); 2.1697 (1.1); 2.0958 (0.5); 2.0862 (0.6); 1.5467 (2.1); 1.5352 (16.0); 1.5292 (3.0); 1.5218 (3.5); 1.5174 (2.1); 0.0080 (1.3); −0.0002 (40.8); −0.0085 (1.4)

Example No. I.1-123

[0335] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5966 (0.8); 7.5854 (0.8); 7.5779 (0.9); 7.5665 (0.9); 7.5255 (0.9); 7.5216 (1.2); 7.5183 (1.8); 7.5071 (0.9); 7.5031 (1.0); 7.3788 (1.7); 7.3703 (1.2); 7.3561 (1.7); 7.3477 (1.1); 7.2930 (0.6); 7.2593 (294.4); 6.9954 (1.6); 6.3536 (2.2); 6.3470 (2.8); 3.9044 (0.7); 3.8941 (0.7); 3.8865 (0.7); 3.8762 (0.8); 3.8534 (0.7); 3.8459 (0.8); 3.8353 (0.7); 3.8282 (0.8); 3.5519 (7.0); 3.0675 (0.6); 3.0488 (0.7); 3.0371 (0.9); 3.0189 (0.6); 2.8549 (1.9); 2.8464 (1.3); 2.8428 (1.2); 2.8346 (1.9); 2.8257 (1.3); 2.8052 (1.0); 2.7905 (0.5); 2.7743 (0.6); 1.5551 (3.6); 1.5477 (4.5); 1.5367 (16.0); 1.5134 (4.3); 1.2655 (1.1); 0.8988 (0.6); 0.8819 (1.6); 0.8641 (0.6); 0.0079 (3.7); −0.0002 (107.4); −0.0085 (4.1)

Example No. I.1-126

[0336] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5920 (2.0); 7.5867 (1.9); 7.5736 (1.9); 7.5181 (2.0); 7.5107 (1.2); 7.4945 (2.0); 7.4761 (1.4); 7.3759 (3.3); 7.3532 (3.6); 7.2594 (316.3); 7.2141 (0.7); 6.9955 (1.8); 6.3441 (10.1); 4.7357 (1.6); 3.9424 (2.3); 3.9244 (3.0); 3.9096 (1.8); 3.6768 (1.3); 3.6471 (2.2); 3.6068 (2.5); 3.5905 (3.6); 3.5715 (4.9); 3.5506 (16.0); 3.5289 (6.2); 3.4839 (0.8); 3.4396 (0.9); 3.4249 (0.6); 1.8265 (1.6); 1.8031 (1.6); 1.7739 (2.0); 1.7149 (1.4); 1.5630 (9.0); 1.5470 (55.4); 1.5208 (10.0); 0.1458 (0.7);−0.0002 (137.6); −0.1497 (0.7)

Example No. I.1-132

[0337] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5182 (1.4); 7.5010 (2.2); 7.4896 (2.3); 7.4827 (2.3); 7.4715 (2.1); 7.3819 (3.6); 7.3591 (3.8); 7.3124 (1.6); 7.2594 (213.2); 7.2153 (1.1); 6.9956 (1.1); 6.3504 (7.4); 4.7940 (1.4); 4.7811 (1.5); 3.9550 (1.0); 3.9373 (3.0); 3.9193 (3.0); 3.9020 (1.0); 3.5544 (16.0); 2.7431 (0.8); 2.7181 (1.9); 2.6910 (2.2); 2.5674 (2.0); 2.5412 (2.4); 2.5096 (1.5); 2.1702 (0.5); 2.0291 (1.2); 2.0198 (1.1); 2.0070 (1.5); 1.9725 (0.9); 1.9404 (1.3); 1.9205 (1.1); 1.8450 (0.7); 1.8253 (1.3); 1.8131 (1.0); 1.8012 (1.2); 1.7709 (0.8); 1.7230 (1.2); 1.5587 (29.7); 1.5392 (14.2); 1.5214 (12.4); 0.0528 (0.7);−0.0002 (92.1); −0.0454 (0.6)

Example No. I.1-142

[0338] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5184 (1.3); 7.4905 (2.1); 7.4812 (2.2); 7.4720 (2.2); 7.4627 (2.2); 7.4273 (2.2); 7.4205 (2.2); 7.4048 (2.2); 7.3979 (2.2); 7.3096 (0.6); 7.2595 (226.6); 7.2254 (0.8); 6.9955 (1.3); 6.3472 (3.7); 6.3422 (3.6); 5.2984 (12.2); 4.9774 (1.2); 3.9975 (0.6); 3.9796 (2.0); 3.9769 (1.9); 3.9617 (2.0); 3.9590 (1.9); 3.9440 (0.6); 3.5489 (10.1); 3.0588 (0.6); 3.0466 (0.6); 3.0242 (1.4); 3.0099 (1.1); 3.0000 (1.1); 2.9869 (1.0); 2.9305 (0.9); 2.8930 (1.2); 2.8673 (0.5); 2.8547 (0.5); 2.2702 (0.8); 2.2610 (1.2); 2.2445 (1.8); 2.2342 (1.8); 2.2057 (0.6); 2.1947 (1.0); 2.1836 (1.5); 2.1695 (4.0); 2.1586 (1.3); 1.5737 (6.8); 1.5695 (6.8); 1.5558 (7.3); 1.5516 (7.4); 1.5356 (16.0); 0.0079 (3.3); −0.0002 (88.9); −0.0085 (3.5)

Example No. I.1-151

[0339] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.3604 (2.4); 7.3586 (2.3); 7.3379 (2.4); 7.3361 (2.3); 7.2630 (22.6); 7.2368 (1.9); 7.2187 (1.9); 7.2114 (1.9); 7.1932 (1.9); 6.7339 (0.5); 6.3406 (3.2); 6.3333 (3.2); 3.8154 (1.4); 3.8079 (1.4); 3.7973 (1.4); 3.7897 (1.4); 3.5487 (4.7); 3.5456 (6.0); 3.5422 (6.1); 3.5390 (4.8); 3.4893 (1.0); 3.4764 (1.1); 3.4388 (0.6); 3.4239 (0.5); 3.4159 (0.8); 3.4098 (0.8); 3.4057 (0.6); 3.3974 (0.6); 3.3916 (0.6); 3.3854 (0.6); 3.3806 (1.2); 3.3668 (1.6); 3.3581 (0.7); 3.3563 (0.7); 3.3499 (1.1); 3.3469 (1.0); 3.3411 (1.3); 3.3251 (1.2); 3.3223 (0.9); 3.3112 (1.7); 3.3082 (1.5); 3.3053 (1.0); 3.2987 (1.5); 3.2917 (1.1); 3.2482 (16.0); 3.2424 (15.6); 2.9549 (1.0); 2.8831 (0.8); 1.6180 (1.5); 1.6002 (5.8); 1.5967 (6.0); 1.5820 (5.8); 1.5785 (5.9); −0.0002 (8.3)

Example No. I.1-180

[0340] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5182 (3.6); 7.3517 (1.1); 7.3442 (2.5); 7.3320 (3.1); 7.3156 (5.2); 7.3092 (4.5); 7.2941 (7.2); 7.2903 (7.2); 7.2766 (4.7); 7.2593 (628.6); 7.2325 (0.6); 7.1698 (1.8); 7.1518 (2.0); 7.1418 (2.0); 7.1237 (1.9); 6.9953 (4.0); 6.3321 (3.4); 6.3235 (3.2); 4.4545 (5.6); 4.4451 (5.7); 3.7489 (1.6); 3.7334 (1.6); 3.7120 (0.6); 3.5363 (5.1); 3.5335 (5.1); 3.5249 (5.1); 3.5221 (4.8); 3.4862 (0.8); 3.4815 (1.0); 3.4687 (1.5); 3.4567 (1.7); 3.4430 (0.9); 3.4358 (0.9); 3.3465 (1.6); 3.3321 (2.2); 3.3165 (1.8); 3.3014 (0.8); 1.7126 (1.6); 1.5514 (16.0); 1.5474 (13.1); 1.5331 (7.9); 1.5291 (7.2); 0.1460 (0.9); 0.0846 (0.7); 0.0496 (1.2); 0.0079 (8.1); −0.0002 (232.9); −0.0084 (8.3); −0.1497 (0.9)

Example No. I.1-181

[0341] .sup.1H-NMR (400.0 MHz, d.sub.6-DMSO): δ=8.2272 (0.6); 7.8121 (1.4); 7.7883 (1.5); 7.6150 (0.8); 7.6036 (0.8); 7.5961 (0.8); 7.5847 (0.7); 6.6143 (1.5); 6.6049 (1.4); 3.9203 (0.7); 3.9036 (0.7); 3.4277 (2.8); 3.4247 (2.8); 3.3787 (6.5); 3.2158 (1.0); 3.1992 (1.0); 2.6693 (0.6); 2.5556 (0.6); 2.5509 (0.6); 2.5227 (2.1); 2.5181 (2.9); 2.5093 (32.0); 2.5048 (66.7); 2.5002 (92.3); 2.4956 (64.0); 2.4910 (29.3); 2.4733 (0.9); 2.4629 (1.4); 2.4550 (1.8); 2.4461 (0.9); 2.4369 (0.5); 2.3270 (0.5); 2.0451 (0.9); 2.0405 (0.9); 2.0278 (16.0); 1.3933 (2.6); 1.3760 (2.6); −0.0002 (6.3)

Example No. I.1-221

[0342] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5185 (2.2); 7.3604 (2.6); 7.3575 (2.7); 7.3494 (3.2); 7.3467 (3.0); 7.3378 (2.8); 7.3349 (2.9); 7.3268 (3.1); 7.3241 (3.1); 7.3201 (2.5); 7.3018 (2.4); 7.2921 (2.9); 7.2738 (3.6); 7.2596 (403.9); 7.2444 (4.0); 7.2280 (2.2); 7.2096 (3.0); 7.2023 (2.4); 7.1844 (2.3); 6.9957 (2.3); 6.7335 (1.3); 6.3348 (9.2); 6.3301 (4.8); 3.8860 (0.8); 3.8797 (0.9); 3.8700 (1.1); 3.8612 (1.2); 3.8429 (2.0); 3.8370 (1.7); 3.8317 (3.4); 3.8244 (3.9); 3.8191 (2.9); 3.8138 (3.5); 3.8062 (3.6); 3.8010 (2.7); 3.7948 (2.4); 3.7881 (1.3); 3.7778 (1.0); 3.7717 (0.6); 3.7507 (0.9); 3.7377 (1.5); 3.7199 (1.3); 3.7048 (1.1); 3.6884 (2.2); 3.6706 (2.5); 3.6533 (1.5); 3.6347 (0.7); 3.5429 (16.0); 3.5118 (0.6); 3.5035 (0.8); 3.4956 (1.0); 3.4879 (0.8); 3.4779 (0.8); 3.4698 (1.0); 3.4614 (1.2); 3.4534 (1.5); 3.4446 (1.2); 3.4384 (0.8); 3.4337 (0.7); 3.4292 (0.7); 3.4229 (0.8); 3.4187 (0.9); 3.4143 (0.8); 3.4090 (1.1); 3.4042 (0.9); 3.3993 (0.8); 3.3951 (0.7); 3.2932 (0.6); 3.2111 (0.7); 3.1970 (0.9); 3.1830 (0.9); 3.1690 (0.7); 3.1652 (0.7); 3.1486 (0.7); 3.1339 (1.0); 3.1289 (0.7); 3.1209 (0.7); 3.1156 (1.0); 3.1103 (0.7); 3.0983 (1.1); 3.0865 (0.6); 3.0818 (0.8); 3.0760 (0.6); 3.0637 (0.6); 2.0049 (6.1); 1.9298 (0.6); 1.9133 (0.8); 1.8966 (1.1); 1.8768 (2.0); 1.8632 (3.2); 1.8466 (3.6); 1.8299 (2.3); 1.8193 (1.7); 1.8082 (1.4); 1.7885 (1.3); 1.7699 (1.1); 1.7455 (1.2); 1.7376 (1.4); 1.7212 (1.4); 1.6105 (7.7); 1.6056 (7.9); 1.5925 (11.0); 1.5887 (11.1); 1.5758 (7.3); 1.5709 (7.2); 1.4915 (0.6); 1.4743 (0.8); 1.4493 (2.0); 1.4435 (1.6); 1.4361 (0.7); 1.4257 (1.1); 1.3507 (0.5); 1.3390 (0.8); 1.3301 (0.8); 1.3212 (0.9); 1.3120 (0.9); 0.1461 (0.6); 0.0080 (4.6); −0.0002 (146.7); −0.0085 (5.7); −0.1497 (0.5)

Example No. I.1-222

[0343] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5209 (0.6); 7.4303 (4.1); 7.4120 (4.0); 7.3730 (3.7); 7.3694 (3.3); 7.3505 (3.8); 7.3468 (3.2); 7.2621 (97.4); 6.9980 (0.5); 6.3663 (4.8); 6.3577 (4.0); 3.7016 (16.0); 3.6618 (5.5); 3.6482 (10.5); 3.5606 (8.9); 3.5500 (11.6); 3.4938 (1.6); −0.0002 (27.1)

Example No. I.1-224

[0344] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5181 (9.0); 7.3541 (3.7); 7.3396 (3.5); 7.3365 (4.1); 7.3316 (3.8); 7.3172 (3.5); 7.3142 (3.4); 7.3090 (1.3); 7.2936 (2.5); 7.2887 (1.2); 7.2755 (5.9); 7.2592 (1610.0); 7.2327 (3.2); 7.2269 (2.2); 7.2085 (1.3); 7.2006 (0.9); 7.1809 (2.7); 7.1631 (2.5); 7.1547 (2.9); 7.1370 (2.9); 7.1095 (0.7); 6.9952 (9.0); 6.8058 (1.0); 6.7098 (0.9); 6.3363 (9.4); 6.3286 (5.2); 3.8605 (2.1); 3.8521 (2.2); 3.8421 (2.4); 3.8374 (2.3); 3.8336 (2.8); 3.8246 (2.1); 3.8192 (2.3); 3.8089 (3.9); 3.7915 (3.8); 3.7876 (3.1); 3.7750 (2.4); 3.7700 (2.2); 3.7545 (1.0); 3.6924 (0.9); 3.6748 (1.8); 3.6607 (1.8); 3.6396 (1.5); 3.5446 (14.4); 3.5383 (14.2); 3.5351 (9.6); 3.3360 (1.0); 3.3205 (1.0); 3.3068 (1.9); 3.2910 (2.0); 3.2862 (1.7); 3.2725 (2.2); 3.2572 (4.7); 3.2414 (2.7); 3.2322 (2.1); 3.2278 (2.0); 3.2192 (2.0); 3.2144 (2.1); 3.1979 (1.1); 3.1937 (1.2); 3.1852 (1.1); 3.1806 (1.2); 2.0047 (1.0); 1.9330 (1.0); 1.9132 (1.2); 1.8977 (1.5); 1.8794 (1.6); 1.8615 (1.5); 1.6739 (1.8); 1.6553 (2.8); 1.6470 (2.2); 1.6265 (10.7); 1.6216 (9.6); 1.6083 (10.7); 1.6039 (13.5); 1.6007 (10.3); 1.5864 (8.9); 1.5824 (8.7); 1.5378 (51.6); 1.4866 (1.7); 1.4655 (1.3); 1.1149 (15.4); 1.1110 (16.0); 1.0587 (13.3); 1.0517 (13.3); 0.1460 (1.9); 0.0340 (0.9); 0.0079 (17.2); −0.0002 (597.4); −0.0085 (18.7); −0.1498 (2.1)

Example No. I.1-227

[0345] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5182 (1.1); 7.4992 (1.8); 7.4891 (1.8); 7.4803 (1.8); 7.4705 (1.8); 7.3781 (3.4); 7.3553 (3.2); 7.3148 (0.6); 7.2595 (177.5); 7.2132 (0.8); 6.9955 (1.0); 6.3498 (5.8); 4.8970 (1.0); 4.8868 (1.3); 4.8764 (1.1); 3.9641 (0.8); 3.9461 (2.5); 3.9284 (2.6); 3.9113 (0.9); 3.8431 (1.1); 3.8164 (2.1); 3.7886 (1.4); 3.5528 (13.3); 3.5149 (1.7); 3.4911 (2.5); 3.4626 (1.4); 1.8719 (0.8); 1.8465 (1.0); 1.7559 (1.1); 1.6113 (16.0); 1.5405 (10.3); 1.5227 (10.4); 1.4937 (1.2); 1.4743 (1.0); 1.4598 (0.8); −0.0002 (76.1)

Example No. I.1-241

[0346] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5185 (1.4); 7.3553 (5.1); 7.3328 (5.1); 7.3093 (1.3); 7.2733 (7.2); 7.2596 (233.2); 7.2135 (1.0); 7.1941 (2.1); 7.1763 (0.9); 6.9955 (1.3); 6.9223 (0.7); 6.7481 (1.3); 6.3368 (7.6); 3.9230 (1.2); 3.8965 (1.4); 3.8472 (1.8); 3.8266 (3.2); 3.8086 (2.7); 3.7907 (1.7); 3.5429 (16.0); 3.4835 (0.8); 3.4256 (0.9); 3.3906 (1.6); 3.3627 (1.3); 3.2808 (1.3); 3.1977 (0.9); 3.1730 (1.0); 3.0580 (0.6); 3.0462 (0.9); 3.0268 (1.2); 3.0120 (1.2); 2.9457 (0.6); 2.9137 (0.8); 1.7080 (6.4); 1.5959 (11.4); 1.5777 (11.1); 1.4638 (7.3); 1.1952 (0.7); 1.1670 (0.6); 1.0793 (0.8); 0.0495 (0.6); −0.0002 (98.6);−0.1489 (0.5)

Example No. I.1-271

[0347] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5210 (0.9); 7.3722 (9.6); 7.3690 (4.8); 7.3497 (9.7); 7.3466 (4.6); 7.2766 (0.5); 7.2693 (1.4); 7.2620 (147.4); 7.2554 (4.4); 7.2435 (4.0); 7.2372 (4.0); 7.2254 (3.9); 7.2132 (4.0); 7.1951 (3.9); 7.1748 (3.5); 7.1568 (3.5); 6.9980 (0.8); 6.5734 (0.9); 6.5584 (1.5); 6.5408 (1.8); 6.3483 (8.5); 6.3410 (6.4); 6.3339 (5.7); 4.4303 (0.6); 4.4219 (1.3); 4.4098 (1.9); 4.4031 (2.4); 4.3969 (2.2); 4.3908 (2.4); 4.3835 (1.7); 4.3721 (1.1); 3.8823 (0.7); 3.8748 (0.6); 3.8596 (1.2); 3.8422 (1.4); 3.8348 (1.4); 3.8239 (1.0); 3.8166 (1.0); 3.8112 (1.0); 3.8070 (1.0); 3.8037 (1.0); 3.7930 (3.4); 3.7890 (3.5); 3.7855 (3.1); 3.7783 (6.0); 3.7752 (4.5); 3.7708 (3.8); 3.7672 (3.7); 3.7651 (3.2); 3.7626 (3.3); 3.7600 (5.3); 3.7546 (5.6); 3.7524 (4.6); 3.7439 (4.3); 3.7411 (6.8); 3.7388 (8.2); 3.7304 (6.1); 3.7240 (3.6); 3.7175 (6.1); 3.7117 (2.5); 3.7063 (3.1); 3.7032 (2.4); 3.6975 (1.9); 3.6934 (1.1); 3.6816 (0.6); 3.5687 (1.6); 3.5617 (2.0); 3.5548 (9.0); 3.5517 (12.3); 3.5486 (14.4); 3.5456 (15.3); 3.5434 (14.7); 3.5403 (16.0); 3.5382 (13.9); 3.5351 (10.5); 3.5250 (1.3); 3.5180 (1.2); 3.5090 (1.5); 3.5015 (2.6); 3.4930 (1.5); 3.4850 (1.2); 3.4773 (2.0); 3.4693 (1.1); 2.2303 (0.7); 2.2264 (0.8); 2.2220 (0.6); 2.2159 (0.7); 2.2099 (1.3); 2.2035 (0.8); 2.1924 (1.8); 2.1764 (1.9); 2.1742 (2.2); 2.1705 (1.6); 2.1590 (1.6); 2.1558 (1.7); 2.1534 (1.6); 2.1434 (1.3); 2.1408 (1.7); 2.1381 (1.2); 2.1225 (1.7); 2.1201 (1.2); 2.1043 (0.6); 2.0051 (8.9); 1.8061 (2.2); 1.7015 (0.7); 1.6931 (0.8); 1.6870 (0.8); 1.6847 (0.8); 1.6791 (1.0); 1.6738 (1.2); 1.6712 (1.2); 1.6680 (1.2); 1.6596 (1.8); 1.6517 (1.5); 1.6493 (1.5); 1.6455 (1.6); 1.6408 (1.7); 1.6387 (1.6); 1.6330 (1.4); 1.6263 (1.5); 1.6186 (1.2); 1.6119 (0.8); 1.5956 (11.7); 1.5925 (13.2); 1.5857 (14.8); 1.5840 (14.9); 1.5775 (12.1); 1.5743 (13.0); 1.5676 (14.1); 1.5659 (13.9); 0.0080 (1.7);−0.0002 (62.9); −0.0085 (1.8)

Example No. I.1-275

[0348] .sup.1H-NMR (400.0 MHz, d.sub.6-DMSO): δ=8.5920 (2.3); 8.5750 (2.3); 8.5121 (4.5); 8.4952 (4.7); 8.1667 (0.6); 7.8379 (7.0); 7.8300 (6.0); 7.8257 (6.2); 7.8140 (7.1); 7.8062 (5.9); 7.8020 (5.9); 7.6412 (9.2); 7.6223 (9.2); 7.5547 (4.2); 7.5359 (4.3); 7.4605 (4.5); 7.4419 (4.6); 6.6232 (9.5); 6.6102 (10.1); 6.5991 (10.2); 6.5745 (8.9); 5.4346 (0.5); 4.3828 (3.4); 4.3662 (3.1); 4.3485 (1.6); 4.2309 (0.5); 4.1917 (0.5); 3.9383 (1.0); 3.9211 (3.6); 3.9138 (1.3); 3.9037 (4.5); 3.8967 (3.9); 3.8869 (5.0); 3.8793 (4.0); 3.8693 (5.0); 3.8500 (3.9); 3.8326 (1.3); 3.7251 (2.5); 3.4269 (33.0); 3.3945 (1.9); 3.3840 (2.0); 3.3738 (2.8); 3.3625 (2.5); 3.3508 (2.8); 3.3403 (3.0); 3.3302 (3.4); 3.3196 (1.8); 3.3108 (1.9); 3.2959 (2.0); 3.2766 (1.8); 3.2354 (2.3); 3.2227 (2.6); 3.2111 (2.8); 3.2018 (2.9); 3.1903 (2.6); 3.1639 (1.4); 3.1433 (3.1); 3.1237 (3.0); 3.1134 (3.3); 3.1059 (2.2); 3.0988 (2.1); 3.0921 (2.8); 3.0827 (1.6); 3.0714 (0.8); 3.0642 (0.8); 2.8798 (1.6); 2.8707 (1.8); 2.8628 (1.6); 2.8523 (1.7); 2.8463 (1.5); 2.8361 (1.5); 2.8301 (1.4); 2.8190 (1.4); 2.7602 (1.6); 2.7527 (1.6); 2.7450 (1.7); 2.7359 (1.5); 2.7265 (1.6); 2.7196 (1.5); 2.7108 (1.4); 2.7020 (1.4); 2.6788 (0.8); 2.6742 (1.6); 2.6695 (2.3); 2.6648 (1.6); 2.5505 (1.4); 2.5230 (8.0); 2.5183 (11.2); 2.5096 (132.9); 2.5050 (280.5); 2.5004 (387.5); 2.4959 (269.5); 2.4913 (124.7); 2.4557 (1.6); 2.4511 (1.6); 2.3934 (0.8); 2.3764 (1.1); 2.3577 (1.6); 2.3320 (3.4); 2.3271 (3.7); 2.3226 (3.5); 2.3182 (3.2); 2.2996 (2.5); 2.2921 (1.7); 2.2854 (2.1); 2.2764 (1.7); 2.2583 (1.2); 2.2431 (0.6); 2.0721 (10.6); 2.0646 (0.7); 2.0447 (1.5); 2.0253 (1.5); 2.0161 (1.6); 1.9936 (1.8); 1.9812 (2.3); 1.9618 (2.7); 1.9444 (2.3); 1.9253 (1.6); 1.9099 (1.2); 1.4221 (11.9); 1.4080 (13.9); 1.4047 (15.9); 1.4000 (16.0); 1.3956 (15.4); 1.3908 (13.6); 1.3826 (14.2); 1.3783 (13.0); 1.2705 (0.5); 1.2527 (1.2); 1.2349 (0.7); 1.1612 (1.1); 1.1435 (0.6); 0.0080 (4.7); −0.0002 (168.4); −0.0085 (5.5)

Example No. I.1-276

[0349] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5187 (2.0); 7.3627 (5.7); 7.3403 (5.8); 7.2595 (306.4); 7.2057 (2.1); 7.1626 (0.8); 6.9952 (1.7); 6.7496 (1.8); 6.3370 (6.7); 3.8891 (2.5); 3.8386 (2.5); 3.8230 (3.1); 3.8049 (2.1); 3.6435 (3.6); 3.6145 (4.8); 3.5373 (16.0); 3.3089 (1.8); 3.2946 (1.7); 3.2802 (1.6); 1.7587 (15.0); 1.6054 (14.6); 1.5873 (14.5); 1.5571 (4.4); 1.5387 (3.5); 1.4486 (1.1); 0.1441 (0.7); −0.0002 (130.4);−0.0539 (1.0); −0.1484 (0.7)

Example No. I.1-331

[0350] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5183 (1.7); 7.3706 (4.3); 7.3484 (4.4); 7.3141 (1.1); 7.2596 (282.3); 7.2140 (2.3); 7.1995 (1.7); 6.9957 (1.6); 6.8010 (0.8); 6.6923 (1.2); 6.3433 (7.3); 3.8646 (0.8); 3.8471 (2.3); 3.8303 (3.0); 3.8127 (1.8); 3.7504 (1.0); 3.7183 (2.9); 3.6879 (4.4); 3.6618 (5.9); 3.6412 (4.8); 3.5946 (1.6); 3.5485 (16.0); 3.4991 (2.0); 3.4750 (1.5); 3.4477 (1.1); 3.4087 (1.2); 3.3932 (1.5); 3.3579 (1.2); 3.3487 (1.1); 3.2593 (0.9); 3.2501 (0.8); 3.2338 (1.1); 3.2245 (1.1); 3.1960 (0.7); 3.1528 (1.5); 3.1435 (1.4); 3.1229 (2.2); 3.1015 (1.4); 3.0899 (1.6); 3.0704 (1.2); 3.0578 (1.1); 3.0387 (0.9); 3.0236 (0.7); 3.0060 (0.6); 1.7893 (6.1); 1.6064 (8.8); 1.6010 (10.0); 1.5886 (8.8); 1.5828 (9.5); 0.1462 (0.6);−0.0002 (122.0); −0.1489 (0.6)

Example No. I.1-333

[0351] Diastereomer 1—.sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5190 (1.6); 7.3798 (4.2); 7.3780 (4.1); 7.3740 (4.1); 7.3700 (3.4); 7.3574 (4.2); 7.3557 (4.2); 7.3517 (4.2); 7.3478 (3.4); 7.3097 (0.5); 7.2944 (0.6); 7.2810 (3.4); 7.2601 (295.8); 7.2436 (3.2); 7.2070 (3.0); 7.1892 (5.6); 7.1714 (2.7); 6.9961 (1.6); 6.8738 (0.9); 6.8310 (1.4); 6.3514 (4.9); 6.3468 (5.3); 6.3364 (5.3); 6.3287 (5.5); 4.4755 (0.8); 4.4676 (0.8); 4.4566 (1.5); 4.4489 (1.7); 4.4388 (2.0); 4.4325 (1.8); 4.4269 (2.6); 4.4138 (2.6); 4.4071 (2.4); 4.3991 (1.5); 4.3891 (1.2); 4.3804 (1.3); 4.1426 (1.1); 4.1362 (1.1); 4.1253 (1.3); 4.1176 (2.6); 4.1127 (1.7); 4.1004 (1.5); 4.0970 (1.4); 4.0938 (1.7); 4.0883 (2.0); 4.0736 (1.1); 4.0673 (1.0); 4.0576 (1.9); 4.0488 (2.7); 4.0385 (3.2); 4.0288 (3.1); 4.0241 (3.4); 4.0160 (2.2); 4.0092 (1.9); 4.0040 (2.4); 3.9983 (2.6); 3.9879 (1.0); 3.9798 (0.9); 3.9693 (0.8); 3.8650 (0.6); 3.8470 (2.6); 3.8286 (4.2); 3.8103 (3.0); 3.7986 (2.4); 3.7945 (2.2); 3.7801 (2.2); 3.7624 (0.7); 3.6491 (0.5); 3.6259 (0.7); 3.6022 (0.9); 3.5851 (1.0); 3.5710 (1.2); 3.5431 (16.0); 3.5373 (11.9); 3.5340 (11.1); 3.5315 (10.2); 3.4965 (0.7); 3.4826 (0.9); 3.4646 (0.7); 3.4513 (0.6); 3.4384 (0.8); 3.4198 (0.8); 3.4066 (0.6); 3.3967 (0.9); 3.3776 (0.9); 3.3590 (1.1); 3.3431 (1.4); 3.3256 (1.2); 3.3094 (0.8); 3.2903 (0.6); 3.1851 (0.6); 3.1672 (5.8); 3.1626 (5.5); 3.1540 (6.1); 3.1444 (7.2); 3.1374 (5.5); 3.1306 (1.9); 3.1242 (1.5); 3.1190 (2.5); 3.0880 (0.5); 2.7364 (0.5); 2.1212 (0.5); 2.1105 (0.9); 2.0909 (1.3); 2.0842 (1.3); 2.0726 (1.6); 2.0604 (1.5); 2.0350 (1.0); 2.0227 (0.8); 1.9712 (0.7); 1.9511 (2.0); 1.9380 (1.9); 1.9324 (2.5); 1.9187 (1.8); 1.9137 (2.0); 1.9002 (1.5); 1.8949 (1.4); 1.8809 (0.9); 1.7487 (0.7); 1.7432 (0.8); 1.7389 (2.5); 1.7311 (0.7); 1.7256 (0.8); 1.7214 (2.4); 1.6147 (15.3); 1.6015 (14.0); 1.5965 (16.4); 1.5835 (12.5); 1.2552 (3.3); 0.8819 (0.8); 0.0079 (2.6); −0.0002 (85.0); −0.0085 (2.7). Diastereomer 2—.sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5186 (2.9); 7.3809 (3.6); 7.3775 (5.4); 7.3715 (3.4); 7.3585 (4.0); 7.3552 (5.6); 7.3493 (3.2); 7.3092 (3.5); 7.2908 (2.0); 7.2718 (6.8); 7.2597 (481.0); 7.2514 (4.8); 7.2326 (4.2); 7.2097 (5.5); 7.2038 (4.6); 7.1857 (4.3); 7.1652 (3.0); 6.9957 (2.8); 6.7862 (0.8); 6.7723 (1.0); 6.7067 (0.9); 6.3508 (4.7); 6.3464 (4.8); 6.3390 (5.0); 6.3320 (5.0); 4.4773 (0.7); 4.4690 (0.6); 4.4508 (1.5); 4.4382 (1.8); 4.4291 (1.9); 4.4190 (1.6); 4.4111 (2.7); 4.4014 (2.2); 4.3937 (1.6); 4.3843 (1.6); 4.1443 (0.8); 4.1373 (0.8); 4.1267 (0.9); 4.1187 (1.8); 4.1020 (0.9); 4.0945 (1.5); 4.0896 (1.4); 4.0750 (0.8); 4.0683 (1.0); 4.0591 (2.2); 4.0489 (2.0); 4.0428 (3.4); 4.0314 (3.9); 4.0193 (2.7); 4.0104 (2.4); 3.9995 (2.0); 3.9944 (1.1); 3.9901 (0.9); 3.9758 (0.8); 3.8401 (0.7); 3.8220 (2.0); 3.8062 (2.6); 3.7892 (3.1); 3.7723 (3.4); 3.7545 (2.5); 3.7362 (0.7); 3.6119 (0.6); 3.5977 (1.0); 3.5767 (1.3); 3.5459 (16.0); 3.5430 (14.9); 3.5008 (2.9); 3.4831 (2.8); 3.4656 (1.5); 3.4478 (0.7); 3.4289 (1.0); 3.4112 (0.9); 3.3963 (0.9); 3.3832 (1.0); 3.3644 (1.1); 3.3552 (1.1); 3.3425 (1.3); 3.3364 (1.3); 3.3299 (1.0); 3.3234 (1.3); 3.3078 (0.9); 3.2887 (0.8); 3.1848 (0.6); 3.1660 (5.5); 3.1625 (5.6); 3.1534 (5.7); 3.1449 (7.7); 3.1381 (5.1); 3.1301 (1.8); 3.1234 (1.7); 3.1195 (2.5); 3.0883 (0.7); 2.3954 (2.0); 2.1167 (0.7); 2.0980 (1.0); 2.0844 (1.3); 2.0686 (1.5); 2.0607 (1.4); 2.0487 (1.4); 2.0379 (1.3); 1.9693 (0.8); 1.9500 (1.8); 1.9307 (2.0); 1.9128 (2.0); 1.8938 (1.3); 1.8775 (0.8); 1.6103 (12.0); 1.5992 (9.6); 1.5970 (10.1); 1.5921 (12.8); 1.5811 (8.9); 1.5789 (8.7); 1.5496 (1.3); 1.5314 (1.0); 1.4320 (2.1); 1.2562 (0.6); 1.2290 (2.0); 1.2114 (3.9); 1.1939 (2.0); 0.1463 (0.7); 0.0494 (0.9); 0.0079 (6.5); −0.0002 (188.2); −0.0085 (6.4); −0.0502 (2.2); −0.1494 (0.8)

Example No. I.1-334

[0352] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5183 (1.9); 7.3597 (5.2); 7.3375 (5.3); 7.3091 (1.8); 7.2595 (311.0); 7.2334 (4.5); 7.2164 (1.4); 6.9954 (1.8); 6.7778 (1.7); 6.3373 (6.4); 6.3278 (3.1); 4.1573 (1.2); 4.1084 (1.2); 3.9764 (1.3); 3.9557 (1.9); 3.9383 (1.2); 3.9031 (1.0); 3.8821 (1.9); 3.8522 (2.1); 3.8340 (2.4); 3.8226 (1.8); 3.5404 (16.0); 3.5145 (1.2); 3.4614 (0.8); 3.4369 (1.0); 3.4265 (1.3); 3.4126 (1.2); 3.4037 (1.6); 3.3817 (3.6); 3.3689 (3.4); 3.3271 (0.6); 3.3128 (1.3); 3.2985 (1.4); 3.2775 (1.0); 3.2640 (0.9); 1.6105 (13.7); 1.5923 (13.9); 1.5386 (73.1); 1.4280 (13.7); 1.3900 (12.4); 1.2875 (9.3); 1.2784 (11.6); 0.1466 (0.7); 0.0494 (0.8); −0.0002 (132.0); −0.1499 (0.6)

Example No. I.1-335

[0353] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5863 (2.0); 7.5816 (0.7); 7.5732 (0.8); 7.5689 (2.5); 7.5675 (2.6); 7.5627 (0.8); 7.5542 (0.7); 7.5502 (2.0); 7.3850 (3.3); 7.3753 (1.2); 7.3622 (3.3); 7.3525 (1.1); 7.2615 (54.0); 6.3544 (3.6); 6.3474 (4.5); 5.7911 (0.6); 5.7802 (0.6); 5.7643 (0.5); 5.7500 (0.5); 5.1598 (1.4); 5.1576 (1.2); 5.1524 (1.1); 5.1477 (1.6); 5.1192 (2.6); 5.0780 (0.6); 4.7494 (0.6); 4.7371 (0.7); 4.7318 (1.0); 4.7196 (1.0); 4.7143 (0.7); 4.7019 (0.6); 4.0587 (1.4); 4.0542 (1.4); 4.0418 (1.5); 4.0373 (1.4); 3.9475 (0.5); 3.9349 (0.8); 3.9310 (0.8); 3.9182 (0.5); 3.8959 (0.7); 3.8917 (0.7); 3.8870 (0.6); 3.8820 (0.7); 3.8780 (0.5); 3.8286 (0.7); 3.8230 (0.9); 3.8178 (0.9); 3.8120 (0.7); 3.7770 (0.6); 3.7719 (0.5); 3.5565 (6.8); 3.5535 (8.6); 3.5500 (8.2); 3.4250 (1.0); 3.4231 (1.0); 3.4071 (0.9); 3.4048 (1.0); 3.3993 (1.6); 3.3974 (1.6); 3.3814 (1.5); 3.3792 (1.4); 3.3394 (1.4); 3.3341 (1.4); 3.3271 (2.0); 3.3220 (1.6); 3.3135 (1.1); 3.3107 (1.1); 3.3085 (1.1); 3.3015 (1.0); 3.2961 (0.9); 3.2897 (0.5); 3.2776 (15.6); 3.2742 (16.0); 3.2616 (4.1); 3.2572 (4.1); 1.5084 (1.4); 1.5033 (1.5); 1.4911 (1.5); 1.4859 (1.6); 1.4682 (5.3); 1.4634 (5.4); 1.4514 (5.4); 1.4465 (5.3); 1.4347 (0.8); 1.3881 (0.7); 1.2161 (2.7); 1.1990 (2.6); 1.1092 (5.3); 1.1003 (5.5); 1.0918 (5.4); 1.0828 (5.3); 0.0080 (0.6); −0.0002 (20.4); −0.0085 (0.6)

Example No. I.1-340

[0354] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5183 (5.2); 7.4046 (3.2); 7.3992 (3.2); 7.3960 (3.0); 7.3929 (2.9); 7.3822 (3.4); 7.3769 (3.4); 7.3735 (3.1); 7.3708 (2.9); 7.3530 (2.9); 7.3349 (3.1); 7.3171 (2.8); 7.2990 (3.0); 7.2881 (5.1); 7.2700 (8.4); 7.2595 (876.8); 7.2497 (2.1); 7.2441 (0.9); 7.2330 (0.6); 7.2100 (0.9); 6.9954 (5.0); 6.6946 (1.2); 6.6696 (1.3); 6.5432 (1.4); 6.5145 (1.4); 6.3435 (8.1); 6.3390 (5.4); 6.3287 (4.0); 3.8262 (1.7); 3.8137 (1.9); 3.8079 (1.9); 3.7957 (2.1); 3.7790 (2.4); 3.7677 (2.3); 3.7608 (2.2); 3.7496 (2.3); 3.7427 (0.7); 3.7314 (0.6); 3.5503 (11.8); 3.5475 (12.2); 3.5326 (9.3); 3.3944 (2.4); 3.3731 (1.9); 3.3677 (3.1); 3.3643 (3.2); 3.3430 (2.1); 3.3318 (2.1); 3.1469 (1.9); 3.1343 (1.7); 3.1171 (1.5); 3.1071 (1.5); 3.0927 (1.3); 3.0665 (2.3); 3.0363 (1.6); 3.0246 (1.1); 3.0164 (1.4); 3.0079 (1.0); 2.9969 (1.4); 2.9862 (0.8); 2.9373 (0.8); 2.9285 (0.9); 2.9179 (1.0); 2.9089 (1.6); 2.9012 (1.2); 2.8899 (1.1); 2.8812 (1.1); 2.8229 (0.8); 2.8146 (0.8); 2.8055 (1.0); 2.7949 (1.3); 2.7860 (0.9); 2.7771 (1.2); 2.7691 (0.8); 2.7493 (1.0); 2.7016 (0.8); 2.6179 (0.7); 2.6021 (1.0); 2.5846 (1.2); 2.5704 (0.8); 2.4438 (1.5); 2.4228 (2.1); 2.4119 (1.9); 2.4038 (1.5); 2.3997 (1.4); 2.3930 (1.6); 2.3785 (1.5); 2.3173 (0.6); 2.2968 (0.8); 2.2843 (1.2); 2.2624 (1.0); 2.2504 (0.7); 2.0052 (0.7); 1.7338 (2.9); 1.6305 (9.5); 1.6169 (9.6); 1.6119 (16.0); 1.5989 (8.5); 1.5934 (8.8); 0.1460 (1.7); 0.0080 (15.6); −0.0002 (517.3); −0.0085 (15.6);−0.0497 (0.8); −0.1497 (1.8)

Example No. I.1-341

[0355] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5177 (9.7); 7.5104 (2.9); 7.4971 (6.4); 7.4916 (2.7); 7.4134 (6.0); 7.3908 (6.1); 7.2923 (1.7); 7.2590 (1346.6); 7.2089 (1.9); 6.9950 (7.2); 6.3591 (7.7); 6.3446 (8.8); 3.9555 (3.5); 3.9379 (5.0); 3.9204 (3.4); 3.8697 (3.4); 3.8499 (4.0); 3.8317 (1.8); 3.7377 (2.0); 3.7261 (2.1); 3.7174 (2.5); 3.7044 (2.8); 3.6964 (2.4); 3.6913 (2.3); 3.6744 (4.0); 3.6577 (3.8); 3.6486 (5.0); 3.6431 (4.9); 3.6356 (3.4); 3.6200 (3.5); 3.5529 (16.0); 1.9935 (1.6); 1.9741 (1.6); 1.7158 (1.6); 1.5591 (15.5); 1.5565 (12.9); 1.5413 (15.1); 1.5387 (12.6); 0.0080 (14.4); −0.0002 (499.6); −0.0085 (14.4);−0.1498 (1.6)

Example No. I.2-71

[0356] Diastereomer 1—.sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5532 (1.4); 7.5465 (1.4); 7.5344 (1.4); 7.5278 (1.4); 7.5181 (2.5); 7.5138 (1.6); 7.4985 (1.4); 7.4951 (1.5); 7.3611 (3.9); 7.3383 (3.9); 7.2594 (306.1); 7.2465 (0.6); 6.9954 (1.7); 6.3443 (6.1); 6.3392 (2.3); 4.1684 (0.7); 4.1596 (0.7); 4.1545 (0.7); 4.1460 (0.8); 4.1405 (0.8); 4.1317 (1.1); 4.1269 (0.9); 4.1183 (0.9); 4.0813 (0.6); 4.0681 (0.8); 4.0623 (1.2); 4.0500 (1.3); 4.0444 (1.2); 4.0351 (0.8); 4.0284 (1.3); 4.0174 (1.0); 4.0129 (1.5); 4.0004 (1.3); 3.9922 (2.1); 3.9861 (1.7); 3.9767 (1.3); 3.9701 (1.0); 3.9649 (1.0); 3.9583 (1.1); 3.9490 (0.7); 3.9422 (0.7); 3.8278 (0.5); 3.8149 (0.6); 3.8109 (1.5); 3.8075 (1.2); 3.7942 (1.3); 3.7903 (1.8); 3.7737 (0.9); 3.7654 (0.9); 3.7469 (1.4); 3.7347 (1.6); 3.7308 (1.8); 3.7181 (1.7); 3.7146 (2.4); 3.7114 (1.4); 3.6982 (1.1); 3.6946 (1.0); 3.5519 (9.2); 3.5488 (10.6); 3.5461 (6.8); 2.0048 (2.5); 1.9846 (1.0); 1.9818 (1.1); 1.9648 (1.4); 1.9463 (1.3); 1.9348 (0.8); 1.9304 (0.8); 1.9134 (0.8); 1.9051 (0.8); 1.9012 (1.0); 1.8922 (0.9); 1.8845 (1.5); 1.8687 (2.1); 1.8663 (2.1); 1.8569 (1.6); 1.8519 (2.1); 1.8480 (2.1); 1.8314 (1.5); 1.8150 (0.8); 1.5660 (2.0); 1.5426 (1.2); 1.5368 (1.0); 1.5230 (0.9); 1.5129 (0.7); 1.5058 (0.9); 1.4938 (0.7); 1.4889 (0.7); 1.0816 (7.2); 1.0631 (16.0); 1.0447 (6.6); 0.3307 (0.6); 0.2375 (0.6); 0.1263 (0.7); 0.0080 (3.8); −0.0002 (127.1); −0.0085 (3.8). Diastereomer 2—.sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5535 (1.6); 7.5469 (1.6); 7.5346 (1.7); 7.5281 (1.6); 7.5177 (1.3); 7.5142 (1.3); 7.4990 (1.2); 7.4955 (1.3); 7.3612 (3.9); 7.3384 (3.9); 7.2606 (53.4); 6.3440 (6.8); 6.3390 (2.2); 4.1679 (0.7); 4.1591 (0.8); 4.1541 (0.8); 4.1456 (0.8); 4.1400 (1.0); 4.1312 (1.1); 4.1266 (1.0); 4.1180 (1.0); 4.0812 (0.5); 4.0681 (0.7); 4.0622 (1.0); 4.0590 (0.9); 4.0502 (1.4); 4.0430 (1.2); 4.0345 (1.1); 4.0284 (1.0); 4.0174 (1.1); 4.0130 (1.3); 4.0008 (1.2); 3.9923 (2.0); 3.9863 (1.9); 3.9773 (1.4); 3.9703 (1.1); 3.9651 (1.2); 3.9584 (1.2); 3.9492 (0.7); 3.9424 (0.7); 3.8272 (0.6); 3.8142 (0.7); 3.8102 (1.6); 3.8066 (1.2); 3.7935 (1.5); 3.7895 (1.8); 3.7729 (0.9); 3.7661 (0.8); 3.7463 (1.3); 3.7343 (1.6); 3.7310 (2.0); 3.7251 (1.0); 3.7183 (2.2); 3.7147 (2.5); 3.7115 (1.6); 3.7071 (0.8); 3.6982 (1.5); 3.6947 (1.3); 3.5515 (10.1); 3.5485 (11.4); 2.0002 (0.8); 1.9844 (1.1); 1.9817 (1.2); 1.9646 (1.6); 1.9462 (1.4); 1.9341 (0.8); 1.9303 (0.9); 1.9263 (0.8); 1.9170 (0.6); 1.9130 (1.0); 1.9082 (0.8); 1.9049 (0.9); 1.9007 (1.0); 1.8924 (1.1); 1.8838 (1.5); 1.8738 (1.4); 1.8686 (2.2); 1.8662 (1.9); 1.8568 (1.8); 1.8518 (2.3); 1.8480 (2.0); 1.8384 (1.4); 1.8355 (1.7); 1.8222 (0.8); 1.8174 (0.9); 1.5559 (11.0); 1.5425 (0.6); 1.5369 (0.5); 1.5236 (0.7); 1.5144 (0.6); 1.5057 (0.9); 1.4967 (0.6); 1.4890 (0.7); 1.2565 (0.5); 1.0817 (7.4); 1.0632 (16.0); 1.0448 (6.8); 0.0692 (2.1); 0.0080 (0.7); −0.0002 (22.2); −0.0085 (0.6)

Example No. I.2-73

[0357] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5451 (1.5); 7.5341 (1.5); 7.5263 (1.6); 7.5189 (0.9); 7.5150 (3.3); 7.5103 (2.0); 7.4961 (1.9); 7.4916 (1.9); 7.3631 (3.0); 7.3521 (3.6); 7.3403 (3.1); 7.3293 (3.6); 7.2601 (108.8); 6.9961 (0.6); 6.3483 (8.6); 4.1122 (0.7); 4.1076 (0.8); 4.1032 (0.8); 4.0987 (0.8); 4.0833 (1.2); 4.0787 (1.3); 4.0743 (1.3); 4.0698 (1.3); 4.0652 (0.6); 4.0476 (0.5); 4.0364 (1.1); 4.0268 (1.1); 4.0187 (1.2); 4.0091 (1.3); 4.0058 (1.4); 3.9998 (1.3); 3.9929 (1.3); 3.9888 (2.1); 3.9835 (2.2); 3.9794 (1.4); 3.9772 (1.0); 3.9709 (0.8); 3.9641 (0.6); 3.9600 (1.2); 3.9544 (1.1); 3.9506 (0.6); 3.9332 (1.3); 3.9288 (1.2); 3.9100 (1.0); 3.9050 (1.2); 3.8996 (1.3); 3.7563 (1.0); 3.7536 (1.0); 3.7498 (1.0); 3.7368 (2.1); 3.7334 (2.2); 3.7298 (1.2); 3.7195 (1.0); 3.7169 (1.1); 3.7132 (1.0); 3.5531 (14.1); 3.5188 (0.5); 3.4630 (0.7); 3.4543 (0.5); 3.4467 (0.7); 3.4412 (0.6); 3.4375 (0.6); 3.4326 (0.6); 3.3960 (1.0); 3.3897 (1.2); 3.3680 (1.4); 3.3627 (1.5); 3.3414 (0.7); 3.3348 (0.6); 2.0144 (0.6); 1.9964 (1.1); 1.9790 (1.5); 1.9609 (1.7); 1.9427 (1.0); 1.8932 (0.6); 1.8896 (0.6); 1.8752 (1.1); 1.8582 (1.5); 1.8547 (1.2); 1.8402 (2.1); 1.8224 (1.5); 1.8052 (1.2); 1.5470 (43.7); 1.5035 (2.2); 1.4856 (4.2); 1.4529 (1.2); 1.4432 (1.0); 1.2545 (0.9); 1.2422 (0.8); 1.2325 (0.6); 1.2238 (0.8); 1.2136 (0.7); 1.0753 (7.5); 1.0569 (16.0); 1.0384 (6.9); 0.0080 (1.2); −0.0002 (39.9); −0.0085 (1.2)

Example No. I.2-81

[0358] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=8.0511 (1.1); 8.0299 (1.3); 7.6910 (0.9); 7.6701 (1.3); 7.5891 (0.7); 7.5868 (0.7); 7.5718 (0.8); 7.5694 (0.9); 7.5509 (0.6); 7.5486 (0.6); 7.5188 (1.1); 7.5132 (2.4); 7.5112 (2.6); 7.4944 (4.4); 7.4925 (4.6); 7.4826 (0.6); 7.4755 (2.1); 7.4737 (2.2); 7.4512 (0.8); 7.4487 (0.8); 7.4338 (0.6); 7.4303 (0.9); 7.4275 (0.7); 7.4128 (0.5); 7.4102 (0.6); 7.3630 (7.3); 7.3403 (7.6); 7.3342 (0.7); 7.2924 (0.5); 7.2599 (156.9); 6.9959 (0.9); 6.3558 (3.8); 6.3528 (3.7); 6.3457 (5.1); 6.2805 (0.8); 6.2266 (9.4); 4.1334 (1.0); 4.1134 (1.4); 4.1057 (2.1); 4.0936 (0.8); 4.0863 (2.9); 4.0778 (1.2); 4.0665 (1.2); 4.0594 (1.3); 4.0249 (1.5); 4.0097 (2.5); 3.9979 (2.3); 3.9936 (1.6); 3.9815 (2.5); 3.9707 (1.0); 3.9663 (1.0); 3.9540 (0.9); 3.7273 (0.9); 3.7242 (1.0); 3.7109 (1.1); 3.7074 (1.8); 3.7037 (1.2); 3.7001 (1.1); 3.6926 (1.3); 3.6873 (1.1); 3.6836 (1.2); 3.6795 (1.3); 3.6766 (1.4); 3.6726 (1.2); 3.6630 (1.0); 3.6561 (1.0); 3.5578 (10.1); 3.5521 (11.4); 3.5489 (10.3); 3.5189 (2.6); 3.5030 (1.6); 3.4862 (1.2); 3.4750 (0.9); 2.8589 (0.7); 2.8473 (1.1); 2.8412 (1.1); 2.8346 (1.6); 2.8249 (1.5); 2.8221 (1.6); 2.8066 (1.8); 2.7900 (2.2); 2.7737 (1.3); 2.7646 (1.0); 2.7481 (0.5); 2.0165 (0.9); 1.9983 (1.7); 1.9851 (2.2); 1.9816 (3.3); 1.9776 (2.2); 1.9614 (4.9); 1.9510 (4.8); 1.9460 (4.5); 1.9427 (3.9); 1.9275 (1.8); 1.9165 (1.1); 1.8943 (1.0); 1.8860 (0.8); 1.8757 (1.4); 1.8680 (1.3); 1.8572 (1.3); 1.8499 (1.2); 1.8407 (1.0); 1.8329 (0.9); 1.8222 (0.5); 1.6925 (0.8); 1.6797 (1.3); 1.6644 (1.4); 1.6512 (1.2); 1.6371 (0.9); 1.5488 (14.4); 1.2557 (1.2); 1.0842 (8.0); 1.0659 (16.0); 1.0475 (7.2); 0.0080 (1.9); −0.0002 (66.2); −0.0085 (2.3)

Example No. I.2-221

[0359] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5187 (2.0); 7.4538 (0.6); 7.4308 (0.6); 7.3512 (2.0); 7.3489 (2.1); 7.3403 (2.1); 7.3387 (2.1); 7.3285 (2.1); 7.3262 (2.2); 7.3213 (2.0); 7.3180 (2.3); 7.3162 (2.2); 7.3102 (0.9); 7.3030 (1.9); 7.2936 (1.8); 7.2888 (0.8); 7.2879 (0.8); 7.2872 (0.8); 7.2863 (0.8); 7.2856 (0.8); 7.2839 (0.9); 7.2832 (1.0); 7.2824 (1.0); 7.2816 (1.0); 7.2808 (1.0); 7.2800 (1.0); 7.2792 (1.2); 7.2784 (1.2); 7.2776 (1.4); 7.2753 (3.0); 7.2737 (2.0); 7.2729 (1.9); 7.2721 (2.0); 7.2712 (2.0); 7.2704 (2.2); 7.2696 (2.5); 7.2689 (2.7); 7.2681 (2.9); 7.2672 (3.3); 7.2664 (3.9); 7.2656 (4.6); 7.2648 (5.7); 7.2640 (7.2); 7.2598 (352.2); 7.2535 (2.7); 7.2527 (2.1); 7.2519 (1.5); 7.2511 (0.9); 7.2503 (0.6); 7.2185 (1.6); 7.2104 (0.6); 7.2004 (1.5); 7.1961 (1.6); 7.1782 (1.4); 6.9958 (2.0); 6.7325 (0.8); 6.3583 (0.7); 6.3328 (5.3); 3.8618 (0.6); 3.8482 (0.7); 3.8311 (0.8); 3.8240 (1.0); 3.8051 (1.4); 3.7881 (1.4); 3.7722 (0.5); 3.7458 (0.6); 3.7332 (1.0); 3.7177 (0.7); 3.7154 (0.8); 3.7002 (0.6); 3.6795 (1.5); 3.6695 (1.2); 3.6636 (2.4); 3.6519 (1.5); 3.6425 (2.8); 3.6350 (0.9); 3.6257 (1.4); 3.5603 (1.4); 3.5570 (1.7); 3.5438 (9.0); 3.5406 (10.4); 3.5378 (9.4); 3.5347 (6.0); 3.5133 (0.6); 3.5050 (0.7); 3.4976 (0.6); 3.4791 (0.5); 3.4725 (0.6); 3.4635 (0.9); 3.4559 (0.9); 3.4499 (0.8); 3.4245 (0.5); 3.4215 (0.5); 3.4155 (0.8); 3.4098 (0.5); 3.2038 (0.6); 3.1865 (0.6); 3.1697 (0.5); 3.1527 (0.5); 3.1382 (0.7); 3.1325 (0.6); 3.1255 (0.6); 3.1197 (0.9); 3.1141 (0.5); 3.1068 (0.5); 3.1017 (0.7); 3.0982 (0.5); 3.0854 (0.7); 2.4455 (3.9); 2.0791 (0.8); 2.0624 (1.4); 2.0439 (2.3); 2.0257 (1.9); 2.0087 (1.4); 1.9402 (0.7); 1.9296 (1.0); 1.9220 (1.3); 1.9128 (1.2); 1.9036 (1.4); 1.8947 (1.5); 1.8864 (1.4); 1.8765 (1.7); 1.8680 (1.6); 1.8594 (2.0); 1.8509 (1.5); 1.8399 (2.0); 1.8273 (1.3); 1.8224 (1.3); 1.8120 (1.0); 1.8018 (0.7); 1.7819 (0.6); 1.5445 (16.0); 1.4716 (0.5); 1.4503 (0.5); 1.4411 (0.8); 1.4225 (0.7); 1.3328 (0.7); 1.3199 (0.6); 1.3106 (0.8); 1.3015 (0.8); 1.2930 (0.6); 1.2843 (0.9); 1.2560 (2.5); 1.1214 (5.6); 1.1029 (11.4); 1.0846 (5.1); 0.8802 (0.6); 0.0144 (0.5); 0.0136 (0.6); 0.0127 (0.6); 0.0120 (0.7); 0.0112 (0.8); 0.0103 (0.9); 0.0080 (4.4); 0.0064 (1.7); 0.0056 (1.8); 0.0048 (2.2); 0.0039 (2.8); −0.0002 (135.1); −0.0050 (2.4); −0.0058 (1.8); −0.0067 (1.5);−0.0084 (3.9); −0.0106 (0.6)

Example No. I.2-224

[0360] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.3473 (2.3); 7.3458 (2.3); 7.3312 (2.2); 7.3290 (2.3); 7.3248 (2.5); 7.3233 (2.4); 7.3088 (2.1); 7.3067 (2.2); 7.2817 (1.9); 7.2610 (80.2); 7.2385 (1.8); 7.1814 (1.6); 7.1635 (1.7); 7.1584 (1.8); 7.1405 (1.6); 6.7717 (0.5); 6.3343 (6.0); 6.3274 (3.4); 3.8225 (1.1); 3.8052 (1.5); 3.7995 (0.9); 3.7946 (1.0); 3.7892 (1.9); 3.7824 (1.9); 3.7775 (1.9); 3.7706 (1.1); 3.7649 (1.1); 3.7606 (1.2); 3.7565 (1.0); 3.7499 (0.5); 3.7028 (0.8); 3.6990 (0.8); 3.6855 (1.7); 3.6684 (1.9); 3.6646 (2.6); 3.6545 (1.2); 3.6474 (3.5); 3.6368 (0.6); 3.6301 (1.9); 3.5453 (8.9); 3.5423 (8.2); 3.5392 (8.2); 3.5364 (9.0); 3.5336 (6.4); 3.3588 (0.7); 3.3422 (0.7); 3.3248 (1.1); 3.3082 (1.0); 3.2649 (4.4); 3.2501 (4.4); 3.2218 (1.0); 3.2168 (1.1); 3.2089 (1.1); 3.2041 (1.0); 3.1878 (0.6); 3.1829 (0.7); 3.1749 (0.6); 3.1701 (0.6); 2.0897 (0.6); 2.0854 (0.5); 2.0727 (1.0); 2.0689 (1.0); 2.0545 (1.6); 2.0503 (1.6); 2.0361 (1.4); 2.0337 (1.3); 2.0319 (1.3); 2.0193 (0.9); 2.0151 (1.0); 1.9572 (0.6); 1.9498 (0.7); 1.9387 (1.2); 1.9314 (1.4); 1.9203 (1.3); 1.9126 (1.6); 1.9096 (1.7); 1.9019 (1.3); 1.8913 (1.8); 1.8848 (1.2); 1.8743 (1.7); 1.8665 (1.0); 1.8569 (1.4); 1.8529 (1.0); 1.8482 (0.8); 1.8406 (1.0); 1.8271 (0.7); 1.8218 (0.7); 1.6718 (0.8); 1.6539 (1.7); 1.6460 (1.6); 1.6305 (1.6); 1.6245 (1.7); 1.6150 (0.9); 1.6095 (1.2); 1.6018 (0.6); 1.5986 (0.7); 1.5935 (0.7); 1.5744 (16.0); 1.5553 (0.6); 1.5438 (1.3); 1.5309 (0.9); 1.5236 (1.0); 1.5101 (0.8); 1.4876 (0.8); 1.4724 (0.7); 1.3039 (0.5); 1.2845 (0.8); 1.2647 (2.6); 1.1361 (3.6); 1.1170 (9.2); 1.1141 (10.9); 1.1100 (10.4); 1.1028 (8.9); 1.0846 (3.5); 1.0525 (9.5); 1.0452 (9.4); 0.8987 (1.3); 0.8818 (4.3); 0.8641 (1.7); 0.0691 (0.9); 0.0079 (1.0); −0.0002 (33.6); −0.0085 (1.1)

Example No. I.2-336

[0361] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5184 (1.9); 7.3794 (0.6); 7.3726 (1.2); 7.3652 (4.9); 7.3499 (1.9); 7.3428 (3.2); 7.3286 (3.6); 7.3066 (3.8); 7.2596 (324.2); 7.1146 (0.7); 7.0983 (2.1); 7.0928 (2.2); 7.0807 (1.6); 7.0750 (1.6); 6.9955 (1.6); 6.8893 (0.8); 6.8643 (0.9); 6.3413 (4.9); 6.3341 (2.6); 6.3186 (2.8); 4.5861 (0.6); 4.5598 (0.8); 4.5393 (0.7); 4.4760 (0.7); 4.2233 (0.8); 4.2053 (1.1); 4.1806 (1.1); 4.1571 (1.0); 4.1387 (0.9); 3.8751 (1.1); 3.8576 (2.1); 3.8501 (1.0); 3.8399 (1.1); 3.8356 (1.2); 3.8310 (1.2); 3.8078 (1.6); 3.7945 (1.6); 3.7773 (0.9); 3.7583 (1.0); 3.7466 (0.9); 3.7381 (1.0); 3.7283 (1.2); 3.7109 (1.6); 3.7060 (1.6); 3.6939 (0.8); 3.6887 (0.7); 3.6235 (0.7); 3.6044 (0.7); 3.5917 (0.8); 3.5737 (0.8); 3.5468 (8.0); 3.5438 (7.8); 3.5325 (4.1); 3.5297 (4.2); 2.0958 (0.5); 2.0775 (0.8); 2.0600 (1.1); 2.0434 (1.5); 2.0182 (1.9); 2.0006 (2.6); 1.9818 (1.9); 1.9636 (0.6); 1.9265 (0.5); 1.9089 (0.8); 1.8943 (1.2); 1.8761 (1.6); 1.8559 (1.6); 1.8361 (1.4); 1.6563 (0.7); 1.5420 (16.0); 1.3768 (0.9); 1.2551 (1.6); 1.1528 (3.4); 1.1340 (7.0); 1.1157 (3.3); 1.1018 (3.9); 1.0833 (8.1); 1.0650 (3.7); 1.0483 (0.7); 1.0253 (0.7); 0.9935 (0.6); 0.3306 (0.8); 0.2374 (0.8); 0.1569 (0.6); 0.1262 (0.7); 0.0688 (3.7); 0.0079 (3.7); −0.0002 (128.2); −0.0085 (4.4)

Example No. I.4-71

[0362] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5634 (0.6); 7.5592 (0.7); 7.5499 (1.9); 7.5440 (2.2); 7.5407 (1.1); 7.5311 (2.0); 7.5251 (1.8); 7.5193 (0.9); 7.5117 (1.6); 7.5058 (1.6); 7.4930 (1.5); 7.4871 (1.6); 7.3673 (2.1); 7.3637 (4.8); 7.3550 (1.1); 7.3443 (2.2); 7.3409 (4.8); 7.3323 (1.2); 7.2742 (0.5); 7.2726 (0.6); 7.2702 (0.8); 7.2694 (0.9); 7.2669 (1.4); 7.2604 (126.2); 6.9964 (0.7); 6.3424 (8.0); 6.3372 (3.0); 6.3242 (0.6); 4.1500 (0.9); 4.1408 (1.0); 4.1335 (1.0); 4.1243 (1.3); 4.1217 (1.3); 4.1126 (1.4); 4.1053 (1.2); 4.0962 (1.4); 4.0509 (0.6); 4.0430 (0.8); 4.0346 (1.2); 4.0275 (1.5); 4.0194 (1.1); 4.0159 (1.5); 4.0116 (1.5); 4.0079 (2.0); 3.9987 (2.3); 3.9928 (0.9); 3.9889 (1.2); 3.9847 (2.2); 3.9727 (1.5); 3.9667 (0.5); 3.9583 (1.1); 3.9552 (0.9); 3.9467 (1.3); 3.9380 (1.8); 3.9306 (1.8); 3.9224 (1.4); 3.9148 (2.3); 3.9099 (1.3); 3.9023 (1.4); 3.8971 (2.0); 3.8945 (2.4); 3.8867 (1.2); 3.8803 (1.1); 3.8767 (2.3); 3.8630 (1.2); 3.8597 (1.9); 3.8562 (1.2); 3.8423 (1.2); 3.8387 (1.1); 3.8315 (0.5); 3.8230 (0.7); 3.8174 (1.0); 3.8146 (0.8); 3.8062 (0.8); 3.8008 (1.4); 3.7971 (1.7); 3.7896 (0.6); 3.7849 (1.5); 3.7801 (2.1); 3.7767 (1.2); 3.7689 (0.9); 3.7633 (1.3); 3.7471 (0.8); 3.7375 (0.5); 3.7269 (1.0); 3.7229 (0.7); 3.7148 (1.2); 3.7122 (1.2); 3.7091 (1.1); 3.7056 (0.9); 3.6993 (0.8); 3.6938 (1.0); 3.6880 (0.5); 3.5492 (11.8); 3.5463 (13.6); 3.5431 (9.6); 1.9568 (0.5); 1.9484 (0.6); 1.9402 (0.8); 1.9352 (0.9); 1.9269 (0.9); 1.9231 (0.9); 1.9182 (1.2); 1.9065 (1.4); 1.8948 (2.2); 1.8898 (1.7); 1.8860 (1.8); 1.8764 (2.5); 1.8695 (2.2); 1.8602 (2.6); 1.8523 (2.0); 1.8449 (2.8); 1.8311 (1.6); 1.8272 (2.6); 1.8147 (1.4); 1.8106 (1.5); 1.8061 (1.0); 1.7979 (1.2); 1.7942 (1.4); 1.7813 (1.3); 1.7781 (1.4); 1.7616 (1.2); 1.7454 (0.7); 1.7142 (0.8); 1.7090 (0.9); 1.7065 (0.9); 1.7025 (0.9); 1.6964 (0.8); 1.6915 (1.2); 1.6853 (1.2); 1.6813 (0.8); 1.6736 (1.0); 1.6686 (1.1); 1.6638 (0.7); 1.6588 (0.9); 1.6561 (0.9); 1.6523 (1.0); 1.6391 (0.6); 1.6354 (0.6); 1.5558 (4.6); 1.5296 (0.6); 1.5180 (0.7); 1.5064 (0.6); 1.5004 (1.0); 1.4885 (0.8); 1.4801 (1.0); 1.4711 (0.8); 1.4631 (0.7); 1.4536 (0.6); 0.9687 (2.0); 0.9578 (9.4); 0.9542 (9.8); 0.9445 (16.0); 0.9399 (9.8); 0.9287 (12.7); 0.9117 (1.3); 0.9091 (1.2); 0.8879 (1.7); 0.8720 (1.7); 0.8627 (1.0); 0.8540 (1.1); 0.8495 (2.1); 0.8382 (1.3); 0.8340 (1.9); 0.0079 (1.7); −0.0002 (54.9); −0.0085 (1.5)

Example No. I.4-72

[0363] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5197 (1.0); 7.4709 (2.4); 7.4659 (2.6); 7.4522 (2.4); 7.4471 (2.6); 7.3790 (4.7); 7.3563 (4.8); 7.3396 (0.9); 7.2722 (0.5); 7.2714 (0.5); 7.2706 (0.6); 7.2698 (0.7); 7.2690 (0.8); 7.2682 (0.9); 7.2674 (1.0); 7.2666 (1.2); 7.2658 (1.5); 7.2650 (1.9); 7.2608 (110.5); 7.2536 (0.5); 6.9968 (0.6); 6.3465 (8.9); 6.3365 (1.2); 4.0936 (0.8); 4.0818 (0.8); 4.0771 (0.8); 4.0663 (1.2); 4.0548 (1.0); 4.0500 (1.0); 4.0377 (0.9); 3.9838 (1.4); 3.9798 (1.3); 3.9676 (2.8); 3.9632 (1.5); 3.9501 (1.5); 3.9482 (1.6); 3.9209 (0.6); 3.8988 (1.2); 3.8944 (1.2); 3.8851 (1.0); 3.8785 (1.9); 3.8747 (1.5); 3.8723 (1.6); 3.8684 (1.4); 3.8618 (1.5); 3.8561 (2.3); 3.8508 (1.7); 3.8473 (1.8); 3.8396 (1.4); 3.8346 (1.2); 3.8216 (1.1); 3.8111 (1.0); 3.8004 (1.8); 3.7862 (1.7); 3.7799 (1.2); 3.7658 (1.2); 3.7619 (1.2); 3.7445 (1.7); 3.7399 (1.5); 3.7345 (1.0); 3.7309 (1.6); 3.7268 (2.1); 3.7233 (2.3); 3.7138 (1.5); 3.7067 (2.0); 3.6950 (1.2); 3.6904 (1.1); 3.6876 (1.1); 3.5500 (14.8); 3.5470 (15.8); 3.4470 (0.9); 3.4318 (1.0); 3.4270 (1.8); 3.4128 (1.9); 3.4053 (1.3); 3.3910 (1.3); 2.4534 (0.5); 2.4354 (0.8); 2.4168 (0.8); 2.3998 (0.5); 1.9800 (0.7); 1.9728 (0.5); 1.9598 (1.0); 1.9478 (0.9); 1.9399 (0.9); 1.9277 (1.1); 1.9153 (0.8); 1.9087 (0.6); 1.8989 (1.0); 1.8831 (1.3); 1.8774 (1.0); 1.8657 (1.4); 1.8614 (1.3); 1.8505 (1.4); 1.8441 (1.2); 1.8283 (1.5); 1.7724 (0.6); 1.7558 (1.1); 1.7388 (1.4); 1.7227 (1.3); 1.7069 (0.8); 1.6879 (1.5); 1.6716 (1.8); 1.6549 (1.5); 1.6385 (1.3); 1.6205 (0.7); 1.5600 (11.4); 1.5376 (1.2); 1.5212 (1.0); 1.5042 (1.0); 1.4891 (0.7); 1.4331 (1.4); 0.9720 (2.4); 0.9569 (15.4); 0.9511 (16.0); 0.9414 (13.9); 0.9350 (15.2); 0.9193 (1.0); 0.9150 (1.0); 0.8954 (2.1); 0.8795 (2.0); 0.8708 (0.8); 0.8653 (0.9); 0.8580 (2.1); 0.8492 (1.0); 0.8422 (2.0); 0.0079 (1.3); −0.0002 (47.2); −0.0085 (1.3)

Example No. I.4-221

[0364] .sup.1H-NMR (400.6 MHz, CDCl.sub.3): δ=7.3505 (0.9); 7.3476 (1.0); 7.3399 (1.7); 7.3381 (1.3); 7.3279 (1.0); 7.3251 (1.1); 7.3216 (1.0); 7.3174 (1.1); 7.3154 (1.2); 7.3128 (1.0); 7.2944 (1.0); 7.2720 (0.5); 7.2714 (0.6); 7.2706 (0.6); 7.2697 (0.7); 7.2689 (0.8); 7.2682 (0.8); 7.2673 (0.9); 7.2623 (69.0); 7.2439 (0.7); 7.2257 (0.8); 7.2214 (0.8); 7.2033 (0.8); 6.3397 (1.4); 6.3341 (2.5); 6.3307 (1.6); 3.8158 (0.5); 3.7995 (0.7); 3.7941 (0.6); 3.7769 (1.1); 3.7600 (1.2); 3.7547 (0.8); 3.7440 (0.6); 3.7408 (0.8); 3.6741 (0.5); 3.6558 (0.7); 3.5512 (2.2); 3.5483 (2.9); 3.5461 (2.8); 3.5430 (2.5); 3.5386 (2.9); 3.5356 (3.5); 3.5328 (2.6); 2.0082 (0.7); 1.8773 (0.8); 1.8654 (1.2); 1.8613 (1.2); 1.8497 (1.4); 1.8447 (1.4); 1.8360 (1.3); 1.8280 (1.4); 1.8199 (1.1); 1.8101 (0.9); 1.8012 (0.6); 1.7131 (0.5); 1.7064 (0.6); 1.6949 (0.6); 1.6927 (0.6); 1.6882 (0.7); 1.6824 (0.6); 1.6674 (0.6); 1.5855 (16.0); 1.2584 (0.6); 0.9780 (3.7); 0.9652 (5.5); 0.9621 (5.8); 0.9515 (2.8); 0.9494 (3.0); 0.9468 (2.6); −0.0002 (4.5)

Example No. I.5-71

[0365] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5347 (1.6); 7.5249 (1.6); 7.5192 (1.8); 7.5158 (1.8); 7.5121 (1.2); 7.5061 (1.6); 7.5009 (1.1); 7.4932 (0.9); 7.4719 (2.0); 7.4678 (0.9); 7.4625 (0.8); 7.4532 (2.0); 7.4492 (0.9); 7.4438 (0.8); 7.3494 (4.6); 7.3266 (4.7); 7.2601 (137.4); 6.9960 (0.8); 6.3397 (11.1); 6.3345 (3.8); 4.1565 (0.8); 4.1514 (0.6); 4.1476 (0.8); 4.1396 (0.8); 4.1309 (1.2); 4.1232 (0.8); 4.1193 (1.1); 4.1117 (1.0); 4.1027 (1.2); 4.0703 (0.7); 4.0634 (0.7); 4.0545 (1.2); 4.0514 (1.3); 4.0458 (1.5); 4.0373 (2.4); 4.0299 (2.0); 4.0214 (2.1); 4.0130 (1.3); 4.0038 (0.8); 3.9943 (1.6); 3.9863 (1.0); 3.9814 (1.7); 3.9773 (1.4); 3.9672 (1.9); 3.9531 (1.9); 3.9480 (1.6); 3.9399 (1.0); 3.9373 (1.2); 3.9325 (1.5); 3.9246 (1.4); 3.9197 (1.0); 3.9120 (0.7); 3.9091 (0.8); 3.9042 (1.1); 3.8206 (0.7); 3.8036 (1.9); 3.7998 (1.9); 3.7830 (2.4); 3.7664 (1.1); 3.7340 (3.2); 3.7125 (5.7); 3.7063 (3.4); 3.6934 (2.8); 3.6901 (2.2); 3.6864 (3.2); 3.5468 (16.0); 2.0360 (0.9); 2.0193 (1.2); 2.0066 (1.2); 1.9894 (0.8); 1.9567 (0.6); 1.9376 (1.0); 1.9246 (1.2); 1.9180 (1.2); 1.9055 (1.8); 1.8937 (1.6); 1.8846 (1.4); 1.8781 (2.0); 1.8601 (2.2); 1.8430 (2.2); 1.8302 (1.8); 1.8258 (1.5); 1.8128 (1.1); 1.8089 (1.1); 1.7986 (0.8); 1.7914 (0.8); 1.7830 (0.7); 1.7652 (0.6); 1.6167 (0.6); 1.5999 (0.8); 1.5814 (1.3); 1.5602 (8.8); 1.5350 (1.3); 1.5141 (1.2); 1.4979 (1.4); 1.4886 (1.2); 1.4816 (1.1); 1.4702 (0.7); 1.3924 (0.5); 1.3735 (0.8); 1.3514 (1.2); 1.3326 (1.4); 1.3169 (1.1); 1.3110 (1.1); 1.2983 (1.1); 1.2767 (0.9); 1.2565 (1.3); 1.1424 (6.4); 1.1386 (7.1); 1.1255 (6.3); 1.1217 (6.8); 1.0625 (7.0); 1.0456 (6.7); 0.9503 (3.6); 0.9441 (7.1); 0.9318 (7.1); 0.9256 (13.7); 0.9133 (3.3); 0.9071 (5.6); 0.8542 (0.5); 0.0080 (1.7); −0.0002 (55.0); −0.0084 (1.8)

Example No. I.5-72

[0366] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5188 (1.0); 7.4487 (1.2); 7.4439 (2.0); 7.4387 (2.5); 7.4346 (1.2); 7.4300 (1.5); 7.4252 (2.0); 7.4199 (2.5); 7.3650 (4.1); 7.3422 (4.1); 7.2598 (168.6); 6.9959 (0.9); 6.3440 (8.0); 4.1024 (0.7); 4.0935 (0.7); 4.0860 (0.8); 4.0759 (1.5); 4.0664 (1.0); 4.0588 (1.0); 4.0495 (1.0); 4.0001 (0.9); 3.9952 (1.0); 3.9840 (1.1); 3.9786 (2.0); 3.9758 (2.2); 3.9566 (1.5); 3.9078 (0.7); 3.9030 (0.7); 3.8884 (0.7); 3.8830 (0.8); 3.8765 (0.7); 3.8612 (0.6); 3.8563 (0.6); 3.8242 (0.9); 3.8095 (1.3); 3.8036 (2.1); 3.7893 (2.2); 3.7833 (1.5); 3.7693 (2.3); 3.7501 (1.6); 3.7367 (1.9); 3.7333 (1.8); 3.7289 (1.9); 3.7159 (2.2); 3.7062 (1.8); 3.6947 (2.6); 3.6891 (2.6); 3.6847 (3.3); 3.6745 (2.2); 3.6688 (1.7); 3.6643 (2.2); 3.5470 (16.0); 3.4565 (1.1); 3.4390 (1.8); 3.4241 (1.7); 3.4180 (1.5); 3.4026 (1.3); 2.4742 (0.7); 2.4577 (1.0); 2.4398 (1.1); 2.4227 (0.7); 2.0161 (0.8); 2.0051 (1.1); 1.9987 (1.3); 1.9888 (1.4); 1.9793 (1.3); 1.9679 (1.6); 1.9553 (1.2); 1.9484 (1.1); 1.9348 (1.1); 1.9245 (0.7); 1.5912 (0.7); 1.5526 (6.1); 1.5288 (2.5); 1.5141 (1.6); 1.4977 (1.1); 1.3756 (0.6); 1.3573 (0.6); 1.3416 (0.6); 1.3294 (0.8); 1.3111 (1.1); 1.2900 (1.0); 1.2770 (0.9); 1.2558 (1.9); 1.1431 (11.4); 1.1261 (11.0); 1.0483 (6.6); 1.0315 (6.4); 0.9594 (3.3); 0.9472 (6.0); 0.9409 (7.3); 0.9288 (11.8); 0.9224 (3.5); 0.9102 (4.7); 0.0690 (0.8); 0.0080 (2.1); −0.0002 (70.1); −0.0085 (2.4)

Example No. I.5-91

[0367] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5349 (1.3); 7.5212 (1.6); 7.5187 (1.7); 7.5160 (1.5); 7.5079 (1.0); 7.5023 (1.5); 7.4891 (1.0); 7.4794 (2.6); 7.4685 (1.7); 7.4607 (2.6); 7.4498 (1.7); 7.3498 (2.9); 7.3388 (3.3); 7.3271 (3.0); 7.3159 (3.3); 7.3087 (0.6); 7.2927 (0.6); 7.2598 (206.5); 7.2220 (0.6); 7.2094 (1.0); 6.9958 (1.1); 6.3446 (8.4); 4.1110 (0.7); 4.1078 (0.7); 4.1004 (0.9); 4.0912 (0.9); 4.0823 (1.0); 4.0789 (1.0); 4.0707 (1.2); 4.0627 (1.0); 4.0431 (0.5); 4.0348 (0.5); 4.0259 (0.5); 4.0170 (1.0); 4.0144 (1.1); 4.0057 (1.2); 3.9970 (1.2); 3.9885 (1.4); 3.9832 (1.2); 3.9734 (1.7); 3.9674 (2.3); 3.9629 (0.9); 3.9552 (1.6); 3.9499 (1.4); 3.9445 (1.3); 3.9383 (1.4); 3.9351 (1.4); 3.9265 (2.1); 3.9210 (1.9); 3.9062 (1.4); 3.8987 (1.5); 3.8896 (1.6); 3.7220 (2.4); 3.7155 (3.0); 3.7004 (3.1); 3.6958 (3.0); 3.5497 (16.0); 3.5190 (0.8); 3.4460 (0.9); 3.4202 (1.0); 3.3835 (1.6); 3.3761 (1.4); 3.3563 (1.8); 3.3489 (1.5); 3.3358 (0.7); 3.3279 (0.9); 2.0371 (0.8); 2.0200 (1.1); 2.0100 (1.2); 1.8310 (1.5); 1.8004 (1.4); 1.7770 (0.7); 1.6047 (0.8); 1.5481 (14.7); 1.4797 (5.5); 1.4415 (1.4); 1.4095 (0.7); 1.3876 (0.6); 1.3680 (0.8); 1.3496 (1.2); 1.3314 (1.2); 1.3095 (1.1); 1.2908 (1.1); 1.2755 (1.0); 1.2568 (1.6); 1.2354 (1.1); 1.2219 (1.0); 1.1340 (9.4); 1.1171 (9.3); 1.0628 (4.5); 1.0571 (4.2); 1.0460 (4.4); 1.0402 (4.0); 0.9437 (4.9); 0.9285 (8.0); 0.9253 (9.4); 0.9226 (8.3); 0.9098 (4.0); 0.9067 (4.2); 0.0080 (3.1); −0.0002 (80.3); −0.0058 (1.7);−0.0085 (2.8)

Example No. I.5-221

[0368] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.3403 (3.2); 7.3303 (3.8); 7.3177 (3.4); 7.3080 (5.6); 7.2896 (2.1); 7.2762 (2.7); 7.2614 (66.2); 7.1829 (1.9); 7.1648 (2.1); 7.1591 (2.0); 7.1410 (2.0); 6.8890 (0.7); 6.8741 (0.8); 6.8567 (1.0); 6.8420 (1.1); 6.8286 (0.8); 6.8164 (0.8); 6.3342 (4.8); 6.3287 (9.1); 3.8612 (1.0); 3.8482 (0.9); 3.8269 (0.6); 3.8193 (1.1); 3.8018 (2.5); 3.7931 (1.7); 3.7840 (2.9); 3.7756 (1.5); 3.7661 (1.3); 3.7571 (0.7); 3.7409 (1.0); 3.7280 (1.5); 3.7127 (1.5); 3.7022 (1.4); 3.6961 (1.3); 3.6822 (1.6); 3.6632 (5.7); 3.6549 (3.1); 3.6476 (5.6); 3.6400 (2.6); 3.6299 (1.6); 3.6102 (0.8); 3.5420 (10.4); 3.5330 (13.0); 3.5171 (0.9); 3.5123 (0.8); 3.5081 (0.8); 3.5003 (0.8); 3.4957 (0.8); 3.4912 (0.8); 3.4826 (0.9); 3.4778 (0.9); 3.4689 (1.4); 3.4611 (1.6); 3.4532 (1.4); 3.4462 (1.0); 3.4351 (0.8); 3.4266 (1.1); 3.4192 (1.0); 3.4119 (1.0); 3.4035 (0.5); 3.2025 (0.6); 3.1883 (1.2); 3.1723 (1.2); 3.1540 (1.1); 3.1379 (1.0); 3.1236 (0.6); 3.1083 (0.7); 3.1032 (0.7); 3.0964 (0.7); 3.0906 (1.0); 3.0844 (0.6); 3.0733 (1.0); 3.0622 (0.6); 3.0563 (0.8); 3.0502 (0.5); 3.0430 (0.5); 2.1401 (0.9); 2.1337 (1.2); 2.1241 (1.4); 2.1177 (1.6); 2.1115 (1.4); 2.1016 (1.3); 2.0950 (1.0); 2.0853 (0.6); 1.9187 (0.6); 1.9060 (0.9); 1.9016 (0.9); 1.8847 (1.4); 1.8655 (2.0); 1.8606 (2.2); 1.8506 (2.2); 1.8437 (2.4); 1.8315 (2.7); 1.8255 (2.7); 1.8142 (2.0); 1.7950 (1.4); 1.7767 (1.2); 1.7579 (0.9); 1.7356 (1.1); 1.7255 (1.5); 1.7171 (1.8); 1.7013 (2.1); 1.6916 (1.7); 1.6825 (2.0); 1.6725 (1.5); 1.6539 (0.9); 1.5910 (7.0); 1.4842 (0.6); 1.4623 (0.8); 1.4549 (0.8); 1.4447 (0.9); 1.4363 (1.3); 1.4276 (0.6); 1.4180 (1.0); 1.3861 (0.8); 1.3739 (1.0); 1.3680 (1.1); 1.3514 (1.6); 1.3453 (1.3); 1.3335 (1.8); 1.3162 (1.6); 1.2987 (1.5); 1.2805 (1.1); 1.2577 (1.4); 1.1228 (11.1); 1.1147 (11.3); 1.1059 (11.2); 1.0977 (10.5); 1.0780 (1.2); 1.0703 (0.6); 1.0599 (1.5); 1.0408 (0.8); 0.9614 (8.3); 0.9431 (16.0); 0.9246 (7.2); 0.0079 (1.4); −0.0002 (26.5); −0.0076 (1.1)

Example No. I.6-71

[0369] Diastereomer 1—.sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5305 (2.5); 7.5216 (2.6); 7.5117 (2.5); 7.5029 (2.4); 7.4791 (1.9); 7.4750 (2.0); 7.4604 (1.9); 7.4564 (1.9); 7.3733 (0.7); 7.3510 (6.3); 7.3282 (6.4); 7.3159 (1.4); 7.3100 (1.4); 7.2932 (1.5); 7.2604 (113.3); 6.9964 (0.6); 6.3411 (10.3); 6.3363 (3.9); 6.3192 (0.6); 4.7508 (0.6); 4.7392 (0.5); 4.1649 (1.3); 4.1559 (1.5); 4.1472 (1.4); 4.1369 (2.0); 4.1277 (1.9); 4.1192 (1.6); 4.1102 (1.8); 4.0775 (1.3); 4.0589 (2.1); 4.0522 (1.7); 4.0426 (3.1); 4.0352 (2.2); 4.0266 (2.3); 4.0181 (1.4); 4.0096 (1.6); 3.9945 (2.2); 3.9785 (2.6); 3.9650 (1.6); 3.9613 (1.5); 3.9554 (2.2); 3.9479 (2.2); 3.9395 (1.3); 3.9317 (1.5); 3.9275 (1.4); 3.9197 (1.4); 3.9114 (1.0); 3.9035 (1.1); 3.8478 (0.6); 3.8278 (1.1); 3.8233 (1.2); 3.8105 (1.5); 3.8063 (2.6); 3.8025 (2.3); 3.7897 (2.4); 3.7854 (2.9); 3.7734 (1.0); 3.7688 (1.6); 3.7473 (1.1); 3.7289 (1.6); 3.7199 (1.6); 3.7139 (2.1); 3.7024 (1.3); 3.6959 (1.5); 3.6815 (0.6); 3.6719 (0.6); 3.6156 (3.4); 3.5942 (3.9); 3.5896 (3.5); 3.5848 (3.4); 3.5684 (3.8); 3.5637 (3.9); 3.5480 (16.0); 2.2721 (0.5); 2.2567 (0.8); 2.2408 (1.4); 2.2234 (1.9); 2.2057 (1.8); 2.1886 (1.1); 1.9616 (1.0); 1.9439 (1.5); 1.9293 (1.7); 1.9225 (1.6); 1.9103 (2.1); 1.8983 (2.0); 1.8934 (2.1); 1.8810 (2.6); 1.8623 (2.3); 1.8489 (2.3); 1.8317 (1.8); 1.8193 (0.9); 1.8148 (1.1); 1.7980 (0.5); 1.5731 (6.5); 1.5505 (1.5); 1.5394 (1.3); 1.5187 (1.4); 1.5104 (1.2); 1.5020 (1.4); 1.4926 (1.1); 1.4851 (1.1); 1.4735 (0.7); 1.2566 (1.4); 1.1983 (2.5); 1.1813 (3.0); 1.1681 (14.0); 1.1512 (12.4); 1.1261 (1.8); 1.0874 (15.4); 1.0707 (14.6); 0.9742 (1.1); 0.9653 (1.1); 0.9567 (1.2); 0.9515 (1.3); 0.9450 (1.3); 0.9343 (1.0); 0.9278 (1.1); 0.8902 (1.1); 0.8844 (1.1); 0.8731 (1.2); 0.8673 (1.5); 0.8525 (1.0); 0.0691 (2.2); 0.0495 (0.6); 0.0080 (2.2); −0.0002 (47.6); −0.0085 (1.4). 2—.sup.1Diastereomer H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5306 (1.0); 7.5218 (1.0); 7.5190 (0.8); 7.5118 (1.0); 7.5030 (0.8); 7.4792 (0.7); 7.4751 (0.7); 7.4605 (0.7); 7.4563 (0.7); 7.3511 (2.4); 7.3283 (2.6); 7.3159 (0.8); 7.2930 (0.9); 7.2600 (87.8); 6.3414 (3.8); 6.3366 (1.4); 4.1561 (0.5); 4.1371 (0.7); 4.1277 (0.6); 4.1193 (0.6); 4.1103 (0.7); 4.0776 (0.5); 4.0592 (0.8); 4.0522 (0.6); 4.0428 (1.1); 4.0354 (0.8); 4.0265 (0.9); 4.0096 (0.6); 3.9946 (0.8); 3.9786 (1.0); 3.9650 (0.6); 3.9556 (0.8); 3.9481 (0.8); 3.9396 (0.5); 3.9318 (0.5); 3.9277 (0.5); 3.8063 (1.0); 3.8025 (0.9); 3.7898 (0.9); 3.7856 (1.1); 3.7688 (0.6); 3.7288 (0.6); 3.7137 (0.8); 3.6958 (0.6); 3.6156 (1.3); 3.5942 (1.4); 3.5896 (1.2); 3.5849 (1.2); 3.5685 (1.3); 3.5637 (1.4); 3.5482 (6.0); 2.2407 (0.5); 2.2235 (0.7); 2.2056 (0.7); 1.9436 (0.5); 1.9304 (0.6); 1.9098 (0.7); 1.8987 (0.8); 1.8936 (0.8); 1.8812 (1.0); 1.8653 (0.9); 1.8490 (0.9); 1.8317 (0.7); 1.5451 (16.0); 1.5117 (0.6); 1.5019 (0.6); 1.2561 (0.5); 1.1978 (0.8); 1.1810 (1.0); 1.1682 (5.2); 1.1512 (4.7); 1.1424 (1.0); 1.1254 (0.8); 1.0875 (5.8); 1.0708 (5.5); 0.9504 (0.5); 0.8669 (0.6); 0.0079 (1.6); −0.0002 (36.7); −0.0085 (1.3)

Example No. I.6-72

[0370] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.4494 (0.8); 7.4422 (0.9); 7.4313 (0.9); 7.4234 (0.8); 7.3668 (1.7); 7.3440 (1.6); 7.2600 (52.6); 7.2486 (4.5); 6.3444 (2.9); 3.9972 (0.5); 3.9828 (1.0); 3.9637 (0.6); 3.8045 (0.8); 3.7905 (0.9); 3.7701 (0.8); 3.7381 (0.8); 3.7293 (0.9); 3.7169 (0.8); 3.6896 (0.6); 3.5670 (1.2); 3.5476 (7.5); 3.4456 (0.7); 3.4240 (0.7); 2.4434 (0.5); 2.2053 (0.6); 2.1849 (0.6); 1.5447 (16.0); 1.5014 (0.5); 1.1698 (5.2); 1.1530 (4.8); 1.0714 (4.6); 1.0548 (4.6); 0.8641 (0.6); −0.0002 (21.5)

Example No. I.8-1

[0371] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5183 (1.0); 7.4509 (1.8); 7.4325 (1.8); 7.3573 (1.8); 7.3347 (1.8); 7.2595 (177.5); 6.9955 (1.0); 6.3526 (2.7); 4.2560 (1.9); 4.2480 (0.9); 4.2444 (1.7); 4.2404 (1.0); 4.2326 (2.0); 3.6814 (7.7); 3.5542 (5.0); 3.5493 (1.9); 3.5426 (1.7); 3.5390 (1.0); 3.5309 (1.9); 3.3345 (15.6); 1.5447 (16.0); 0.0079 (2.0); −0.0002 (66.1); −0.0085 (1.8)

Example No. I.8-71

[0372] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.4556 (3.8); 7.4533 (3.8); 7.4373 (3.8); 7.4350 (3.8); 7.3539 (6.5); 7.3313 (6.4); 7.2612 (22.7); 6.3513 (5.6); 6.3468 (5.7); 4.1694 (1.5); 4.1634 (3.1); 4.1439 (3.9); 4.1371 (2.3); 4.0831 (1.2); 4.0732 (1.3); 4.0661 (1.8); 4.0598 (1.6); 4.0562 (1.7); 4.0501 (4.1); 4.0468 (4.1); 4.0413 (1.6); 4.0389 (1.7); 4.0333 (0.9); 4.0239 (2.5); 4.0222 (2.5); 4.0071 (1.2); 4.0052 (1.1); 3.8570 (1.4); 3.8399 (2.5); 3.8359 (2.4); 3.8232 (1.6); 3.8189 (3.6); 3.8026 (1.6); 3.7669 (1.6); 3.7492 (2.3); 3.7335 (2.0); 3.7284 (1.7); 3.7129 (0.9); 3.6874 (14.5); 3.6848 (15.2); 3.6468 (0.6); 3.5553 (11.1); 3.5523 (16.0); 3.5491 (11.7); 1.9827 (0.5); 1.9758 (0.6); 1.9653 (0.9); 1.9541 (0.9); 1.9444 (1.1); 1.9392 (0.8); 1.9325 (1.2); 1.9248 (1.1); 1.9182 (1.0); 1.9142 (1.3); 1.9027 (1.5); 1.8991 (1.5); 1.8941 (1.0); 1.8839 (2.8); 1.8790 (1.5); 1.8666 (2.8); 1.8631 (2.1); 1.8534 (0.9); 1.8492 (1.3); 1.8460 (1.4); 1.8370 (0.5); 1.8286 (0.7); 1.5678 (0.6); 1.5579 (5.6); 1.5515 (1.4); 1.5424 (0.8); 1.5380 (0.8); 1.5339 (1.0); 1.5300 (1.1); 1.5206 (0.8); 1.5167 (0.8); 1.5024 (0.6); 1.2561 (0.7); 0.0080 (1.0); −0.0002 (28.3);−0.0084 (1.0)

Example No. I.8-72

[0373] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.4132 (1.8); 7.4110 (1.8); 7.3949 (1.8); 7.3927 (1.8); 7.3672 (3.1); 7.3446 (3.1); 7.2602 (33.7); 6.3546 (4.8); 4.1376 (0.7); 4.1212 (0.8); 4.1106 (1.2); 4.0943 (1.2); 4.0203 (1.6); 4.0007 (1.7); 3.9932 (1.1); 3.9736 (1.1); 3.8260 (0.9); 3.8125 (1.0); 3.8055 (0.7); 3.7916 (0.6); 3.7776 (1.2); 3.7596 (1.4); 3.7554 (1.6); 3.7378 (2.2); 3.7194 (1.3); 3.7015 (1.1); 3.6804 (0.7); 3.6561 (11.2); 3.5559 (7.3); 3.5529 (7.3); 3.5036 (1.2); 3.4900 (1.3); 3.4813 (1.1); 3.4679 (1.0); 2.5140 (0.6); 2.0444 (0.8); 1.9916 (0.6); 1.9711 (0.6); 1.9581 (0.5); 1.5876 (0.5); 1.5705 (0.7); 1.5534 (0.7); 1.5403 (16.0); 1.2590 (0.9); 0.8818 (1.1); 0.0079 (1.4); −0.0002 (42.1); −0.0085 (1.5)

Example No. I.8-271

[0374] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5191 (1.1); 7.3651 (7.4); 7.3428 (7.2); 7.2603 (202.8); 7.2103 (1.2); 7.1112 (4.1); 7.0928 (6.0); 7.0745 (3.8); 6.9962 (1.1); 6.7496 (1.2); 6.7299 (1.2); 6.3497 (6.8); 6.3426 (6.4); 5.2988 (5.1); 4.9359 (1.3); 4.4655 (1.2); 4.4591 (1.3); 4.4534 (1.3); 4.4469 (1.2); 3.8564 (0.7); 3.8523 (0.7); 3.8345 (2.2); 3.8162 (2.5); 3.7981 (1.2); 3.7939 (1.2); 3.7863 (2.1); 3.7804 (2.2); 3.7728 (2.1); 3.7669 (2.4); 3.7625 (4.8); 3.7563 (2.9); 3.7487 (4.9); 3.7420 (4.7); 3.7272 (3.7); 3.7195 (1.6); 3.7054 (1.5); 3.6196 (15.1); 3.6167 (16.0); 3.5822 (2.6); 3.5759 (2.2); 3.5517 (10.6); 3.5484 (11.9); 3.5446 (12.3); 3.5413 (10.3); 2.2411 (1.0); 2.2232 (1.7); 2.2200 (1.2); 2.2079 (1.3); 2.2054 (1.3); 2.2019 (1.7); 2.1902 (2.0); 2.1868 (1.5); 2.1842 (1.2); 2.1721 (1.3); 2.1688 (1.9); 2.1509 (1.1); 2.0053 (0.5); 1.7305 (0.7); 1.7228 (0.8); 1.7173 (0.8); 1.7117 (1.1); 1.7036 (1.1); 1.6971 (1.0); 1.6897 (1.0); 1.6841 (0.8); 1.6779 (0.7); 1.6699 (0.6); 1.5550 (4.8); 1.2554 (1.8); 0.0689 (14.7); 0.0080 (2.4); −0.0002 (85.2); −0.0085 (2.4); −0.0501 (0.6)

Example No. I.12-71

[0375] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5355 (0.6); 7.5317 (0.6); 7.5176 (0.6); 7.5129 (0.5); 7.3540 (1.2); 7.3311 (1.2); 7.2598 (43.5); 4.1310 (0.6); 4.0497 (0.6); 4.0064 (0.7); 3.9911 (0.6); 3.9883 (0.5); 3.9809 (0.5); 3.7488 (0.6); 3.7325 (1.0); 3.7156 (1.0); 3.6957 (0.6); 3.5474 (3.2); 3.5421 (3.5); 3.5370 (1.9); 2.2520 (1.0); 2.2405 (2.6); 2.2290 (2.5); 2.2175 (0.9); 1.9789 (0.5); 1.9605 (0.6); 1.9435 (0.5); 1.9129 (0.5); 1.8807 (0.7); 1.8627 (0.8); 1.8516 (0.8); 1.8460 (0.7); 1.8335 (0.6); 1.5402 (16.0); 1.0789 (2.0); 1.0605 (3.8); 1.0421 (1.7); 0.0075 (1.4); −0.0002 (15.4); −0.0084 (0.6)

Example No. I.12-72

[0376] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.4641 (0.9); 7.4595 (0.9); 7.4454 (0.8); 7.4407 (0.8); 7.3689 (1.3); 7.3462 (1.2); 7.2599 (46.1); 5.2985 (1.5); 3.9504 (0.6); 3.8097 (0.6); 3.7957 (0.6); 3.7761 (0.7); 3.7589 (0.6); 3.7545 (0.6); 3.7381 (0.9); 3.7304 (0.5); 3.7251 (0.8); 3.7209 (1.2); 3.7092 (1.0); 3.7043 (1.0); 3.6886 (0.6); 3.5533 (1.8); 3.5482 (4.1); 3.5427 (4.1); 3.5373 (1.6); 3.4568 (0.7); 3.4347 (0.5); 2.2518 (1.3); 2.2404 (3.5); 2.2288 (3.5); 2.2173 (1.2); 1.9843 (0.5); 1.9679 (0.7); 1.9642 (0.7); 1.9495 (0.8); 1.9290 (0.6); 1.8624 (0.6); 1.8458 (0.6); 1.5585 (0.7); 1.5414 (16.0); 1.0712 (2.2); 1.0528 (4.3); 1.0344 (1.9); 0.0078 (1.1); −0.0002 (17.5); −0.0085 (0.7)

Example No. I.14-72

[0377] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.2595 (57.5); 6.2266 (1.7); 3.5467 (1.2); 3.5415 (1.1); 2.2410 (1.0); 2.2292 (1.0); 1.5330 (16.0); 1.4813 (0.6); 0.9650 (0.7); 0.9536 (1.4); 0.9485 (1.0); 0.9399 (1.9); 0.9250 (1.3); 0.0078 (0.8); −0.0002 (22.0); −0.0080 (1.0)

Example No. I.14-91

[0378] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.2594 (42.0); 3.5396 (0.5); 1.5350 (16.0); 0.9566 (0.6); 0.9511 (0.6); 0.9406 (0.7); 0.9350 (0.6); −0.0002 (14.2); −0.0084 (0.6)

Example No. I.42-71

[0379] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5184 (0.9); 7.3265 (2.4); 7.3038 (2.4); 7.2907 (2.2); 7.2758 (0.6); 7.2720 (2.6); 7.2686 (1.1); 7.2678 (1.1); 7.2670 (1.3); 7.2662 (1.4); 7.2595 (171.6); 7.2092 (1.3); 6.9956 (1.0); 6.3599 (3.3); 4.0376 (2.5); 4.0274 (1.6); 4.0230 (1.9); 3.5622 (4.7); 3.5595 (4.8); 3.3916 (0.6); 3.3884 (0.6); 3.1374 (3.5); 3.1325 (3.4); 1.5744 (0.7); 1.5387 (15.2); 1.5151 (0.7); 1.5038 (1.4); 1.4951 (1.1); 1.4631 (0.5); 1.3242 (16.0); 1.2841 (0.6); 1.2701 (1.1); 1.2567 (0.5); 1.2341 (0.8); 1.2195 (0.7); 1.2097 (0.8); 1.2059 (1.2); 0.0080 (2.0); −0.0002 (71.0); −0.0085 (2.2); −0.0506 (0.6)

Example No. I.42-72

[0380] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.3060 (3.0); 7.2836 (3.0); 7.2690 (0.5); 7.2599 (81.8); 6.9494 (2.9); 6.9312 (2.9); 6.3268 (4.4); 4.0856 (0.6); 4.0680 (0.6); 4.0582 (1.0); 4.0423 (1.0); 3.9787 (0.9); 3.9756 (0.9); 3.9594 (1.0); 3.9560 (0.9); 3.9518 (0.6); 3.9486 (0.6); 3.9324 (0.6); 3.9290 (0.6); 3.7782 (0.8); 3.7636 (0.8); 3.7578 (0.6); 3.7437 (0.5); 3.7096 (0.9); 3.7063 (0.8); 3.6889 (1.5); 3.6734 (1.0); 3.6663 (0.9); 3.5364 (6.2); 3.5334 (6.5); 3.3840 (0.8); 3.3698 (0.8); 3.3630 (0.7); 3.3494 (0.7); 2.4233 (0.5); 2.2017 (16.0); 2.1577 (14.4); 1.5484 (1.4); 1.4985 (0.6); 1.4827 (0.6); 1.4668 (0.6); 1.2560 (2.7); 0.8802 (0.6); 0.8531 (0.6); 0.0080 (1.0); −0.0002 (35.4); −0.0085 (1.0)

Example No. I.48-71

[0381] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.3292 (2.2); 7.3067 (3.9); 7.2888 (2.0); 7.2608 (27.8); 6.3583 (3.2); 4.1147 (0.8); 4.1055 (1.2); 4.0965 (0.6); 4.0888 (1.0); 4.0831 (1.6); 4.0740 (0.8); 4.0704 (0.6); 4.0394 (0.9); 4.0211 (1.0); 4.0081 (0.9); 3.8519 (0.8); 3.8481 (0.8); 3.8311 (1.3); 3.8147 (0.6); 3.7679 (0.7); 3.7508 (0.6); 3.5589 (4.3); 3.1366 (3.6); 3.1328 (3.8); 1.8940 (0.9); 1.8895 (0.6); 1.8774 (0.8); 1.8735 (0.8); 1.8565 (0.6); 1.5567 (2.0); 1.3283 (16.0); 1.2700 (0.8); 1.2410 (0.6); 1.2195 (0.6); 1.2103 (0.6); 1.2058 (0.8); −0.0002 (10.8)

Example No. I.48-72

[0382] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.3382 (1.7); 7.3155 (1.7); 7.2963 (1.6); 7.2779 (1.7); 7.2651 (0.6); 7.2642 (0.8); 7.2601 (41.8); 6.3600 (2.5); 4.0840 (0.6); 4.0677 (0.6); 4.0569 (0.9); 4.0405 (0.9); 3.9738 (1.0); 3.9542 (1.0); 3.9467 (0.6); 3.9271 (0.6); 3.8456 (0.6); 3.8327 (0.9); 3.8156 (0.6); 3.8116 (1.0); 3.7938 (0.6); 3.7425 (0.7); 3.7235 (0.5); 3.5614 (4.0); 3.5586 (4.0); 3.5467 (0.6); 3.5384 (0.5); 3.1124 (5.6); 3.0120 (0.6); 1.3111 (16.0); 1.2929 (1.9); 1.2705 (0.7); 1.2196 (0.6); 1.2080 (0.7); 0.0079 (0.5);−0.0002 (16.4); −0.0085 (0.5)

Example No. I.48-73

[0383] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.3371 (0.6); 7.3145 (0.6); 7.2942 (0.7); 7.2755 (1.0); 7.2593 (74.0); 6.3593 (1.3); 3.5591 (2.1); 3.1085 (2.5); 1.5314 (16.0); 1.3083 (7.0); 1.2623 (1.1); 1.2471 (0.9); 1.2224 (1.5); 1.2071 (1.6); 0.0080 (1.0); −0.0002 (28.2); −0.0084 (1.1)

Example No. I.48-81

[0384] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.3323 (1.9); 7.3094 (1.9); 7.3040 (1.5); 7.2856 (1.5); 7.2664 (0.6); 7.2656 (0.7); 7.2648 (0.8); 7.2639 (1.1); 7.2598 (65.4); 6.3605 (2.7); 4.1032 (0.8); 4.0835 (0.7); 4.0760 (1.1); 4.0563 (1.2); 4.0142 (1.2); 3.9978 (1.3); 3.9870 (0.6); 3.9705 (0.7); 3.5633 (4.1); 3.5603 (4.3); 3.1239 (3.7); 3.1224 (3.9); 2.8527 (0.6); 2.8378 (0.6); 2.0039 (0.8); 1.9975 (0.7); 1.9929 (1.1); 1.9892 (1.4); 1.9831 (0.8); 1.9807 (0.8); 1.9772 (0.7); 1.9739 (0.9); 1.7617 (0.5); 1.5482 (1.5); 1.3181 (16.0); 0.0080 (0.8); −0.0002 (25.8); −0.0085 (0.7)

Example No. I.48-82

[0385] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.3366 (1.2); 7.2593 (67.6); 7.2564 (64.9); 7.2508 (34.0); 6.3598 (1.6); 4.0843 (0.7); 4.0355 (0.6); 3.5596 (3.8); 3.1158 (2.7); 2.8813 (1.0); 2.8630 (1.4); 2.5976 (0.6); 2.1008 (0.6); 1.5306 (16.0); 1.5277 (15.3); 1.5221 (8.1); 1.3151 (7.9); −0.0002 (24.0); −0.0031 (23.2);−0.0087 (12.6)

Example No. I.48-91

[0386] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5184 (0.9); 7.3265 (2.4); 7.3038 (2.4); 7.2907 (2.2); 7.2758 (0.6); 7.2720 (2.6); 7.2686 (1.1); 7.2678 (1.1); 7.2670 (1.3); 7.2662 (1.4); 7.2595 (171.6); 7.2092 (1.3); 6.9956 (1.0); 6.3599 (3.3); 4.0376 (2.5); 4.0274 (1.6); 4.0230 (1.9); 3.5622 (4.7); 3.5595 (4.8); 3.3916 (0.6); 3.3884 (0.6); 3.1374 (3.5); 3.1325 (3.4); 1.5744 (0.7); 1.5387 (15.2); 1.5151 (0.7); 1.5038 (1.4); 1.4951 (1.1); 1.4631 (0.5); 1.3242 (16.0); 1.2841 (0.6); 1.2701 (1.1); 1.2567 (0.5); 1.2341 (0.8); 1.2195 (0.7); 1.2097 (0.8); 1.2059 (1.2); 0.0080 (2.0); −0.0002 (71.0); −0.0085 (2.2); −0.0506 (0.6)

Example No. I.48-93

[0387] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5183 (0.7); 7.3344 (1.5); 7.3117 (1.6); 7.2861 (1.7); 7.2594 (115.4); 6.9954 (0.6); 6.3597 (2.6); 3.9796 (0.6); 3.9694 (0.6); 3.9501 (0.7); 3.9418 (0.7); 3.9197 (2.6); 3.9036 (2.6); 3.5617 (4.0); 3.5591 (3.9); 3.4026 (0.6); 3.3973 (0.7); 3.3731 (1.2); 3.3681 (1.2); 3.3437 (0.6); 3.3387 (0.6); 3.1160 (5.2); 2.0436 (1.1); 1.6081 (0.6); 1.5766 (0.8); 1.5325 (15.9); 1.3793 (0.6); 1.3676 (0.6); 1.3464 (0.6); 1.3345 (0.7); 1.3177 (16.0); 1.2897 (0.5); 1.2765 (0.5); 1.2587 (1.3); 0.0080 (1.7);−0.0002 (44.1); −0.0085 (1.4)

Example No. I.48-121

[0388] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5182 (0.5); 7.3372 (1.1); 7.3281 (0.6); 7.3234 (0.6); 7.3145 (1.1); 7.3051 (0.6); 7.2594 (86.1); 6.3602 (1.6); 3.8787 (0.6); 3.8738 (0.6); 3.8675 (0.6); 3.8352 (0.5); 3.5596 (2.7); 3.1196 (1.0); 3.1166 (1.0); 3.1113 (1.1); 3.1080 (1.0); 3.0915 (0.6); 1.5312 (16.0); 1.3010 (7.9); 1.2943 (2.5); 1.2586 (0.5); 1.2026 (2.0); 0.8819 (0.6); 0.0079 (1.0); −0.0002 (33.9); −0.0085 (1.4)

Example No. I.48-221

[0389] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.3103 (0.9); 7.2876 (1.0); 7.2594 (77.1); 6.3567 (1.2); 3.5597 (1.8); 3.5569 (1.8); 3.1559 (0.5); 3.1446 (0.5); 3.1241 (0.5); 1.5359 (16.0); 1.3178 (3.1); 1.3132 (2.1); 1.3074 (1.7); 0.0079 (1.1); −0.0002 (28.7); −0.0085 (1.0)

Example No. I.49-71

[0390] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5196 (0.7); 7.4294 (4.1); 7.4269 (4.4); 7.4107 (4.2); 7.4082 (4.4); 7.3731 (8.2); 7.3501 (8.2); 7.2728 (0.5); 7.2721 (0.6); 7.2712 (0.6); 7.2705 (0.7); 7.2696 (0.8); 7.2689 (0.9); 7.2680 (1.0); 7.2672 (1.2); 7.2664 (1.4); 7.2656 (1.7); 7.2648 (2.2); 7.2607 (122.4); 6.9966 (0.7); 6.3693 (1.3); 6.3586 (6.3); 6.3546 (6.2); 4.1857 (1.4); 4.1770 (1.7); 4.1735 (1.1); 4.1709 (1.0); 4.1651 (1.1); 4.1626 (1.2); 4.1579 (1.7); 4.1492 (2.6); 4.1461 (1.4); 4.1436 (1.2); 4.1376 (1.8); 4.1353 (1.8); 4.1282 (0.5); 4.1207 (0.7); 4.1113 (1.5); 4.1039 (1.7); 4.0943 (1.6); 4.0863 (1.8); 4.0792 (1.3); 4.0690 (0.8); 4.0621 (0.6); 4.0365 (2.1); 4.0203 (3.9); 4.0090 (1.4); 4.0034 (1.9); 3.9925 (2.8); 3.9756 (1.4); 3.8871 (0.8); 3.8832 (0.7); 3.8700 (1.6); 3.8662 (2.5); 3.8627 (1.2); 3.8535 (1.0); 3.8492 (3.0); 3.8455 (2.0); 3.8325 (1.1); 3.8284 (1.0); 3.7965 (1.0); 3.7927 (0.9); 3.7764 (2.0); 3.7586 (1.8); 3.7422 (0.6); 3.7042 (1.1); 3.6887 (1.7); 3.6835 (1.4); 3.6719 (1.5); 3.6682 (1.8); 3.6514 (1.2); 3.5631 (11.1); 3.5600 (16.0); 3.5569 (11.6); 2.7333 (1.6); 2.7185 (1.7); 2.6938 (2.6); 2.6790 (2.6); 2.5796 (3.0); 2.5764 (1.6); 2.5589 (2.8); 2.5557 (1.5); 2.5401 (1.8); 2.5370 (1.0); 2.5194 (1.7); 2.5163 (0.9); 2.0187 (0.7); 2.0140 (0.8); 2.0016 (1.3); 1.9944 (0.9); 1.9896 (0.8); 1.9808 (1.7); 1.9730 (0.8); 1.9683 (1.3); 1.9512 (1.2); 1.9363 (0.7); 1.9331 (0.8); 1.9246 (1.1); 1.9163 (1.4); 1.9072 (3.1); 1.9034 (1.8); 1.9001 (1.7); 1.8907 (2.8); 1.8871 (2.4); 1.8728 (1.4); 1.8699 (2.1); 1.8524 (0.8); 1.6316 (0.5); 1.6236 (0.8); 1.6134 (1.1); 1.6096 (0.9); 1.6015 (1.1); 1.5919 (1.5); 1.5833 (1.2); 1.5743 (1.3); 1.5572 (8.3); 1.3735 (16.0); 1.3566 (15.6); 1.2562 (0.9); 0.0080 (1.5); −0.0002 (47.8); −0.0085 (1.3)

Example No. I.49-72

[0391] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.4106 (1.7); 7.4041 (2.3); 7.4005 (2.0); 7.3919 (1.8); 7.3854 (2.5); 7.3803 (6.7); 7.3573 (6.1); 7.2683 (0.5); 7.2674 (0.6); 7.2666 (0.7); 7.2658 (0.9); 7.2650 (1.2); 7.2642 (1.6); 7.2608 (84.6); 7.2544 (0.8); 7.2536 (0.6); 7.2528 (0.5); 6.3611 (5.5); 4.1353 (0.6); 4.1308 (0.6); 4.1189 (0.7); 4.1145 (1.5); 4.1082 (1.0); 4.1036 (1.0); 4.0983 (1.0); 4.0917 (1.0); 4.0874 (2.4); 4.0712 (1.5); 4.0250 (1.1); 4.0216 (1.1); 4.0054 (1.2); 4.0011 (1.5); 3.9971 (1.5); 3.9770 (1.4); 3.9697 (0.8); 3.9531 (0.7); 3.9496 (0.7); 3.8716 (0.9); 3.8576 (1.0); 3.8508 (2.0); 3.8366 (3.3); 3.8302 (1.5); 3.8170 (3.7); 3.7955 (1.9); 3.7629 (1.2); 3.7437 (2.6); 3.7244 (2.0); 3.7051 (0.9); 3.6919 (1.1); 3.6751 (1.5); 3.6715 (1.4); 3.6548 (1.6); 3.6393 (1.1); 3.5730 (2.8); 3.5637 (9.4); 3.5603 (14.9); 3.5571 (10.6); 3.5533 (4.2); 3.5372 (2.2); 2.7027 (0.6); 2.6980 (0.8); 2.6926 (0.6); 2.6879 (0.6); 2.6835 (0.8); 2.6775 (0.6); 2.6633 (1.0); 2.6587 (1.3); 2.6533 (1.1); 2.6486 (1.0); 2.6439 (1.3); 2.6383 (0.9); 2.5794 (0.9); 2.5615 (1.1); 2.5423 (2.0); 2.5389 (2.5); 2.5354 (1.4); 2.5219 (1.4); 2.5184 (2.1); 2.5147 (1.2); 2.5030 (0.8); 2.4996 (1.3); 2.4961 (0.8); 2.4827 (0.8); 2.4791 (1.3); 2.4754 (0.8); 2.0520 (0.8); 2.0389 (1.1); 2.0296 (0.8); 2.0201 (1.2); 2.0070 (0.8); 1.6590 (0.7); 1.6413 (1.1); 1.6271 (1.4); 1.6074 (1.4); 1.5925 (1.1); 1.5748 (2.4); 1.3725 (16.0); 1.3555 (15.6); 1.2557 (0.8); 0.0080 (1.0); −0.0002 (35.6); −0.0085 (1.0)

Example No. I.49-91

[0392] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5192 (1.1); 7.4199 (3.9); 7.4168 (3.7); 7.4122 (0.8); 7.4012 (3.9); 7.3981 (3.6); 7.3894 (0.6); 7.3718 (6.7); 7.3489 (6.7); 7.2748 (0.5); 7.2740 (0.6); 7.2732 (0.6); 7.2717 (0.8); 7.2708 (0.9); 7.2701 (1.0); 7.2692 (1.1); 7.2685 (1.3); 7.2677 (1.4); 7.2668 (1.7); 7.2660 (2.0); 7.2652 (2.5); 7.2644 (3.2); 7.2603 (192.6); 7.2539 (1.5); 7.2514 (0.5); 6.9963 (1.1); 6.4032 (0.6); 6.3602 (5.9); 6.3561 (6.0); 5.9753 (1.4); 4.1184 (1.2); 4.1100 (1.4); 4.0981 (0.7); 4.0894 (2.4); 4.0810 (2.5); 4.0781 (1.9); 4.0691 (1.6); 4.0522 (2.6); 4.0355 (2.7); 4.0323 (1.6); 4.0302 (1.5); 4.0231 (0.9); 4.0147 (1.5); 4.0127 (1.5); 4.0064 (1.5); 4.0009 (1.7); 3.9951 (1.4); 3.9859 (1.4); 3.9714 (1.3); 3.9671 (1.3); 3.9612 (1.2); 3.7055 (1.0); 3.6905 (1.5); 3.6735 (1.4); 3.6694 (1.6); 3.6529 (1.1); 3.5949 (0.9); 3.5917 (1.0); 3.5642 (10.4); 3.5610 (15.2); 3.5576 (11.4); 3.5298 (1.1); 3.5210 (1.0); 3.5036 (1.0); 3.4972 (0.7); 3.4451 (1.1); 3.4407 (1.0); 3.4174 (1.9); 3.4127 (1.5); 3.3889 (0.9); 2.7355 (1.2); 2.7226 (1.2); 2.6957 (2.0); 2.6813 (1.9); 2.5817 (2.3); 2.5607 (2.2); 2.5422 (1.5); 2.5213 (1.4); 1.8716 (1.1); 1.8589 (0.9); 1.8426 (0.9); 1.7458 (1.0); 1.7284 (1.0); 1.5951 (1.4); 1.5627 (4.3); 1.5527 (4.0); 1.5347 (4.4); 1.5247 (3.8); 1.5179 (4.0); 1.5098 (3.1); 1.4869 (1.8); 1.4780 (1.5); 1.4685 (0.7); 1.4474 (0.5); 1.3679 (16.0); 1.3510 (15.7); 1.3238 (1.0); 1.3092 (0.9); 1.2951 (0.8); 1.2846 (0.7); 1.2558 (1.6); 0.0080 (2.6); 0.0064 (0.9); 0.0056 (1.0); 0.0048 (1.2); 0.0039 (1.5); −0.0002 (78.4); −0.0067 (0.7); −0.0084 (2.1)

Example No. I.54-71

[0393] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.3208 (1.3); 7.2979 (1.7); 7.2912 (1.7); 7.2726 (2.6); 7.2593 (70.2); 4.0864 (0.7); 3.5567 (1.6); 3.5515 (1.5); 3.1329 (1.5); 3.1297 (1.5); 2.2606 (0.5); 2.2492 (1.4); 2.2378 (1.5); 2.2262 (0.5); 1.5330 (16.0); 1.3269 (6.7); −0.0002 (24.8);−0.0084 (0.8)

Example No. I.54-82

[0394] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5183 (0.5); 7.3313 (1.4); 7.3086 (1.5); 7.2883 (1.4); 7.2697 (1.9); 7.2594 (89.8); 5.2984 (0.6); 4.0886 (0.6); 4.0728 (0.6); 4.0707 (0.6); 4.0401 (0.6); 4.0245 (0.6); 3.5636 (1.1); 3.5585 (3.1); 3.5531 (3.2); 3.5477 (1.2); 3.1156 (4.8); 2.9201 (0.6); 2.9102 (0.6); 2.8940 (0.6); 2.8830 (1.3); 2.8686 (1.5); 2.8636 (1.5); 2.8492 (1.3); 2.6274 (0.6); 2.6084 (0.7); 2.5822 (0.7); 2.2619 (0.8); 2.2504 (2.7); 2.2389 (2.9); 2.2274 (1.0); 1.5303 (16.0); 1.3159 (14.4); 0.0080 (1.1); −0.0002 (35.1); −0.0085 (1.4)

Example No. I.54-221

[0395] Diastereomer 1—.sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.3038 (3.1); 7.2871 (1.2); 7.2813 (2.5); 7.2599 (71.2); 5.2983 (2.7); 3.9383 (0.5); 3.8513 (0.7); 3.8472 (0.6); 3.8308 (0.9); 3.7432 (0.9); 3.7266 (0.6); 3.7227 (0.6); 3.5559 (4.7); 3.5505 (4.9); 3.5451 (1.9); 3.1943 (0.6); 3.1787 (0.8); 3.1742 (0.7); 3.1486 (1.5); 3.1439 (1.6); 3.1151 (1.5); 3.1107 (1.4); 3.0847 (0.6); 3.0805 (0.6); 2.2599 (1.2); 2.2485 (3.9); 2.2369 (4.1); 2.2254 (1.4); 1.9451 (0.5); 1.9179 (0.8); 1.9023 (1.2); 1.8833 (1.3); 1.8662 (0.8); 1.5497 (16.0); 1.3156 (8.3); 1.3076 (7.1); 1.2954 (0.5); 1.1850 (0.5); 0.0080 (0.8); −0.0002 (26.3); −0.0084 (0.9). Diastereomer 2-.sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.3105 (0.7); 7.3038 (5.6); 7.2870 (2.3); 7.2837 (2.7); 7.2812 (4.5); 7.2601 (82.6); 6.1429 (0.8); 5.2984 (6.5); 3.9465 (0.9); 3.9382 (0.9); 3.9292 (0.9); 3.9207 (0.9); 3.8682 (0.7); 3.8512 (1.4); 3.8472 (1.2); 3.8349 (0.9); 3.8307 (1.8); 3.8144 (0.9); 3.7606 (0.9); 3.7433 (1.7); 3.7266 (1.1); 3.7230 (1.1); 3.7062 (0.6); 3.5608 (3.0); 3.5558 (8.8); 3.5504 (9.1); 3.5450 (3.6); 3.5344 (0.6); 3.5236 (0.6); 3.5210 (0.6); 3.5152 (0.7); 3.5125 (0.7); 3.5083 (0.7); 3.5058 (0.6); 3.4999 (0.6); 3.4972 (0.6); 3.2110 (0.6); 3.2072 (0.6); 3.1983 (0.6); 3.1941 (1.1); 3.1899 (0.6); 3.1786 (1.5); 3.1742 (1.4); 3.1637 (0.6); 3.1596 (0.9); 3.1552 (0.6); 3.1485 (2.8); 3.1438 (3.0); 3.1151 (2.8); 3.1106 (2.6); 3.0848 (1.0); 3.0803 (1.1); 2.2598 (2.2); 2.2484 (7.3); 2.2368 (7.7); 2.2253 (2.6); 2.0434 (1.8); 1.9626 (0.7); 1.9452 (1.0); 1.9332 (0.8); 1.9178 (1.6); 1.9022 (2.4); 1.8833 (2.5); 1.8663 (1.5); 1.5585 (9.3); 1.5390 (0.9); 1.5198 (0.7); 1.3155 (16.0); 1.3075 (12.5); 1.2764 (0.7); 1.2585 (1.5); 1.2407 (0.6); 0.0080 (1.0); −0.0002 (30.8); −0.0083 (1.2)

Example No. I.60-72

[0396] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.4902 (1.0); 7.4720 (1.0); 7.3788 (1.2); 7.3563 (1.2); 7.2601 (25.5); 3.9388 (0.6); 3.9266 (0.7); 3.9208 (0.6); 3.9086 (0.7); 3.9023 (0.6); 3.8099 (0.7); 3.7955 (0.7); 3.7748 (0.8); 3.7559 (0.8); 3.7347 (0.9); 3.7166 (0.8); 3.5418 (3.1); 3.5362 (3.0); 3.4569 (0.6); 3.4343 (0.5); 2.7202 (0.7); 2.7131 (0.8); 2.7030 (0.8); 2.6947 (0.7); 1.5374 (16.0); 1.5144 (3.9); 1.1448 (1.8); 1.1265 (3.4); 1.1080 (1.6); −0.0002 (31.4); −0.0083 (1.2)

Example No. I.60-91

[0397] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.5351 (0.7); 7.3697 (0.8); 7.3570 (0.8); 7.3456 (0.8); 7.3351 (0.9); 7.2601 (21.1); 7.2584 (18.4); 4.0615 (0.5); 3.9939 (0.7); 3.9325 (1.0); 3.5401 (3.4); 3.3978 (0.5); 3.3753 (0.6); 2.7173 (0.9); 1.8352 (0.5); 1.5375 (16.0); 1.5185 (2.7); 1.5086 (2.4); 1.4872 (1.8); 1.2587 (0.6); 1.1470 (1.7); 1.1285 (2.9); 1.1109 (1.3); −0.0002 (25.4); −0.0019 (21.9)

Example No. I.60-221

[0398] .sup.1H-NMR (400.0 MHz, CDCl.sub.3): δ=7.3528 (0.6); 7.3419 (0.5); 7.3300 (0.6); 7.3202 (0.5); 7.2603 (26.0); 3.8155 (0.6); 3.7989 (0.6); 3.5293 (2.0); 3.5237 (1.3); 2.0449 (1.4); 1.6044 (1.6); 1.5879 (2.1); 1.5706 (1.7); 1.5435 (16.0); 1.2771 (0.5); 1.2592 (1.1); 1.1388 (0.6); 1.1257 (1.3); 1.1216 (1.2); 1.1075 (0.7); 0.8819 (0.6); 0.0080 (0.9); −0.0002 (30.9); −0.0085 (1.6)

[0399] The present invention further provides for the use of one or more inventive compounds of the formula (I) and/or salts thereof, as defined above, preferably in a configuration identified as preferred or particularly preferred, especially of one or more compounds of the formulae (I.1) to (I.60) and/or salts thereof, each as defined above, as herbicide and/or plant growth regulator, preferably in crops of useful plants and/or ornamentals.

[0400] The present invention further provides a method of controlling harmful plants and/or of regulating the growth of plants, characterized in that an effective amount of one or more inventive compounds of the formula (I) and/or salts thereof, as defined above, preferably in a configuration identified as preferred or particularly preferred, especially of one or more compounds of the formulae (I.1) to (I.60) and/or salts thereof, each as defined above, or [0401] a composition of the invention, as defined below, is applied to the (harmful) plants, (harmful) plant seeds, the soil in or on which the (harmful) plants grow, or the cultivation area.

[0402] The present invention also provides a method of controlling unwanted plants, preferably in crops of useful plants, characterized in that an effective amount of [0403] one or more compounds of the formula (I) and/or salts thereof, as defined above, preferably in a configuration identified as preferred or particularly preferred, especially of one or more compounds of the formulae (I.1) to (I.60) and/or salts thereof, each as defined above, or [0404] a composition of the invention, as defined below,

[0405] is applied to unwanted plants (for example harmful plants such as mono- or dicotyledonous weeds or unwanted crop plants), the seed of the unwanted plants (i.e. plant seeds, e.g. grains, seeds or vegetative propagation organs such as tubers or parts of shoots with buds), the soil in or on which the unwanted plants grow (for example the soil of cropland or non-cropland), or the cultivation area (i.e. the area in which the unwanted plants will grow).

[0406] The present invention additionally also provides methods of controlling of regulating the growth of plants, preferably of useful plants, characterized in that an effective amount of one or more compounds of the formula (I) and/or salts thereof, as defined above, preferably in a configuration identified as preferred or particularly preferred, especially of one or more compounds of the formulae (I.1) to (I.60) and/or salts thereof, each as defined above, or [0407] a composition of the invention, as defined below, is applied the plant, the seed of the plant (i.e. plant seeds, e.g. grains, seeds or vegetative propagation organs such as tubers or parts of shoots with buds), the soil in or on which the plants grow (for example the soil of cropland or non-cropland), or the cultivation area (i.e. the area in which the plants will grow).

[0408] It is possible here for the compounds of the invention or the compositions of the invention to be deployed, for example, at the pre-seeding stage (possibly even by being incorporated into the soil), pre-emergence and/or post-emergence. Specific examples of some representatives of the monocotyledonous and dicotyledonous weed flora which can be controlled by the compounds of the invention are as follows, though there is no intention to restrict the enumeration to particular species.

[0409] In a method of the invention for controlling harmful plants or for regulating the growth of plants, preference is given to using one or more compounds of the formula (I) and/or salts thereof for controlling harmful plants or for regulating growth in crops of useful plants or ornamentals, wherein the useful plants or ornamentals in a preferred configuration are transgenic plants.

[0410] The inventive compounds formula (I) and/or salts thereof are suitable for controlling the following genera of monocotyledonous and dicotyledonous harmful plants:

[0411] Monocotyledonous harmful plants of the genera: Aegilops, Agropyron, Agrostis, Alopecurus, Apera, Avena, Brachiaria, Bromus, Cenchrus, Commelina, Cynodon, Cyperus, Dactyloctenium, Digitaria, Echinochloa, Eleocharis, Eleusine, Eragrostis, Eriochloa, Festuca, Fimbristylis, Heteranthera, Imperata, Ischaemum, Leptochloa, Lolium, Monochoria, Panicum, Paspalum, Phalaris, Phleum, Poa, Rottboellia, Sagittaria, Scirpus, Setaria, Sorghum.

[0412] Dicotyledonous harmful plants of the genera: Abutilon, Amaranthus, Ambrosia, Anoda, Anthemis, Aphanes, Artemisia, Atriplex, Bellis, Bidens, Capsella, Carduus, Cassia, Centaurea, Chenopodium, Cirsium, Convolvulus, Datura, Desmodium, Emex, Erysimum, Euphorbia, Galeopsis, Galinsoga, Galium, Hibiscus, Ipomoea, Kochia, Lamium, Lepidium, Lindernia, Matricaria, Mentha, Mercurialis, Mullugo, Myosotis, Papaver, Pharbitis, Plantago, Polygonum, Portulaca, Ranunculus, Raphanus, Rorippa, Rotala, Rumex, Salsola, Senecio, Sesbania, Sida, Sinapis, Solanum, Sonchus, Sphenoclea, Stellaria, Taraxacum, Thlaspi, Trifolium, Urtica, Veronica, Viola, Xanthium.

[0413] If the compounds of the invention are applied to the soil surface before the germination of the harmful plants (weed grasses and/or broad-leaved weeds), either the emergence of the weed grass seedlings and/or broad-leaved weed seedlings is prevented completely or the weeds grow until they have reached the cotyledon stage, but then they stop growing and ultimately die completely after three to four weeks.

[0414] When the active ingredients are applied post-emergence to the green parts of the plants, growth stops after the treatment, and the harmful plants remain at the growth stage at the time of application, or they die completely after a certain time, such that competition by the weeds, which is harmful to the crop plants, is thus eliminated very early and in a lasting manner.

[0415] Although the compounds of the invention have excellent herbicidal activity against monocotyledonous and dicotyledonous weeds, crop plants of economically important crops, for example dicotyledonous crops of the genera Arachis, Beta, Brassica, Cucumis, Cucurbita, Helianthus, Daucus, Glycine, Gossypium, Ipomoea, Lactuca, Linum, Lycopersicon, Miscanthus, Nicotiana, Phaseolus, Pisum, Solanum, Vicia, or monocotyledonous crops of the genera Allium, Ananas, Asparagus, Avena, Hordeum, Oryza, Panicum, Saccharum, Secale, Sorghum, Triticale, Triticum, Zea, will be damaged only insignificantly, if at all, depending on the structure of the particular compound of the invention and its application rate. For these reasons, the present compounds are of very good suitability for selective control of unwanted plant growth in plant crops such as plantations of agriculturally useful plants or ornamentals.

[0416] In addition, the compounds of the invention (depending on their particular structure and the application rate deployed) have excellent growth-regulating properties in crop plants. They intervene in the plants' own metabolism with regulatory effect, and can thus be used for controlled influencing of plant constituents and to facilitate harvesting, for example by triggering desiccation and stunted growth. In addition, they are also suitable for general control and inhibition of unwanted vegetative growth without killing the plants in the process. Inhibition of vegetative growth plays a major role for many mono- and dicotyledonous crops since, for example, this can reduce or completely prevent lodging.

[0417] Owing to their herbicidal and plant growth regulatory properties, the active ingredients can also be used to control harmful plants in crops of genetically modified plants or plants modified by conventional mutagenesis. In general, transgenic plants are notable for particular advantageous properties, for example for resistances to certain pesticides, in particular certain herbicides, resistances to plant diseases or pathogens of plant diseases, such as certain insects, or microorganisms such as fungi, bacteria or viruses. Other particular characteristics relate, for example, to the harvested material with regard to quantity, quality, storability, composition and specific constituents. For instance, there are known transgenic plants with an elevated starch content or altered starch quality, or with a different fatty acid composition of the harvested material.

[0418] With regard to transgenic crops, preference is given to the use of the inventive compounds and/or salts thereof in economically important transgenic crops of useful plants and ornamentals, for example of cereal such as wheat, barley, rye, oats, millet/sorghum, rice and corn, or else crops of sugar beet, cotton, soybean, oilseed rape, potatoes, tomatoes, peas and other vegetables.

[0419] The compounds of the invention can preferably also be used as herbicides in crops of useful plants that are resistant, or have been made resistant by recombinant means, to the phytotoxic effects of the herbicides.

[0420] Owing to their herbicidal and plant growth regulatory properties, the active ingredients can also be used to control harmful plants in crops of genetically modified plants that are known or yet to be developed. In general, transgenic plants are notable for particular advantageous properties, for example for resistances to certain pesticides, in particular certain herbicides, resistances to plant diseases or pathogens of plant diseases, such as certain insects, or microorganisms such as fungi, bacteria or viruses. Other particular characteristics relate, for example, to the harvested material with regard to quantity, quality, storability, composition and specific constituents. For instance, there are known transgenic plants with an elevated starch content or altered starch quality, or with a different fatty acid composition of the harvested material. Further particular properties may be tolerance or resistance to abiotic stress factors, for example heat, cold, drought, salinity and ultraviolet radiation.

[0421] Preference is given to the use of the inventive compounds of the formula (I) or salts thereof in economically important transgenic crops of useful plants and ornamentals, for example of cereal such as wheat, barley, rye, oats, triticale, millet/sorghum, rice, cassava and corn, or else crops of sugar beet, cotton, soybean, oilseed rape, potatoes, tomatoes, peas and other vegetables.

[0422] The compounds of the formula (I) can preferably also be used as herbicides in crops of useful plants that are resistant, or have been made resistant by recombinant means, to the phytotoxic effects of the herbicides.

[0423] Conventional ways of producing novel plants which have modified properties compared to existing plants involve, for example, conventional cultivation methods and the generation of mutants. Alternatively, novel plants with altered properties can be generated with the aid of recombinant methods.

[0424] Numerous molecular biology techniques by which novel transgenic plants with modified properties can be produced are known to the person skilled in the art. For such recombinant manipulations, nucleic acid molecules which allow mutagenesis or sequence alteration by recombination of DNA sequences can be introduced into plasmids. With the aid of standard methods, it is possible, for example, to undertake base exchanges, remove part sequences, or add natural or synthetic sequences. For the connection of the DNA fragments to one another, it is possible to add adapters or linkers to the fragments.

[0425] For example, the production of plant cells with a reduced activity of a gene product can be achieved by the expression of at least one corresponding antisense RNA, or a sense RNA for achieving a cosuppression effect, or the expression of at least one appropriately constructed ribozyme which specifically cleaves transcripts of the abovementioned gene product.

[0426] To this end, it is firstly possible to use DNA molecules which encompass the entire coding sequence of a gene product including any flanking sequences that may be present, and also DNA molecules which encompass only portions of the coding sequence, in which case it is necessary for these portions to be long enough to have an antisense effect in the cells. It is also possible to use DNA sequences which have a high degree of homology to the coding sequences of a gene product, but are not completely identical.

[0427] When expressing nucleic acid molecules in plants, the protein synthesized may be localized in any desired compartment of the plant cell. However, in order to achieve localization in a particular compartment, it is possible, for example, to join the coding region to DNA sequences which assure localization in a particular compartment. Such sequences are known to those skilled in the art (see, for example, Braun et al., EMBO J. 11 (1992), 3219-3227). The nucleic acid molecules can also be expressed in the organelles of the plant cells.

[0428] The transgenic plant cells can be regenerated by known techniques to give rise to whole plants. In principle, the transgenic plants may be plants of any desired plant species, i.e. not only monocotyledonous but also dicotyledonous plants.

[0429] In this way, transgenic plants having properties altered by overexpression, suppression or inhibition of homologous (=natural) genes or gene sequences or expression of heterologous (=foreign) genes or gene sequences are obtainable.

[0430] The inventive compounds (I) can be used with preference in transgenic crops that are resistant to growth regulators, for example dicamba, or to herbicides that inhibit essential plant enzymes, for example acetolactate synthases (ALS), EPSP synthases, glutamine synthases (GS) or hydroxyphenylpyruvate dioxygenases (HPPD), or to herbicides from the group of the sulfonylureas, the glyphosates, glufosinates or benzoylisoxazoles and analogous active ingredients.

[0431] When the active ingredients of the invention are used in transgenic crops, not only do the effects toward harmful plants that are to be observed in other crops occur, but often also effects that are specific to application in the particular transgenic crop, for example an altered or specifically widened spectrum of weeds that can be controlled, altered application rates that can be used for the application, preferably good combinability with the herbicides to which the transgenic crop is resistant, and influencing of growth and yield of the transgenic crop plants.

[0432] The invention therefore also provides for the use of the inventive compounds of the formula (I) and/or salts thereof as herbicides for controlling harmful plants in crops of useful plants or ornamentals, if appropriate in transgenic crop plants.

[0433] Preference is given to using cereal, preferably corn, wheat, barley, rye, oats, millet/sorghum, or rice, pre- or post-emergence.

[0434] Preference is also given to use in soybean, pre- or post-emergence.

[0435] The inventive use for control of harmful plants or for regulation of plant growth also includes the case in which the active ingredient of the formula (I) or salt thereof is formed only after deployment on the plant, in the plant or in the soil from a precursor substance (“prodrug”).

[0436] The invention also provides for use of one or more compounds of the formula (I) or salts thereof or of an inventive composition (as defined below) (in a method) for control of harmful plants or for regulating the growth of plants, characterized in that an effective amount of one or more compounds of the formula (I) or salts thereof is applied to the plants (harmful plants, if appropriate together with the crop plants), plant seeds, the soil in or on which the plants grow, or the cultivation area.

[0437] The invention also provides a herbicidal and/or plant growth-regulating composition, characterized in that the composition comprises

[0438] (a) one or more compounds of the formula (I) and/or salts thereof, as defined above, preferably in a configuration identified as preferred or particularly preferred, especially of one or more compounds of the formulae (I.1) to (I.XX) and/or salts thereof, each as defined above, and

[0439] (b) one or more further substances selected from the groups (i) and/or (ii): [0440] (i) one or more further active agrochemical ingredients, preferably selected from the group consisting of insecticides, acaricides, nematicides, further herbicides (i.e. those that do not conform to the above-defined formula (I)), fungicides, safeners, fertilizers and/or further growth regulators, [0441] (ii) one or more formulation auxiliaries customary in crop protection.

[0442] The further active agrochemical ingredients of constituent (i) of a composition of the invention are preferably selected from the group of substances specified in “The Pesticide Manual”, 16th edition, The British Crop Protection Council and the Royal Soc. of Chemistry, 2012.

[0443] A herbicidal or plant growth-regulating composition of the invention preferably comprises one, two, three or more formulation auxiliaries (ii) that are customary in crop protection, selected from the group consisting of surfactants, emulsifiers, dispersants, film formers, thickeners, inorganic salts, dusting agents, carriers that are solid at 25° C. and 1013 mbar, preferably adsorptive granulated inert materials, wetting agents, antioxidants, stabilizers, buffer substances, antifoams, water, organic solvents, preferably organic solvents that are miscible with water in any desired ratio at 25° C. and 1013 mbar.

[0444] The inventive compounds (I) may be employed in the form of wettable powders, emulsifiable concentrates, sprayable solutions, dusting products or granules in the customary formulations. The invention therefore also provides herbicidal and plant-growth-regulating compositions comprising the compounds of the formula (I) and/or salts thereof.

[0445] The compounds of the formula (I) and/or salts thereof can be formulated in various ways, according to the biological and/or physicochemical parameters required. Possible formulations include, for example: wettable powders (WP), water-soluble powders (SP), water-soluble concentrates, emulsifiable concentrates (EC), emulsions (EW), such as oil-in-water and water-in-oil emulsions, sprayable solutions, suspension concentrates (SC), dispersions based on oil or water, oil-miscible solutions, capsule suspensions (CS), dustable powders (DP), seed dressings, granules for scattering and soil application, granules (GR) in the form of microgranules, spray granules, absorption and adsorption granules, water-dispersible granules (WG), water-soluble granules (SG), ULV formulations, microcapsules and waxes.

[0446] These individual formulation types and the formulation auxiliaries such as inert materials, surfactants, solvents and further additives are known to the person skilled in the art, and are described, for example, in: Watkins, “Handbook of Insecticide Dust Diluents and Carriers”, 2nd ed., Darland Books, Caldwell N.J., H. v. Olphen, “Introduction to Clay Colloid Chemistry”; 2nd ed., J. Wiley & Sons, N.Y.; C. Marsden, “Solvents Guide”; 2nd Ed., Interscience, N.Y. 1963; McCutcheon's “Detergents and Emulsifiers Annual”, MC Publ. Corp., Ridgewood N.J.; Sisley and Wood, “Encyclopedia of Surface Active Agents”, Chem. Publ. Co. Inc., N.Y. 1964; Schonfeldt, “Grenzflächenaktive Äthylenoxidaddukte” [Interface-Active Ethylene Oxide Adducts], Wiss. Verlagsgesellschaft, Stuttgart 1976; Winnacker-Küchler, “Chemische Technologic” [Chemical Technology], volume 7, C. Hanser Verlag Munich, 4th ed. 1986.

[0447] Wettable powders are preparations that are dispersible uniformly in water and, in addition to the active ingredient, apart from a diluent or inert substance, also comprise ionic and/or nonionic surfactants (wetting agents, dispersants), for example polyethoxylated alkylphenols, polyethoxylated fatty alcohols, polyethoxylated fatty amines, fatty alcohol polyglycol ether sulfates, alkanesulfonates, alkylbenzenesulfonates, sodium lignosulfonate, sodium 2,2′-dinaphthylmethane-6,6′-disulfonate, sodium dibutylnaphthalenesulfonate or else sodium oleoylmethyltaurate. The wettable powders are produced by finely grinding the active herbicidal ingredients, for example in customary apparatuses such as hammer mills, blower mills and air jet mills, and simultaneously or subsequently mixing with the formulation auxiliaries.

[0448] Emulsifiable concentrates are produced by dissolving the active ingredient in an organic solvent, for example butanol, cyclohexanone, dimethylformamide, xylene, or else relatively high-boiling aromatics or hydrocarbons or mixtures of the organic solvents, with addition of one or more ionic and/or nonionic surfactants (emulsifiers). Examples of emulsifiers that may be used are: calcium alkylarylsulfonates such as calcium dodecylbenzenesulfonate, or nonionic emulsifiers such as fatty acid polyglycol esters, alkylaryl polyglycol ethers, fatty alcohol polyglycol ethers, propylene oxide-ethylene oxide condensation products, alkyl polyethers, sorbitan esters, for example sorbitan fatty acid esters, or polyoxyethylene sorbitan esters, for example polyoxyethylene sorbitan fatty acid esters.

[0449] Dustable powders are obtained by grinding the active ingredient with finely divided solid materials, for example talc, natural clays such as kaolin, bentonite and pyrophyllite, or diatomaceous earth.

[0450] Suspension concentrates may be water- or oil-based. They may be produced, for example, by wet grinding by means of commercial bead mills and optional addition of surfactants as already listed above, for example, for the other formulation types.

[0451] Emulsions, for example oil-in-water emulsions (EW), can be produced, for example, by means of stirrers, colloid mills and/or static mixers using aqueous organic solvents and optionally surfactants as already listed above, for example, for the other formulation types.

[0452] Granules can be produced either by spraying the active ingredient onto adsorptive granular inert material or by applying active ingredient concentrates to the surface of carriers, such as sand, kaolinites or granular inert material, by means of stickers, for example polyvinyl alcohol, sodium polyacrylate or else mineral oils. Suitable active ingredients can also be granulated in the manner customary for the production of fertilizer granules—if desired as a mixture with fertilizers.

[0453] Water-dispersible granules are produced generally by the customary processes such as spray-drying, fluidized bed granulation, pan granulation, mixing with high-speed mixers and extrusion without solid inert material.

[0454] For the production of pan, fluidized-bed, extruder and spray granules, see, for example, processes in “Spray Drying Handbook” 3rd Ed. 1979, G. Goodwin Ltd., London, J. E. Browning, “Agglomeration”, Chemical and Engineering 1967, pages 147 ff.; “Perry's Chemical Engineer's Handbook”, 5th ed., McGraw-Hill, New York 1973, p. 8-57.

[0455] For further details regarding the formulation of crop protection compositions, see, for example, G. C. Klingman, “Weed Control as a Science”, John Wiley and Sons, Inc., New York, 1961, pages 81-96 and J. D. Freyer, S. A. Evans, “Weed Control Handbook”, 5th Ed., Blackwell Scientific Publications, Oxford, 1968, pages 101-103.

[0456] The agrochemical preparations, preferably herbicidal or plant growth-regulating compositions of the present invention, preferably contain a total amount of 0.1 to 99% by weight, preferably 0.5% to 95% by weight, further preferably 1% to 90% by weight, especially preferably 2% to 80% by weight, of active ingredients of the formula (I) and salts thereof.

[0457] In wettable powders, the active ingredient concentration is, for example, about 10% to 90% by weight, the remainder to 100% by weight consisting of customary formulation constituents. In emulsifiable concentrates, the active ingredient concentration may be about 1% to 90% and preferably 5% to 80% by weight. Formulations in dustable form contain 1% to 30% by weight of active ingredient, preferably usually 5% to 20% by weight of active ingredient; sprayable solutions contain about 0.05% to 80% by weight, preferably 2% to 50% by weight of active ingredient. In the case of water-dispersible granules, the active ingredient content depends partially on whether the active compound is in liquid or solid form and on which granulation auxiliaries, fillers, etc., are used. In water-dispersible granules, the content of active ingredient is, for example, between 1% and 95% by weight, preferably between 10% and 80% by weight.

[0458] In addition, the active ingredient formulations mentioned optionally comprise the respective customary stickers, wetters, dispersants, emulsifiers, penetrants, preservatives, antifreezes and solvents, fillers, carriers and dyes, defoamers, evaporation inhibitors, and pH and viscosity modifiers. Examples of formulation auxiliaries are described inter alia in “Chemistry and Technology of Agrochemical Formulations”, ed. D. A. Knowles, Kluwer Academic Publishers (1998).

[0459] The compounds of the formula (I) or salts thereof may be used as such or in combination in the form of their preparations (formulations) with other pesticidally substances, for example insecticides, acaricides, nematicides, herbicides, fungicides, safeners, fertilizers and/or growth regulators, for example as a ready-made formulation or in the form of tankmixes. The combined formulations may be produced here on the basis of the abovementioned formulations, taking account of the physical properties and stabilities of the active ingredients to be combined.

[0460] Combination partners usable for the inventive compounds of the formula (I) in mixed formulations or in a tankmix are, for example, known active ingredients based on inhibition of, for example, acetolactate synthase, acetyl-CoA carboxylase, cellulose synthase, enolpyruvylshikimate-3-phosphate synthase, glutamine synthetase, p-hydroxyphenylpyruvate dioxygenase, phytoene desaturase, photosystem I, photosystem II, protoporphyrinogen oxidase, as described, for example, in Weed Research 26 (1986) 441-445 or “The Pesticide Manual”, 16th edition, The British Crop Protection Council and the Royal Soc. of Chemistry, 2012 and the literature cited therein.

[0461] Of particular interest is the selective control of harmful plants in crops of useful plants and ornamentals. Although the inventive compounds (I) already have very good to adequate selectivity in many crops, it is possible in principle for phytotoxicities on the crop plants to occur in some crops, and particularly also in the case of mixtures with other herbicides that are less selective. Of particular interest in this regard are combinations of inventive compounds (I) that comprise the compounds (I) or combinations thereof with other herbicides or pesticides and safeners. The safeners, which are used in an antidotically effective content, reduce the phytotoxic side effects of the herbicides/pesticides used, for example in economically important crops such as cereal (wheat, barley, rye, corn, rice, millet/sorghum), sugar beet, sugar cane, oilseed rape, cotton and soybean, preferably cereal.

[0462] The weight ratios of (herbicide) mixture to safener generally depend on the application rate of herbicide and the efficacy of the respective safener, and may vary within broad limits, for example in the range from 200:1 to 1:200, preferably 100:1 to 1:100, especially 20:1 to 1:20. The safeners may be formulated analogously to the compounds (I) or mixtures thereof with further herbicides/pesticides, and be provided and applied as a ready-made formulation or tankmix with the herbicides.

[0463] For application, the herbicide or herbicide-safener formulations in commercial form are diluted if appropriate by means of water, for example in the case of wettable powders, emulsifiable concentrates, dispersions and water-dispersible granules. Dustable formulations, granules for soil application or scattering, and sprayable solutions are typically not diluted with further inert substances prior to application.

[0464] External conditions such as temperature, humidity etc. affect the application rate of the compounds of the formula (I) and/or salts thereof to a certain degree. The application rate may vary within broad limits. For application as herbicide for control of harmful plants, the total amount of compounds of the formula (I) and salts thereof is preferably in the range from 0.001 to 10.0 kg/ha, preferably in the range from 0.005 to 5 kg/ha, further preferably in the range from 0.01 to I.5 kg/ha, especially preferably in the range from 0.05 to 1 kg/ha. This applies to application both pre- and post-emergence.

[0465] When compounds of the formula (I) and/or salts thereof are used as plant growth regulators, for example as stem shortener in the case of crop plants as specified above, preferably in the case of cereal plants such as wheat, barley, rye, triticale, millet/sorghum, rice or corn, the total application rate is preferably in the range from 0.001 to 2 kg/ha, preferably in the range from 0.005 to 1 kg/ha, especially in the range from 10 to 500 g/ha, most preferably in the range from 20 to 250 g/ha. This applies to application both pre- and post-emergence.

[0466] Application as a stem shortener can be effected at various stages of the growth of the plant. Preference is given, for example, to application after tillering at the start of linear growth.

[0467] An alternative option in the case of use as plant growth regulator is also the treatment of the seed, which includes different seed dressing and coating techniques. The application rate depends on the individual techniques and can be ascertained in preliminary tests.

[0468] Combination partners usable for the inventive compounds of the formula (I) in compositions of the invention (for example mixed formulations or in a tankmix) are, for example, known active ingredients based on inhibition of, for example, acetolactate synthase, acetyl-CoA carboxylase, cellulose synthase, enolpyruvylshikimate-3-phosphate synthase, glutamine synthetase, p-hydroxyphenylpyruvate dioxygenase, phytoene desaturase, photosystem I, photosystem II or protoporphyrinogen oxidase, as described, for example, from Weed Research 26 (1986) 441-445 or “The Pesticide Manual”, 16th edition, The British Crop Protection Council and the Royal Soc. of Chemistry, 2012 and literature cited therein. Specified hereinafter by way of example are known herbicides or plant growth regulators that can be combined with the compounds of the invention, with designation of these active ingredients either by their common name in the English-language variant according to the International Organization for Standardization (ISO) or by the chemical name or by the code number. These always include all use forms, for example acids, salts, esters and all isomeric forms such as stereoisomers and optical isomers, even if these are not mentioned explicitly.

[0469] Combination partners usable for the compounds of the invention in mixed formulations or in a tankmix are, for example, known active ingredients based on inhibition of, for example, acetolactate synthase, acetyl-CoA carboxylase, cellulose synthase, enolpyruvylshikimate-3-phosphate synthase, glutamine synthetase, p-hydroxyphenylpyruvate dioxygenase, phytoene desaturase, photosystem I, photosystem II or protoporphyrinogen oxidase, as described, for example, from Weed Research 26 (1986) 441-445 or “The Pesticide Manual”, 16th edition, The British Crop Protection Council and the Royal Soc. of Chemistry, 2,006 and literature cited therein. Specified hereinafter by way of example are known herbicides or plant growth regulators that can be combined with the compounds of the invention, with designation of these active ingredients either by their common name in the English-language variant according to the International Organization for Standardization (ISO) or by the chemical name or by the code number. These always include all use forms, for example acids, salts, esters and all isomeric forms such as stereoisomers and optical isomers, even if these are not mentioned explicitly.

[0470] Examples of such herbicidal mixing partners are:

[0471] acetochlor, acifluorfen, acifluorfen-sodium, aclonifen, alachlor, allidochlor, alloxydim, alloxydim-sodium, ametryn, amicarbazone, amidochlor, amidosulfuron, aminocyclopyrachlor, aminocyclopyrachlor-potassium, aminocyclopyrachlor-methyl, aminopyralid, amitrole, ammoniumsulfamate, anilofos, asulam, atrazine, azafenidin, azimsulfuron, beflubutamid, benazolin, benazolin-ethyl, benfluralin, benfuresate, bensulfuron, bensulfuron-methyl, bensulide, bentazone, benzobicyclon, benzofenap, bicyclopyron, bifenox, bilanafos, bilanafos-sodium, bispyribac, bispyribac-sodium, bromacil, bromobutide, bromofenoxim, bromoxynil, bromoxynil-butyrate, -potassium, -heptanoate and -octanoate, busoxinone, butachlor, butafenacil, butamifos, butenachlor, butralin, butroxydim, butylate, cafenstrole, carbetamide, carfentrazone, carfentrazone-ethyl, chloramben, chlorbromuron, chlorfenac, chlorfenac-sodium, chlorfenprop, chlorflurenol, chlorflurenol-methyl, chloridazon, chlorimuron, chlorimuron-ethyl, chlorophthalim, chlorotoluron, chlorthal-dimethyl, chlorsulfuron, cinidon, cinidon-ethyl, cinmethylin, cinosulfuron, clacyfos, clethodim, clodinafop, clodinafop-propargyl, clomazone, clomeprop, clopyralid, cloransulam, cloransulam-methyl, cumyluron, cyanamide, cyanazine, cycloate, cyclopyranil, cyclopyrimorate, cyclosulfamuron, cycloxydim, cyhalofop, cyhalofop-butyl, cyprazine, 2,4-D, 2,4-D-butotyl, -butyl, -dimethylammonium, -diolamin, -ethyl, 2-ethylhexyl, -isobutyl, -isooctyl, -isopropylammonium, -potassium, -triisopropanolammonium and -trolamine, 2,4-DB, 2,4-DB-butyl, -dimethylammonium, isooctyl, -potassium and -sodium, daimuron (dymron), dalapon, dazomet, n-decanol, desmedipham, detosyl-pyrazolate (DTP), dicamba, dichlobenil, 2-(2,4-dichlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one, 2-(2,5-dichlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one, dichlorprop, dichlorprop-P, diclofop, diclofop-methyl, diclofop-P-methyl, diclosulam, difenzoquat, diflufenican, diflufenzopyr, diflufenzopyr-sodium, dimefuron, dimepiperate, dimethachlor, dimethametryn, dimethenamid, dimethenamid-P, dimetrasulfuron, dinitramine, dinoterb, diphenamid, diquat, diquat-dibromid, dithiopyr, diuron, DNOC, endothal, EPTC, esprocarb, ethalfluralin, ethametsulfuron, ethametsulfuron-methyl, ethiozin, ethofumesate, ethoxyfen, ethoxyfen-ethyl, ethoxysulfuron, etobenzanid, F-9600, F-5231, i.e. N-[2-chloro-4-fluoro-5-[4-(3-fluoropropyl)-4,5-dihydro-5-oxo-1H-tetrazol-1-yl]-phenyl]ethanesulfonamide, F-7967, i.e. 3-[7-chloro-5-fluoro-2-(trifluoromethyl)-1H-benzimidazol-4-yl]-1-methyl-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione, fenoxaprop, fenoxaprop-P, fenoxaprop-ethyl, fenoxaprop-P-ethyl, fenoxasulfone, fenquinotrione, fentrazamide, flamprop, flamprop-M-isopropyl, flamprop-M-methyl, flazasulfuron, florasulam, florpyrauxifen, florpyrauxifen-benzyl, fluazifop, fluazifop-P, fluazifop-butyl, fluazifop-P-butyl, flucarbazone, flucarbazone-sodium, flucetosulfuron, fluchloralin, flufenacet, flufenpyr, flufenpyr-ethyl, flumetsulam, flumiclorac, flumiclorac-pentyl, flumioxazin, fluometuron, flurenol, flurenol-butyl, -dimethylammonium and -methyl, fluoroglycofen, fluoroglycofen-ethyl, flupropanate, flupyrsulfuron, flupyrsulfuron-methyl-sodium, fluridone, flurochloridone, fluroxypyr, fluroxypyr-meptyl, flurtamone, fluthiacet, fluthiacet-methyl, fomesafen, fomesafen-sodium, foramsulfuron, fosamine, glufosinate, glufosinate-ammonium, glufosinate-P-sodium, glufosinate-P-ammonium, glufosinate-P-sodium, glyphosate, glyphosate-ammonium, -isopropylammonium, -diammonium, -dimethylammonium, -potassium, -sodium and -trimesium, H-9201, i.e. O-(2,4-dimethyl-6-nitrophenyl)-O-ethyl isopropylphosphoramidothioate, halauxifen, halauxifen-methyl, halosafen, halosulfuron, halosulfuron-methyl, haloxyfop, haloxyfop-P, haloxyfop-ethoxyethyl, haloxyfop-P-ethoxyethyl, haloxyfop-methyl, haloxyfop-P-methyl, hexazinone, HW-02, i.e. 1-(dimethoxyphosphoryl)ethyl (2,4-dichlorophenoxy)acetate, imazamethabenz, imazamethabenz-methyl, imazamox, imazamox-ammonium, imazapic, imazapic-ammonium, imazapyr, imazapyr-isopropylammonium, imazaquin, imazaquin-ammonium, imazethapyr, imazethapyr-immonium, imazosulfuron, indanofan, indaziflam, iodosulfuron, iodosulfuron-methyl-sodium, ioxynil, ioxynil-octanoate, -potassium and sodium, ipfencarbazone, isoproturon, isouron, isoxaben, isoxaflutole, karbutilate, KUH-043, i.e. 3-({[5-(difluoromethyl)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl}sulfonyl)-5,5-dimethyl-4,5-dihydro-1,2-oxazole, ketospiradox, lactofen, lenacil, linuron, MCPA, MCPA-butotyl, -dimethylammonium, -2-ethylhexyl, -isopropylammonium, -potassium and -sodium, MCPB, MCPB-methyl, -ethyl and -sodium, mecoprop, mecoprop-sodium, and -butotyl, mecoprop-P, mecoprop-P-butotyl, -dimethylammonium, -2-ethylhexyl and -potassium, mefenacet, mefluidide, mesosulfuron, mesosulfuron-methyl, mesotrione, methabenzthiazuron, metam, metamifop, metamitron, metazachlor, metazosulfuron, methabenzthiazuron, methiopyrsulfuron, methiozolin, methyl isothiocyanate, metobromuron, metolachlor, S-metolachlor, metosulam, metoxuron, metribuzin, metsulfuron, metsulfuron-methyl, molinat, monolinuron, monosulfuron, monosulfuron-ester, MT-5950, i.e. N-[3-chloro-4-(1-methylethyl)-phenyl]-2-methylpentanamide, NGGC-011, napropamide, NC-310, i.e. 4-(2,4-dichlorobenzoyl)-1-methyl-5-benzyloxypyrazole, neburon, nicosulfuron, nonanoic acid (pelargonic acid), norflurazon, oleic acid (fatty acids), orbencarb, orthosulfamuron, oryzalin, oxadiargyl, oxadiazon, oxasulfuron, oxaziclomefon, oxotrione (lancotrione), oxyfluorfen, paraquat, paraquat dichloride, pebulate, pendimethalin, penoxsulam, pentachlorphenol, pentoxazone, pethoxamid, petroleum oils, phenmedipham, picloram, picolinafen, pinoxaden, piperophos, pretilachlor, primisulfuron, primisulfuron-methyl, prodiamine, profoxydim, prometon, prometryn, propachlor, propanil, propaquizafop, propazine, propham, propisochlor, propoxycarbazone, propoxycarbazone-sodium, propyrisulfuron, propyzamide, prosulfocarb, prosulfuron, pyraclonil, pyraflufen, pyraflufen-ethyl, pyrasulfotole, pyrazolynate (pyrazolate), pyrazosulfuron, pyrazosulfuron-ethyl, pyrazoxyfen, pyribambenz, pyribambenz-isopropyl, pyribambenz-propyl, pyribenzoxim, pyributicarb, pyridafol, pyridate, pyriftalid, pyriminobac, pyriminobac-methyl, pyrimisulfan, pyrithiobac, pyrithiobac-sodium, pyroxasulfone, pyroxsulam, quinclorac, quinmerac, quinoclamine, quizalofop, quizalofop-ethyl, quizalofop-P, quizalofop-P-ethyl, quizalofop-P-tefuryl, rimsulfuron, saflufenacil, sethoxydim, siduron, simazine, simetryn, sulcotrione, sulfentrazone, sulfometuron, sulfometuron-methyl, sulfosulfuron, SYN-523, SYP-249, i.e. 1-ethoxy-3-methyl-1-oxobut-3-en-2-yl5-[2-chloro-4-(trifluoromethyl)phenoxy]-2-nitrobenzoate, SYP-300, i.e. 1-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-3-propyl-2-thioxoimidazolidine-4,5-dione, 2,3,6-TBA, TCA (trifluoroacetic acid), TCA-sodium, tebuthiuron, tefuryltrione, tembotrione, tepraloxydim, terbacil, terbucarb, terbumeton, terbuthylazin, terbutryn, thenylchlor, thiazopyr, thiencarbazone, thiencarbazone-methyl, thifensulfuron, thifensulfuron-methyl, thiobencarb, tiafenacil, tolpyralate, topramezone, tralkoxydim, triafamone, tri-allate, triasulfuron, triaziflam, tribenuron, tribenuron-methyl, triclopyr, trietazine, trifloxysulfuron, trifloxysulfuron-sodium, trifludimoxazin, trifluralin, triflusulfuron, triflusulfuron-methyl, tritosulfuron, urea sulfate, vernolate, ZJ-0862, i.e. 3,4-dichloro-N-{2-[(4,6-dimethoxypyrimidin-2-yl)oxy]benzyl}aniline, and the following compounds:

##STR00125##

[0472] Examples of plant growth regulators as possible mixing partners are:

[0473] acibenzolar, acibenzolar-S-methyl, 5-aminolevulic acid, ancymidol, 6-benzylaminopurine, brassinolide, catechol, chlormequat chloride, cloprop, cyclanilide, 3-(cycloprop-1-enyl)propionic acid, daminozide, dazomet, n-decanol, dikegulac, dikegulac-sodium, endothal, endothal-dipotassium, -disodium, and mono(N,N-dimethylalkylammonium), ethephon, flumetralin, flurenol, flurenol-butyl, flurprimidol, forchlorfenuron, gibberellic acid, inabenfide, indole-3-acetic acid (IAA), 4-indol-3-ylbutyric acid, isoprothiolane, probenazole, jasmonic acid, jasmonic acid methyl ester, maleic hydrazide, mepiquat chloride, 1-methylcyclopropene, 2-(1-naphthyl)acetamide, 1-naphthylacetic acid, 2-naphthyloxyacetic acid, nitrophenolate mixture, 4-oxo-4[(2-phenylethyl)amino]butyric acid, paclobutrazol, N-phenylphthalamic acid, prohexadione, prohexadione-calcium, prohydrojasmone, salicylic acid, strigolactone, tecnazene, thidiazuron, triacontanol, trinexapac, trinexapac-ethyl, tsitodef, uniconazole, uniconazole-P.

[0474] Likewise possible as combination partners for the inventive compounds of the formula (I) include, for example, the following safeners: [0475] S1) Compounds from the group of heterocyclic carboxylic acid derivatives: [0476] S1.sup.a) Compounds of the dichlorophenylpyrazoline-3-carboxylic acid type (S1.sup.a), preferably compounds such as [0477] 1-(2,4-dichlorophenyl)-5-(ethoxycarbonyl)-5-methyl-2-pyrazoline-3-carboxylic acid, ethyl 1-(2,4-dichlorophenyl)-5-(ethoxycarbonyl)-5-methyl-2-pyrazoline-3-carboxylate (S1-1) (“mefenpyr-diethyl”), and related compounds as described in WO-A-91/07874; [0478] S1.sup.b) Derivatives of dichlorophenylpyrazolecarboxylic acid (S1.sup.b), preferably compounds such as ethyl 1-(2,4-dichlorophenyl)-5-methylpyrazole-3-carboxylate (S1-2), ethyl 1-(2,4-dichlorophenyl)-5-isopropylpyrazole-3-carboxylate (S1-3), ethyl 1-(2,4-dichlorophenyl)-5-(1,1-dimethylethyl)pyrazole-3-carboxylate (S1-4) and related compounds as described in EP-A-333 131 and EP-A-269 806; [0479] S1.sup.c) Derivatives of 1,5-diphenylpyrazole-3-carboxylic acid (S1.sup.c), preferably compounds such as ethyl 1-(2,4-dichlorophenyl)-5-phenylpyrazole-3-carboxylate (S1-5), methyl 1-(2-chlorophenyl)-5-phenylpyrazole-3-carboxylate (S1-6) and related compounds as described, for example, in EP-A-268 554; [0480] S1.sup.d) Compounds of the triazolecarboxylic acid type (S1.sup.d), preferably compounds such as fenchlorazole (ethyl ester), i.e. ethyl 1-(2,4-dichlorophenyl)-5-trichloromethyl-(1H)-1,2,4-triazole-3-carboxylate (S1-7), and related compounds, as described in EP-A-174 562 and EP-A-346 620; [0481] S1.sup.e) Compounds of the 5-benzyl- or 5-phenyl-2-isoxazoline-3-carboxylic acid or of the 5,5-diphenyl-2-isoxazoline-3-carboxylic acid type (S1.sup.e), preferably compounds such as ethyl 5-(2,4-dichlorobenzyl)-2-isoxazoline-3-carboxylate (S1-8) or ethyl 5-phenyl-2-isoxazoline-3-carboxylate (51-9) and related compounds as described in WO-A-91/08202, or 5,5-diphenyl-2-isoxazolinecarboxylic acid (S1-10) or ethyl 5,5-diphenyl-2-isoxazoline-3-carboxylate (S1-11) (“isoxadifen-ethyl”) or n-propyl 5,5-diphenyl-2-isoxazoline-3-carboxylate (S1-12) or ethyl 5-(4-fluorophenyl)-5-phenyl-2-isoxazoline-3-carboxylate (S1-13), as described in patent application WO-A-95/07897. [0482] S2) Compounds from the group of the 8-quinolinoxy derivatives (S2): [0483] S2.sup.a) Compounds of the 8-quinolinoxyacetic acid type (52a), preferably 1-methylhexyl (5-chloro-8-quinolinoxy)acetate (“cloquintocet-mexyl”) (S2-1), 1,3-dimethylbut-1-yl (5-chloro-8-quinolinoxy)acetate (S2-2), 4-allyloxybutyl (5-chloro-8-quinolinoxy)acetate (S2-3), 1-allyloxyprop-2-yl (5-chloro-8-quinolinoxy)acetate (S2-4), ethyl (5-chloro-8-quinolinoxy)acetate (S2-5), [0484] methyl 5-chloro-8-quinolinoxyacetate (S2-6), [0485] allyl (5-chloro-8-quinolinoxy)acetate (S2-7), 2-(2-propylideneiminoxy)-1-ethyl (5-chloro-8-quinolinoxy)acetate (S2-8), 2-oxoprop-1-yl (5-chloro-8-quinolinoxy)acetate (S2-9) and related compounds, as described in EP-A-86 750, EP-A-94 349 and EP-A-191 736 or EP-A-0 492 366, and also (5-chloro-8-quinolinoxy)acetic acid (S2-10), hydrates and salts thereof, for example the lithium, sodium, potassium, calcium, magnesium, aluminum, iron, ammonium, quaternary ammonium, sulfonium or phosphonium salts thereof, as described in WO-A-2002/34048; [0486] S2.sup.b) Compounds of the (5-chloro-8-quinolinoxy)malonic acid type (S2.sup.b), preferably compounds such as diethyl (5-chloro-8-quinolinoxy)malonate, diallyl (5-chloro-8-quinolinoxy)malonate, methyl ethyl (5-chloro-8-quinolinoxy)malonate and related compounds, as described in EP-A-0 582 198. [0487] S3) Active ingredients of the dichloroacetamide type (S3), which are frequently used as pre-emergence safeners (soil-acting safeners), for example

[0488] “dichlormid” (N,N-diallyl-2,2-dichloroacetamide) (S3-1),

[0489] “R-29148” (3-dichloroacetyl-2,2,5-trimethyl-1,3-oxazolidine) from Stauffer (S3-2),

[0490] “R-28725” (3-dichloroacetyl-2,2-dimethyl-1,3-oxazolidine) from Stauffer (S3-3), [0491] “benoxacor” (4-dichloroacetyl-3,4-dihydro-3-methyl-2H-1,4-benzoxazine) (S3-4), [0492] “PPG-1292” (N-allyl-N-[(1,3-dioxolan-2-yl)methyl]dichloroacetamide) from PPG Industries (S3-5), [0493] “DKA-24” (N-allyl-N-[(allylaminocarbonyl)methyl]dichloroacetamide) from Sagro-Chem (S3-6), [0494] “AD-67” or “MON 4660” (3-dichloroacetyl-1-oxa-3-azaspiro[4.5]decane) from Nitrokemia or Monsanto (S3-7), [0495] “TI-35” (1-dichloroacetylazepane) from TRI-Chemical RT (S3-8), [0496] “Diclonon” (dicyclonon) or “BAS145138” or “LAB145138” (S3-9), [0497] ((RS)-1-dichloroacetyl-3,3,8a-trimethylperhydropyrrolo[1,2-a]pyrimidin-6-one) from BASF, [0498] “furilazole” or “MON 13900” ((RS)-3-dichloroacetyl-5-(2-furyl)-2,2-dimethyloxazolidine) (S3-10), and the (R) isomer thereof (S3-11). [0499] S4) Compounds from the class of the acylsulfonamides (S4): [0500] S4.sup.a) N-Acylsulfonamides of the formula (S4.sup.a) and salts thereof, as described in WO-A-97/45016,

##STR00126## [0501] in which [0502] R.sub.A.sup.1 is (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.6)cycloalkyl, where the 2 latter radicals are substituted by v.sub.A substituents from the group of halogen, (C.sub.1-C.sub.4)alkoxy, (C.sub.1-C.sub.6)haloalkoxy and (C.sub.1-C.sub.4)alkylthio and, in the case of cyclic radicals, also by (C.sub.1-C.sub.4)alkyl and (C.sub.1-C.sub.4)haloalkyl; [0503] R.sub.A.sup.2 is halogen, (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy, CF.sub.3; [0504] m.sub.A is 1 or 2;

[0505] V.sub.A is 0, 1, 2 or 3; [0506] S4.sup.a) Compounds of the 4-(benzoylsulfamoyl)benzamide type of the formula (S4.sup.b) and salts thereof, as described in WO-A-99/16744,

##STR00127## [0507] in which [0508] R.sub.B.sup.1, R.sub.B.sup.2 are, independently, hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.6)cycloalkyl, (C.sub.3-C.sub.6)alkenyl, (C.sub.3-C.sub.6)alkynyl, [0509] R.sub.B.sup.3 is halogen, (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)haloalkyl or (C.sub.1-C.sub.4)alkoxy and [0510] m.sub.B is 1 or 2, [0511] for example those in which [0512] R.sub.B.sup.1=cyclopropyl, R.sub.B.sup.2=hydrogen and (R.sub.B.sup.3)=2-OMe (“cyprosulfamide”, S4-1), [0513] R.sub.B.sup.1=cyclopropyl, R.sub.B.sup.2=hydrogen and (R.sub.B.sup.3)=5-Cl-2-OMe (S4-2), [0514] R.sub.B.sup.1=ethyl, R.sub.B.sup.2=hydrogen and (R.sub.B.sup.3)=2-OMe (S4-3), [0515] R.sub.B.sup.1=isopropyl, R.sub.B.sup.2=hydrogen and (R.sub.B.sup.3)=5-Cl-2-OMe (S4-4) and [0516] R.sub.B.sup.1=isopropyl, R.sub.B.sup.2=hydrogen and (R.sub.B.sup.3)=2-OMe (S4-5). [0517] S4.sup.c) Compounds from the class of the benzoylsulfamoylphenylureas of the formula (S4.sup.c), as described in EP-A-365 484,

##STR00128## [0518] in which [0519] R.sub.C.sup.1, R.sub.C.sup.2 are independently hydrogen, (C.sub.1-C.sub.8)alkyl, (C.sub.3-C.sub.8)cycloalkyl, (C.sub.3-C.sub.6)alkenyl, (C.sub.3-C.sub.6)alkynyl, [0520] R.sub.C.sup.3 is halogen, (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy, CF.sub.3 and [0521] m.sub.C is 1 or 2; [0522] for example: [0523] 1-[4-(N-2-methoxybenzoylsulfamoyl)phenyl]-3-methylurea, [0524] 1-[4-(N-2-methoxybenzoylsulfamoyl)phenyl]-3,3-dimethylurea, [0525] 1-[4-(N-4,5-dimethylbenzoylsulfamoyl)phenyl]-3-methylurea; [0526] S4.sup.d) Compounds of the N-phenylsulfonylterephthalamide type of the formula (S4.sup.d) and salts thereof, which are known, for example, from CN 101838227,

##STR00129## [0527] in which [0528] R.sub.D.sup.4 is halogen, (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy, CF.sub.3; [0529] m.sub.D is 1 or 2; [0530] R.sub.D.sup.5 is hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.6)cycloalkyl, (C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl, (C.sub.5-C.sub.6)cycloalkenyl. [0531] S5) Active ingredients from the class of the hydroxyaromatics and the aromatic-aliphatic carboxylic acid derivatives (S5), for example [0532] ethyl 3,4,5-triacetoxybenzoate, 3,5-dimethoxy-4-hydroxybenzoic acid, 3,5-dihydroxybenzoic acid, 4-hydroxysalicylic acid, 4-fluorosalicyclic acid, 2-hydroxycinnamic acid, 2,4-dichlorocinnamic acid, as described in WO-A-2004/084631, WO-A-2005/015994, WO-A-2005/016001. [0533] S6) Active ingredients from the class of the 1,2-dihydroquinoxalin-2-ones (S6), for example [0534] 1-methyl-3-(2-thienyl)-1,2-dihydroquinoxalin-2-one, 1-methyl-3-(2-thienyl)-1,2-dihydroquinoxaline-2-thione, 1-(2-aminoethyl)-3-(2-thienyl)-1,2-dihydroquinoxalin-2-one hydrochloride, 1-(2-methylsulfonylaminoethyl)-3-(2-thienyl)-1,2-dihydroquinoxalin-2-one, as described in WO-A-2005/112630. [0535] S7) Compounds from the class of the diphenylmethoxyacetic acid derivatives (S7), for example methyl diphenylmethoxyacetate (CAS Reg. No. 41858-19-9) (S7-1), ethyl diphenylmethoxyacetate or diphenylmethoxyacetic acid, as described in WO-A-98/38856. [0536] S8) Compounds of the formula (S8), as described in WO-A-98/27049,

##STR00130## [0537] in which the symbols and indices are defined as follows: [0538] R.sub.D.sup.1 is halogen, (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)haloalkyl, (C.sub.1-C.sub.4)alkoxy, (C.sub.1-C.sub.4)haloalkoxy, [0539] R.sub.D.sup.2 is hydrogen or (C.sub.1-C.sub.4)alkyl, [0540] R.sub.D.sup.3 is hydrogen, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.4)alkenyl, (C.sub.2-C.sub.4)alkynyl, or aryl, where each of the aforementioned carbon-containing radicals is unsubstituted or substituted by one or more, preferably up to three identical or different radicals from the group consisting of halogen and alkoxy; or salts thereof, [0541] n.sub.D is an integer from 0 to 2. [0542] s9) Active ingredients from the class of the 3-(5-tetrazolylcarbonyl)-2-quinolones (S9), for example [0543] 1,2-dihydro-4-hydroxy-1-ethyl-3-(5-tetrazolylcarbonyl)-2-quinolone (CAS Reg. No.: 219479-18-2), 1,2-dihydro-4-hydroxy-1-methyl-3-(5-tetrazolylcarbonyl)-2-quinolone (CAS Reg. No. 95855-00-8), as described in WO-A-1999/000020. [0544] S10) Compounds of the formula (S10a) or (S10.sup.b) [0545] as described in WO-A-2007/023719 and WO-A-2007/023764, [0546] in which

##STR00131## [0547] R.sub.E.sup.1 is halogen, (C.sub.1-C.sub.4)alkyl, methoxy, nitro, cyano, CF.sub.3, OCF.sub.3 [0548] Y.sub.E, Z.sub.E are independently O or S, [0549] n.sub.E is an integer from 0 to 4, [0550] R.sub.E.sup.2 is (C.sub.1-C.sub.16)alkyl, (C.sub.2-C.sub.6)alkenyl, (C.sub.3-C.sub.6)cycloalkyl, aryl; benzyl, halobenzyl, [0551] R.sub.E.sup.3 is hydrogen or (C.sub.1-C.sub.6)alkyl. [0552] S11) Active ingredients of the oxyimino compound type (S11) that are known as seed-dressing agents, for example [0553] “oxabetrinil” ((Z)-1,3-dioxolan-2-ylmethoxyimino(phenyl)acetonitrile) (S11-1), which is known as a seed-dressing safener for millet/sorghum against metolachlor damage, [0554] “fluxofenim” (1-(4-chlorophenyl)-2,2,2-trifluoro-1-ethanone 0-(1,3-dioxolan-2-ylmethyl)oxime) (S11-2), which is known as a seed-dressing safener for millet/sorghum against metolachlor damage, and [0555] “cyometrinil” or “CGA-43089” ((Z)-cyanomethoxyimino(phenyl)acetonitrile) (S11-3), which is known as a seed-dressing safener for millet/sorghum against metolachlor damage. [0556] S12) Active ingredients from the class of the isothiochromanones (S12), for example methyl [(3-oxo-1H-2-benzothiopyran-4(3H)-ylidene)methoxy]acetate (CAS Reg. No. 205121-04-6) (512-1) and related compounds from WO-A-1998/13361. [0557] S13) One or more compounds from group (S13): [0558] “naphthalic anhydride” (1,8-naphthalenedicarboxylic anhydride) (S13-1), which is known as a seed-dressing safener for corn against thiocarbamate herbicide damage, [0559] “fenclorim” (4,6-dichloro-2-phenylpyrimidine) (513-2), which is known as a safener for pretilachlor in sown rice, [0560] “flurazole” (benzyl 2-chloro-4-trifluoromethyl-1,3-thiazole-5-carboxylate) (S13-3), which is known as a seed-dressing safener for millet/sorghum against alachlor and metolachlor damage, [0561] “CL 304415” (CAS Reg. No. 31541-57-8) [0562] (4-carboxy-3,4-dihydro-2H-1-benzopyran-4-acetic acid) (S13-4) from American Cyanamid, which is known as a safener for corn against damage by imidazolinones, [0563] “MG 191” (CAS Reg. No. 96420-72-3) (2-dichloromethyl-2-methyl-1,3-dioxolane) (S13-5) from Nitrokemia, which is known as a safener for corn, [0564] “MG 838” (CAS Reg. No. 133993-74-5), [0565] (2-propenyl 1-oxa-4-azaspiro[4.5]decane-4-carbodithioate) (S13-6) from Nitrokemia, [0566] “disulfoton” (O,O-diethyl S-2-ethylthioethyl phosphorodithioate) (S13-7), [0567] “dietholate” (0,0-diethyl 0-phenyl phosphorothioate) (S13-8), [0568] “mephenate” (4-chlorophenyl methylcarbamate) (S13-9). [0569] S14) Active ingredients which, in addition to herbicidal action against weeds, also have safener action on crop plants such as rice, for example [0570] “dimepiperate” or “MY-93” (S-1-methyl 1-phenylethylpiperidine-1-carbothioate), which is known as a safener for rice against damage by the herbicide molinate, [0571] “daimuron” or “SK 23” (1-(1-methyl-1-phenylethyl)-3-p-tolylurea), which is known as safener for rice against imazosulfuron herbicide damage, [0572] “cumyluron”=“JC-940” (3-(2-chlorophenylmethyl)-1-(1-methyl-1-phenylethyl)urea, see JP-A-60087254), which is known as safener for rice against damage by some herbicides, [0573] “methoxyphenone” or “NK 049” (3,3′-dimethyl-4-methoxybenzophenone), which is known as a safener for rice against damage by some herbicides, [0574] “CSB” (1-bromo-4-(chloromethylsulfonyl)benzene) from Kumiai, (CAS Reg. No. 54091-06-4), which is known as a safener against damage by some herbicides in rice. [0575] S15) Compounds of the formula (S15) or tautomers thereof

##STR00132## [0576] as described in WO-A-2008/131861 and WO-A-2008/131860, [0577] in which [0578] R.sub.H.sup.1 is a (C.sub.1-C.sub.6)haloalkyl radical and [0579] R.sub.H.sup.2 is hydrogen or halogen and [0580] R.sub.H.sup.3, R.sub.H.sup.4 are independently hydrogen, (C.sub.1-C.sub.16)alkyl, (C.sub.2-C.sub.16)alkenyl or (C.sub.2-C.sub.16)alkynyl, where each of the 3 latter radicals is unsubstituted or substituted by one or more radicals from the group of halogen, hydroxyl, cyano, (C.sub.1-C.sub.4)alkoxy, (C.sub.1-C.sub.4)haloalkoxy, (C.sub.1-C.sub.4)alkylthio, (C.sub.1-C.sub.4)alkylamino, di[(C.sub.1-C.sub.4)alkyl]amino, [(C.sub.1-C.sub.4)alkoxy]carbonyl, [(C.sub.1-C.sub.4)haloalkoxy]carbonyl, (C.sub.3-C.sub.6)cycloalkyl which is unsubstituted or substituted, phenyl which is unsubstituted or substituted, and heterocyclyl which is unsubstituted or substituted, [0581] or (C.sub.3-C.sub.6)cycloalkyl, (C.sub.4-C.sub.6)cycloalkenyl, (C.sub.3-C.sub.6)cycloalkyl fused on one side of the ring to a 4 to 6-membered saturated or unsaturated carbocyclic ring, or (C.sub.4-C.sub.6)-cycloalkenyl fused on one side of the ring to a 4 to 6-membered saturated or unsaturated carbocyclic ring, [0582] where each of the 4 latter radicals is unsubstituted or substituted by one or more radicals from the group of halogen, hydroxyl, cyano, (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)haloalkyl, (C.sub.1-C.sub.4)alkoxy, (C.sub.1-C.sub.4)haloalkoxy, (C.sub.1-C.sub.4)alkylthio, (C.sub.1-C.sub.4)alkylamino, di[(C.sub.1-C.sub.4)alkyl]amino, [(C.sub.1-C.sub.4)alkoxy]carbonyl, [(C.sub.1-C.sub.4)haloalkoxy]carbonyl, (C.sub.3-C.sub.6)cycloalkyl which is unsubstituted or substituted, phenyl which is unsubstituted or substituted, and heterocyclyl which is unsubstituted or substituted, [0583] or [0584] R.sub.H.sup.3 is (C.sub.1-C.sub.4)alkoxy, (C.sub.2-C.sub.4)alkenyloxy, (C.sub.2-C.sub.6)alkynyloxy or (C.sub.2-C.sub.4)haloalkoxy and [0585] R.sub.H.sup.4 is hydrogen or (C.sub.1-C.sub.4)-alkyl or [0586] R.sub.H.sup.3 and R.sub.H.sup.4 together with the directly bonded nitrogen atom are a four- to eight-membered heterocyclic ring which, as well as the nitrogen atom, may also contain further ring heteroatoms, preferably up to two further ring heteroatoms from the group of N, O and S, and which is unsubstituted or substituted by one or more radicals from the group of halogen, cyano, nitro, (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)haloalkyl, (C.sub.1-C.sub.4)alkoxy, (C.sub.1-C.sub.4)haloalkoxy and (C.sub.1-C.sub.4)alkylthio. [0587] S16) Active ingredients which are used primarily as herbicides but also have safener action on crop plants, for example [0588] (2,4-dichlorophenoxy)acetic acid (2,4-D), [0589] (4-chlorophenoxy)acetic acid, [0590] (R,S)-2-(4-chloro-o-tolyloxy)propionic acid (mecoprop), [0591] 4-(2,4-dichlorophenoxy)butyric acid (2,4-DB), [0592] (4-chloro-o-tolyloxy)acetic acid (MCPA), [0593] 4-(4-chloro-o-tolyloxy)butyric acid, [0594] 4-(4-chlorophenoxy)butyric acid, [0595] 3,6-dichloro-2-methoxybenzoic acid (dicamba), [0596] 1-(ethoxycarbonyl)ethyl 3,6-dichloro-2-methoxybenzoate (lactidichlor-ethyl).

[0597] Preferred safeners in combination with the inventive compounds of the formula (I) and/or salts thereof, especially with the compounds of the formulae (I.1) to (I.60) and/or salts thereof, are: cloquintocet-mexyl, cyprosulfamide, fenchlorazole-ethyl ester, isoxadifen-ethyl, mefenpyr-diethyl, fenclorim, cumyluron, S4-1 and S4-5, and particularly preferred safeners are: cloquintocet-mexyl, cyprosulfamide, isoxadifen-ethyl and mefenpyr-diethyl.

Biological Examples

[0598] A. Herbicidal Action and Crop Compatibility Post-Emergence

[0599] Seeds of mono- and dicotyledonous weed plants and crop plants are laid out in sandy loam soil in plastic or wood-fiber pots, covered with earth and grown under controlled growth conditions in a greenhouse. 2 to 3 weeks after sowing, the trial plants are treated at the one-leaf stage. The compounds of the invention formulated in the form of wettable powders (WP) or emulsion concentrates (EC) were then sprayed onto the green parts of the plant as an aqueous suspension or emulsion with addition of 0.5% additive at a water application rate equivalent to 600 L/ha. After the trial plants had stood for about 3 weeks in the greenhouse, under optimal growth conditions, the effect of the preparations was scored visually by comparison with untreated controls. For example, 100% efficacy=plants have died, 0% efficacy=like control plants.

[0600] Crop plant compatibilities were also scored correspondingly.

[0601] Tables A1 to A15 below show the efficacies of selected compounds of the general formula (I) according to tables I.1 to I.60 on various harmful plants and an application rate corresponding to 80 g/ha or lower that were obtained by the aforementioned trial method.

TABLE-US-00002 TABLE A1 Compound Alopecurus myosuroides Application rate Example No. (Efficacy in %) [g/ha] I.2-72 90 80 I.1-73 90 80 I.48-71 90 80 I.1-26 80 80 I.1-222 90 80 I.1-221 90 80 I.1-341 90 80 I.1-27 90 80 I.48-72 90 80 I.8-271 100 80 I.1-2 90 80 I.1-271 100 80 I.1-1 80 80 I.1-275 90 80 I.1-224 80 80 I.1-115 80 20 I.2-336 80 20 I.2-92 80 20 I.2-91 90 20 I.6-71 80 20 I.6-221 90 20 I.12-91 80 20 I.48-93 80 20 I.48-121 80 20 I.1-181 80 80 I.1-51 80 20

TABLE-US-00003 TABLE A2 Compound Echinochloa crus-galli Application rate Example No. (Efficacy in %) [g/ha] I.2-72 100 80 I.1-73 100 80 I.48-71 100 80 I.1-26 100 80 I.1-222 100 80 I.1-221 100 80 I.1-341 100 80 I.1-27 100 80 I.48-72 100 80 I.8-271 80 80 I.1-2 100 80 I.1-72 100 80 I.1-271 90 80 I.1-71 100 80 I.1-1 100 80 I.1-275 90 80 I.8-1 100 80 I.1-6 90 20 I.1-30 100 20 I.2-71 80 20 I.48-81 90 20 I.48-91 100 20 I.42-72 90 20 I.2-92 100 20 I.2-91 100 20 I.2-81 100 20 I.6-71 90 20 I.6-72 80 20 I.5-71 90 20 I.5-72 90 20 I.5-221 80 20 I.5-91 80 20 I.6-221 80 20 I.4-221 80 20 I.12-71 100 20 I.12-91 100 20 I.12-72 100 20 I.54-71 80 20 I.1-181 100 20 I.1-82 100 20 I.1-92 100 20 I.1-123 100 20 I.1-41 100 20 I.1-121 100 20 I.1-51 100 20 I.1-48 100 20

TABLE-US-00004 TABLE A3 Compound Setaria viridis Application rate Example No. (Efficacy in %) [g/ha] I.2-72 100 80 I.1-73 100 80 I.48-71 100 80 I.1-26 100 80 I.1-222 100 80 I.1-221 100 80 I.1-341 100 80 I.1-27 100 80 I.48-72 100 80 I.8-271 100 80 I.1-2 100 80 I.1-72 100 80 I.1-271 100 80 I.1-71 100 80 I.1-1 100 80 I.1-275 100 80 I.1-335 100 80 I.8-1 100 80 I.1-224 100 80 I.1-115 100 20 I.2-71 90 20 I.1-6 100 20 I.1-30 100 20 I.2-73 90 20 I.42-72 100 20 I.2-336 100 20 I.2-92 100 20 I.2-91 100 20 I.2-81 100 20 I.6-71 100 20 I.6-72 90 20 I.5-71 90 20 I.5-72 80 20 I.5-221 100 20 I.5-91 90 20 I.6-221 100 20 I.4-221 100 20 I.12-91 80 20 I.14-72 100 20 I.54-71 100 20 I.54-241 100 20 I.48-92 100 20 I.1-181 100 20 I.1-151 100 20 I.1-82 80 20 I.1-241 100 20 I.1-334 90 20 I.1-126 100 20 I.1-92 100 20 I.1-276 100 20 I.1-123 100 20 I.1-41 100 20 I.1-121 100 20 I.1-51 100 20 I.1-48 100 20 I.1-340 80 80

TABLE-US-00005 TABLE A4 Compound Abutilon theophrasti Application rate Example No. (Efficacy in %) [g/ha] I.2-72 100 80 I.1-73 100 80 I.48-71 100 80 I.1-26 100 80 I.1-222 100 80 I.1-221 100 80 I.1-341 100 80 I.1-27 100 80 I.48-72 100 80 I.8-271 100 80 I.1-2 100 80 I.1-72 100 80 I.1-271 100 80 I.1-71 100 80 I.1-1 100 80 I.1-275 100 80 I.1-335 100 80 I.8-1 100 80 I.1-224 100 80 I.1-333 100 80 I.1-340 100 80 I.1-115 100 20 I.2-71 100 20 I.1-180 100 20 I.1-6 100 20 I.1-30 100 20 I.2-73 100 20 I.48-221 100 20 I.48-91 100 20 I.48-81 100 20 I.49-71 100 20 I.49-72 100 20 I.49-221 100 20 I.42-72 100 20 I.2-336 100 20 I.2-92 100 20 I.2-91 100 20 I.2-81 100 20 I.6-71 100 20 I.6-72 100 20 I.5-71 100 20 I.5-72 100 20 I.5-221 100 20 I.5-91 100 20 I.6-221 100 20 I.4-221 100 20 I.12-221 100 20 I.12-71 100 20 I.12-91 100 20 I.12-72 100 20 I.14-221 90 20 I.14-71 100 20 I.14-91 100 20 I.14-72 80 20 I.54-221 100 20 I.54-71 100 20 I.54-241 100 20 I.54-82 100 20 I.48-82 100 20 I.48-73 100 20 I.48-93 100 20 I.48-121 100 20 I.48-92 100 20 I.48-127 100 20 I.1-181 100 20 I.1-151 100 20 I.1-81 100 20 I.1-82 100 20 I.1-132 100 20 I.1-241 100 20 I.1-334 100 20 I.1-331 100 20 I.1-227 100 20 I.1-126 100 20 I.1-91 100 20 I.1-92 100 20 I.1-276 100 20 I.1-123 100 20 I.1-41 100 20 I.1-121 100 20 I.1-51 100 20 I.1-48 100 20

TABLE-US-00006 TABLE A5 Compound Amaranthus retroflexus Application rate Example No. (Efficacy in %) [g/ha] I.2-72 100 80 I.1-73 100 80 I.48-71 100 80 I.1-26 100 80 I.1-222 100 80 I.1-221 100 80 I.1-341 100 80 I.1-27 100 80 I.48-72 100 80 I.8-271 100 80 I.1-2 100 80 I.1-72 100 80 I.1-271 100 80 I.1-71 100 80 I.1-1 100 80 I.1-275 100 80 I.1-335 100 80 I.8-1 100 80 I.1-224 100 80 I.1-333 100 80 I.1-115 100 20 I.2-71 100 20 I.1-180 100 20 I.1-6 100 20 I.1-30 100 20 I.2-73 100 20 I.48-221 90 20 I.48-91 100 20 I.48-81 100 20 I.49-71 100 20 I.49-72 100 20 I.49-221 100 20 I.42-72 100 20 I.2-336 100 20 I.2-92 100 20 I.2-91 100 20 I.2-81 100 20 I.6-71 100 20 I.6-72 100 20 I.5-71 100 20 I.5-72 100 20 I.5-221 100 20 I.5-91 100 20 I.6-221 100 20 I.4-221 100 20 I.12-221 100 20 I.12-71 100 20 I.12-91 100 20 I.12-72 100 20 I.14-221 100 20 I.14-71 100 20 I.14-91 100 20 I.14-72 100 20 I.54-221 100 20 I.54-71 100 20 I.54-241 100 20 I.54-82 100 20 I.48-82 100 20 I.48-73 100 20 I.48-93 100 20 I.48-121 100 20 I.48-92 100 20 I.48-127 100 20 I.1-181 100 20 I.1-151 100 20 I.1-81 100 20 I.1-82 100 20 I.1-132 100 20 I.1-241 100 20 I.1-334 100 20 I.1-331 100 20 I.1-227 100 20 I.1-126 100 20 I.1-91 100 20 I.1-92 100 20 I.1-276 100 20 I.1-123 100 20 I.1-41 100 20 I.1-121 100 20 I.1-51 100 20 I.1-48 100 20

TABLE-US-00007 TABLE A6 Compound Matricaria inodora Application rate Example No. (Efficacy in %) [g/ha] I.2-72 100 80 I.1-73 100 80 I.48-71 100 80 I.1-26 100 80 I.1-222 100 80 I.1-221 100 80 I.1-341 100 80 I.1-27 100 80 I.48-72 100 80 I.8-271 100 80 I.1-2 100 80 I.1-72 100 80 I.1-271 100 80 I.1-71 100 80 I.1-1 100 80 I.1-275 100 80 I.1-335 100 80 I.8-1 100 80 I.1-224 100 80 I.1-333 100 80 I.1-340 100 80 I.1-115 100 20 I.2-71 100 20 I.1-180 100 20 I.1-6 100 20 I.1-30 100 20 I.2-73 100 20 I.48-221 80 20 I.48-91 100 20 I.48-81 100 20 I.49-71 100 20 I.49-72 90 20 I.49-221 90 20 I.42-72 100 20 I.2-336 100 20 I.2-92 100 20 I.2-91 100 20 I.2-81 100 20 I.6-71 100 20 I.6-72 100 20 I.5-71 100 20 I.5-72 90 20 I.5-221 100 20 I.5-91 90 20 I.6-221 100 20 I.4-221 100 20 I.12-221 100 20 I.12-71 80 20 I.12-91 80 20 I.12-72 100 20 I.14-221 80 20 I.14-72 80 20 I.54-221 100 20 I.48-73 80 20 I.48-121 100 20 I.48-127 90 20 I.1-181 100 20 I.1-151 100 20 I.1-81 90 20 I.1-82 100 20 I.1-132 100 20 I.1-241 100 20 I.1-334 100 20 I.1-331 90 20 I.1-227 100 20 I.1-126 90 20 I.1-91 100 20 I.1-92 80 20 I.1-276 100 20 I.1-123 100 20 I.1-41 90 20 I.1-121 100 20 I.1-51 100 20 I.1-48 100 20

TABLE-US-00008 TABLE A7 Compound Polygonum convolvulus Application rate Example No. (Efficacy in %) [g/ha] I.2-72 100 80 I.1-73 100 80 I.48-71 100 80 I.1-26 100 80 I.1-222 100 80 I.1-221 100 80 I.1-341 100 80 I.1-27 100 80 I.48-72 100 80 I.8-271 100 80 I.1-2 100 80 I.1-72 100 80 I.1-271 100 80 I.1-71 100 80 I.1-1 100 80 I.1-275 100 80 I.1-335 100 80 I.8-1 100 80 I.1-224 100 80 I.1-333 100 80 I.1-340 100 80 I.1-115 100 20 I.2-71 100 20 I.1-180 100 20 I.1-6 100 20 I.1-30 100 20 I.2-73 100 20 I.48-91 100 20 I.48-81 100 20 I.49-71 100 20 I.49-221 100 20 I.42-72 100 20 I.2-336 100 20 I.2-92 100 20 I.2-91 100 20 I.2-81 100 20 I.6-71 100 20 I.6-72 100 20 I.5-71 100 20 I.5-72 90 20 I.5-221 100 20 I.5-91 90 20 I.6-221 100 20 I.4-221 100 20 I.12-221 100 20 I.12-71 80 20 I.12-91 80 20 I.12-72 100 20 I.14-221 80 20 I.14-72 80 20 I.54-221 100 20 I.54-71 100 20 I.54-241 100 20 I.48-82 100 20 I.48-93 80 20 I.48-73 80 20 I.48-92 80 20 I.48-121 100 20 I.48-127 90 20 I.1-181 100 20 I.1-151 100 20 I.1-81 90 20 I.1-82 100 20 I.1-132 100 20 I.1-241 100 20 I.1-334 90 20 I.1-227 100 20 I.1-91 100 20 I.1-92 100 20 I.1-276 100 20 I.1-123 100 20 I.1-41 100 20 I.1-121 100 20 I.1-51 100 20 I.1-48 100 20

TABLE-US-00009 TABLE A8 Compound Stellaria media Application rate Example No. (Efficacy in %) [g/ha] I.2-72 100 80 I.1-73 100 80 I.48-71 100 80 I.1-26 100 80 I.1-222 100 80 I.1-221 100 80 I.1-341 100 80 I.1-27 100 80 I.48-72 100 80 I.8-271 100 80 I.1-2 100 80 I.1-72 100 80 I.1-271 100 80 I.1-71 100 80 I.1-1 100 80 I.1-275 100 80 I.1-335 100 80 I.8-1 100 80 I.1-224 80 80 I.1-115 100 20 I.2-71 100 20 I.1-180 90 20 I.1-6 90 20 I.1-30 90 20 I.2-73 100 20 I.48-221 100 20 I.48-91 100 20 I.48-81 100 20 I.49-71 100 20 I.49-221 90 20 I.42-72 90 20 I.2-92 100 20 I.2-91 80 20 I.2-81 100 20 I.6-71 100 20 I.6-72 90 20 I.5-71 80 20 I.5-221 90 20 I.6-221 80 20 I.4-221 80 20 I.12-221 80 20 I.12-71 100 20 I.12-91 100 20 I.12-72 100 20 I.54-221 80 20 I.54-71 80 20 I.54-241 80 20 I.48-93 100 20 I.48-73 100 20 I.48-92 100 20 I.48-121 80 20 I.48-127 100 20 I.1-181 100 20 I.1-151 100 20 I.1-82 80 20 I.1-132 80 20 I.1-241 100 20 I.1-334 90 20 I.1-331 80 20 I.1-126 100 20 I.1-276 100 20 I.1-123 100 20 I.1-121 100 20 I.1-51 80 20 I.1-48 100 20

TABLE-US-00010 TABLE A9 Compound Viola tricolor Application rate Example No. (Efficacy in %) [g/ha] I.2-72 100 80 I.1-73 100 80 I.48-71 100 80 I.1-26 100 80 I.1-222 100 80 I.1-221 100 80 I.1-341 100 80 I.1-27 100 80 I.48-72 100 80 I.8-271 100 80 I.1-2 100 80 I.1-72 100 80 I.1-271 100 80 I.1-71 100 80 I.1-1 100 80 I.1-275 100 80 I.1-335 100 80 I.8-1 100 80 I.1-224 100 80 I.1-333 100 80 I.1-340 100 80 I.1-115 100 20 I.2-71 100 20 I.1-180 100 20 I.1-6 100 20 I.1-30 100 20 I.2-73 100 20 I.48-221 100 20 I.48-91 100 20 I.48-81 100 20 I.49-71 100 20 I.49-72 100 20 I.42-72 100 20 I.2-336 100 20 I.2-92 100 20 I.2-91 100 20 I.2-81 100 20 I.6-71 100 20 I.6-72 100 20 I.5-71 100 20 I.5-72 100 20 I.5-221 100 20 I.5-91 100 20 I.6-221 100 20 I.4-221 100 20 I.12-221 100 20 I.12-71 100 20 I.12-91 100 20 I.12-72 100 20 I.14-221 100 20 I.14-91 100 20 I.14-72 100 20 I.54-71 100 20 I.54-82 90 20 I.48-73 100 20 I.48-93 100 20 I.48-121 100 20 I.48-92 100 20 I.48-127 100 20 I.1-181 100 20 I.1-151 100 20 I.1-81 100 20 I.1-82 100 20 I.1-132 100 20 I.1-241 100 20 I.1-334 100 20 I.1-331 100 20 I.1-227 80 20 I.1-126 100 20 I.1-91 100 20 I.1-92 100 20 I.1-276 100 20 I.1-123 100 20 I.1-41 100 20 I.1-51 100 20 I.1-48 100 20

TABLE-US-00011 TABLE A10 Compound Veronica persica Application rate Example No. (Efficacy in %) [g/ha] I.2-72 100 80 I.1-73 100 80 I.48-71 100 80 I.1-26 100 80 I.1-222 100 80 I.1-221 100 80 I.1-341 100 80 I.1-27 100 80 I.48-72 100 80 I.8-271 100 80 I.1-2 100 80 I.1-72 100 80 I.1-271 100 80 I.1-71 100 80 I.1-1 100 80 I.1-275 100 80 I.1-335 100 80 I.8-1 100 80 I.1-224 100 80 I.1-333 80 80 I.1-115 100 20 I.2-71 100 20 I.1-180 100 20 I.1-6 100 20 I.1-30 100 20 I.2-73 100 20 I.48-221 100 20 I.48-91 100 20 I.48-81 100 20 I.49-71 100 20 I.49-72 100 20 I.49-221 100 20 I.42-72 100 20 I.2-336 100 20 I.2-92 100 20 I.2-91 100 20 I.2-81 100 20 I.6-71 100 20 I.6-72 100 20 I.5-71 100 20 I.5-72 100 20 I.5-221 100 20 I.5-91 100 20 I.6-221 100 20 I.4-221 100 20 I.12-221 100 20 I.12-71 100 20 I.12-91 100 20 I.12-72 100 20 I.14-221 100 20 I.14-71 100 20 I.14-91 100 20 I.14-72 100 20 I.54-221 80 20 I.54-71 100 20 I.54-241 100 20 I.54-82 80 20 I.48-73 100 20 I.48-93 100 20 I.48-121 100 20 I.48-92 100 20 I.48-127 100 20 I.1-181 100 20 I.1-151 100 20 I.1-81 100 20 I.1-82 100 20 I.1-132 100 20 I.1-241 100 20 I.1-334 100 20 I.1-331 100 20 I.1-227 100 20 I.1-126 100 20 I.1-91 100 20 I.1-92 100 20 I.1-276 100 20 I.1-123 100 20 I.1-41 100 20 I.1-121 100 20 I.1-51 100 20 I.1-48 100 20

TABLE-US-00012 TABLE A11 Compound Pharbitis purpurea Application rate Example No. (Efficacy in %) [g/ha] I.2-72 100 80 I.1-73 100 80 I.48-71 100 80 I.1-26 100 80 I.1-222 100 80 I.1-221 100 80 I.1-341 100 80 I.1-27 100 80 I.48-72 100 80 I.8-271 100 80 I.1-2 100 80 I.1-72 100 80 I.1-271 100 80 I.1-71 100 80 I.1-1 100 80 I.1-275 100 80 I.1-335 100 80 I.8-1 100 80 I.1-224 100 80 I.1-333 80 80 I.1-340 100 80 I.1-115 100 20 I.2-71 100 20 I.1-180 100 20 I.1-6 100 20 I.1-30 100 20 I.48-91 100 20 I.48-81 100 20 I.49-71 100 20 I.49-221 100 20 I.42-72 100 20 I.2-336 100 20 I.2-92 100 20 I.2-91 100 20 I.2-81 100 20 I.6-71 100 20 I.6-72 100 20 I.5-71 100 20 I.5-72 100 20 I.5-221 100 20 I.5-91 100 20 I.6-221 100 20 I.4-221 100 20 I.12-71 100 20 I.12-91 100 20 I.14-221 100 20 I.14-71 100 20 I.14-91 80 20 I.14-72 80 20 I.54-221 100 20 I.54-71 100 20 I.48-73 100 20 I.48-93 100 20 I.48-121 100 20 I.48-127 90 20 I.1-151 100 20 I.1-82 100 20 I.1-132 100 20 I.1-227 100 20 I.1-126 100 20 I.1-91 100 20 I.1-92 100 20 I.1-123 100 20 I.1-41 100 20 I.1-121 100 20 I.1-51 100 20 I.1-48 100 20

TABLE-US-00013 TABLE A12 Compound Hordeum murinum Application rate Example No. (Efficacy in %) [g/ha] I.2-72 80 80 I.1-73 80 80 I.48-71 80 80 I.1-26 90 80 I.1-221 80 80 I.1-341 90 80 I.1-27 80 80 I.1-72 80 80 I.1-71 80 80 I.1-115 100 20 I.2-336 80 20 I.6-71 80 20 I.4-221 80 20 I.1-121 80 20 I.1-48 80 20

TABLE-US-00014 TABLE A13 Compound Avena fatua Application rate Example No. (Efficacy in %) [g/ha] I.2-72 80 80 I.1-222 80 80 I.1-221 80 80 I.1-341 90 80 I.8-271 90 80 I.1-72 80 80 I.1-72 80 80 I.1-115 80 20 I.1-121 80 20

TABLE-US-00015 TABLE A14 Compound Digitaria sanguinalis Application rate Example No. (Efficacy in %) [g/ha] I.2-72 100 80 I.1-73 100 80 I.48-71 100 80 I.1-26 100 80 I.1-27 100 80 I.48-72 100 80 I.1-2 100 80 I.1-115 100 20 I.2-71 100 20 I.1-6 100 20 I.1-30 100 20 I.48-91 100 20 I.48-81 100 20 I.42-72 100 20 I.2-92 100 20 I.2-81 100 20 I.4-221 100 20 I.6-71 100 20 I.6-72 100 20 I.5-71 100 20 I.5-72 100 20 I.5-221 80 20 I.6-221 100 20 I.54-71 80 20 I.54-241 80 20 I.48-121 80 20 I.1-151 80 20 I.1-82 100 20 I.1-241 100 20 I.1-126 80 20 I.1-123 80 20 I.1-41 100 20 I.1-121 100 20 I.1-51 100 20 I.1-48 100 20

TABLE-US-00016 TABLE A15 Compound Lolium rigidum Application rate Example No. (Efficacy in %) [g/ha] I.2-72 80 80 I.1-73 90 80 I.48-71 80 80 I.1-26 90 80 I.1-222 90 80 I.1-221 90 80 I.1-341 100 80 I.1-27 80 80 I.48-72 80 80 I.1-2 100 80 I.1-72 100 80 I.1-271 100 80 I.1-1 90 80 I.1-275 80 80 I.5-221 80 20 I.6-221 80 20 I.1-181 80 20 I.1-121 80 20

[0602] Tables A16 to A20 below show the crop compatibilities of selected compounds of the general formula (I) according to tables I.1 to I.60 at an application rate corresponding to 80 g/ha or lower that were observed in trials according to the aforementioned trial method. The effects observed are reported here on selected crop plants by comparison with the untreated controls (values in %).

TABLE-US-00017 TABLE A16 Compound Oryza sativa Application rate Example No. (Efficacy in %) [g/ha] I.1-271 10 20 I.1-222 20 80 I.1-221 0 20 I.1-335 10 20 I.1-1 20 5 I.8-1 10 5 I.1-71 20 5 I.1-115 0 5 I.2-71 20 20 I.1-180 0 20 I.1-6 0 5 I.1-30 0 20 I.2-72 20 5 I.2-73 10 20 I.48-72 10 20 I.48-71 20 20 I.48-221 10 20 I.49-71 10 20 I.49-72 10 20 I.49-221 10 20 I.2-336 0 5 I.12-221 20 20 I.12-71 0 20 I.12-91 0 20 I.12-72 20 20 I.14-221 10 20 I.14-71 0 20 I.14-91 0 20 I.14-72 0 20 I.54-221 20 20 I.54-71 0 5 I.54-241 0 20 I.54-82 0 20 I.48-72 0 5 I.48-73 0 20 I.48-93 0 20 I.48-121 0 20 I.48-92 10 20 I.48-127 0 20 I.1-333 0 80 I.1-181 10 80 I.1-224 10 20 I.1-275 20 20 I.1-340 10 20 I.1-341 10 5 I.1-151 20 20 I.1-81 0 20 I.1-82 10 20 I.1-132 0 20 I.1-241 10 20 I.1-334 10 20 I.1-331 10 20 I.1-227 0 20 I.1-126 0 20 I.1-91 10 20 I.1-92 0 20 I.1-276 10 5 I.1-26 10 5 I.1-27 10 5 I.1-23 10 5 I.1-73 5 20

TABLE-US-00018 TABLE A17 Compound Zea mays Application rate Example No. (Efficacy in %) [g/ha] I.1-271 10 20 I.8-271 20 80 I.1-222 20 20 I.1-221 10 5 I.1-335 10 80 I.1-1 20 20 I.8-1 20 5 I.1-71 20 80 I.1-72 20 20 I.1-115 20 5 I.2-71 0 5 I.48-221 20 80 I.12-221 0 5 I.12-71 0 5 I.12-91 0 5 I.12-72 0 5 I.14-71 0 20 I.14-91 20 20 I.54-221 00 20 I.54-82 20 5 I.48-92 10 5 I.48-127 20 5 I.1-333 0 80 I.1-181 20 80 I.1-224 20 80 I.1-340 0 80 I.1-341 10 20 I.1-151 20 5 I.1-81 10 20 I.1-82 20 20 I.1-132 20 20 I.1-334 20 20 I.1-227 20 20 I.1-126 20 20 I.1-91 20 20 I.1-92 20 20

TABLE-US-00019 TABLE A18 Compound Brassica napis Application rate Example No. (Efficacy in %) [g/ha] I.1-271 20 5 I.2-71 20 5 I.12-221 0 5 I.54-241 0 5 I.54-82 0 5 I.48-82 20 5 I.48-121 20 5 I.1-333 0 20 I.1-224 20 20 I.1-340 10 20 I.1-341 0 5 I.1-81 10 5 I.1-82 0 5 I.1-227 0 5 I.1-126 10 5 I.1-91 10 5

TABLE-US-00020 TABLE A19 Compound Glycine max Application rate Example No. (Efficacy in %) [g/ha] I.1-271 20 5 I.8-1 20 5 I.1-71 20 20 I.1-72 10 20 I.54-82 0 5 I.4-221 20 5 I.12-91 0 5 I.12-72 20 5 I.14-71 0 20 I.14-91 20 20 I.14-72 20 20 I.54-82 20 5 I.1-333 20 20 I.1-181 20 20 I.1-340 20 20 I.1-341 10 25 I.1-227 20 5

TABLE-US-00021 TABLE A20 Compound Triticum aestivum Application rate Example No. (Efficacy in %) [g/ha] I.1-271 20 20 I.1-222 20 80 I.1-221 20 20 I.1-335 20 80 I.1-1 20 5 I.1-71 20 80 I.1-72 0 20 I.2-71 20 20 I.1-180 20 20 I.1-30 20 20 I.2-72 20 80 I.48-72 20 20 I.48-71 20 20 I.48-91 20 5 I.48-81 20 20 I.49-71 20 20 I.42-72 20 20 I.2-92 20 5 I.2-91 20 5 I.2-81 20 20 I.6-71 20 20 I.6-72 20 5 I.5-71 10 20 I.5-72 20 20 I.5-221 20 20 I.5-91 10 20 I.12-221 20 20 I.12-71 0 5 I.12-91 0 5 I.12-72 0 20 I.14-221 20 20 I.14-71 0 20 I.14-91 20 20 I.14-72 20 20 I.54-221 0 20 I.54-71 20 5 I.54-241 0 20 I.54-82 0 5 I.48-82 0 5 I.48-73 0 20 I.48-93 0 20 I.48-121 0 20 I.48-92 0 20 I.48-127 10 20 I.1-333 10 20 I.1-181 20 20 I.1-224 20 20 I.1-275 20 20 I.1-340 20 20 I.1-341 10 20 I.1-151 20 5 I.1-81 20 20 I.1-82 0 5 I.1-132 10 5 I.1-241 20 5 I.1-227 10 5 I.1-126 20 20 I.1-91 10 5 I.1-92 10 20 I.1-2 20 5 I.1-26 20 5 I.1-27 10 5 I.1-73 20 80 I.1-123 20 20 I.1-41 20 20 I.1-51 20 20 I.1-48 10 5

[0603] As the results show, inventive compounds of the general formula (I) in the case of post-emergence treatment exhibit good herbicidal efficacy against harmful plants such as, for example, Abufilon theophrasti, Alopecurus myosuroides, Amaranthus retroflexus, Avena fatua, Digitaria sanguinalis, Echinochloa crus-galli, Hordeum murinum, Lolium rigidum, Matricaria inodora, Pharbitis purpurea, Polygonum convolvulus, Setaria viridis, Stellaria media, Veronica persica and Viola tricolor at an application rate 0.02 to 0.08 kg of active substance per hectare.

[0604] The tested crop plants Brassica napus, Glycine max, Oryza sativa, Triticum aestivum and Zea mays are impaired only to a minor degree, if at all, after application of inventive compounds of the general formula (I) at an application rate of 0.005 to 0.08 kg of active substance per hectare.

[0605] B. Herbicidal Action and Crop Compatibility Pre-Emergence

[0606] Seeds of mono- and dicotyledonous weeds and crop plants were laid out in plastic or organic plant pots and covered with soil. The compounds of the invention formulated in the form of wettable powders (WP) or emulsion concentrates (EC) were then applied to the surface of the covering soil as an aqueous suspension or emulsion with addition of 0.5% additive at a water application rate equivalent to 600 L/ha. After the treatment, the pots were placed in a greenhouse and kept under good growth conditions for the test plants. After about 3 weeks, the efficacy of the preparations was scored visually as a percentage by comparison with untreated controls. For example, 100% efficacy=plants have died, 0% efficacy=like control plants.

[0607] Crop compatibilities were also scored correspondingly.

[0608] Tables B1 to B16 below show the efficacies of selected compounds of the general formula (I) according to tables I.1 to I.60 on various harmful plants and an application rate corresponding to 320 g/ha or lower that were obtained by the aforementioned trial method.

TABLE-US-00022 TABLE B1 Compound Alopecurus myosuroides Application rate Example No. (Efficacy in %) [g/ha] I.1-271 100 320 I.8-271 90 320 I.1-222 100 320 I.1-221 90 320 I.1-335 90 320 I.1-1 80 320 I.1-27 80 320 I.1-71 100 320 I.1-72 90 320 I.2-72 100 320 I.48-72 90 320 I.48-71 100 320 I.1-333 100 320 I.1-224 100 320 I.1-275 100 320 I.1-340 90 320 I.1-341 90 320 I.1-2 80 320 I.1-181 100 320

TABLE-US-00023 TABLE B2 Compound Echinochloa crus-galli Application rate Example No. (Efficacy in %) [g/ha] I.1-271 100 320 I.8-271 80 320 I.1-222 100 320 I.1-221 100 320 I.1-335 100 320 I.1-1 100 320 I.8-1 100 320 I.1-71 100 320 I.1-72 100 320 I.2-72 100 320 I.48-72 100 320 I.48-71 100 320 I.1-333 100 320 I.1-224 100 320 I.1-275 100 320 I.1-340 100 320 I.1-341 100 320 I.1-2 100 320 I.1-26 100 320 I.1-27 100 320 I.1-23 100 320 I.1-73 100 320 I.2-71 100 80 I.1-181 100 320

TABLE-US-00024 TABLE B3 Compound Setaria viridis Application rate Example No. (Efficacy in %) [g/ha] I.1-271 100 320 I.1-275 100 320 I.1-27 100 320 I.1-341 100 320 I.1-335 100 320 I.1-1 100 320 I.8-1 100 320 I.1-71 100 320 I.1-72 100 320 I.2-72 100 320 I.1-73 100 320 I.1-26 100 320 I.1-333 90 320 I.1-224 100 320 I.8-271 100 320 I.1-222 100 320 I.1-221 100 320 I.48-72 100 320 I.48-71 100 320 I.1-340 100 320 I.1-2 100 320 I.1-23 100 320 I.2-71 100 80 I.1-181 100 320 I.1-82 100 80

TABLE-US-00025 TABLE B4 Compound Abutilon theophrasti Application rate Example No. (Efficacy in %) [g/ha] I.1-271 100 320 I.1-275 100 320 I.1-27 100 320 I.1-341 100 320 I.1-335 100 320 I.1-1 100 320 I.8-1 100 320 I.1-71 100 320 I.1-72 100 320 I.2-72 100 320 I.1-73 100 320 I.1-26 100 320 I.1-333 100 320 I.1-224 100 320 I.8-271 100 320 I.1-222 100 320 I.1-221 100 320 I.48-72 100 320 I.48-71 100 320 I.1-340 100 320 I.1-2 100 320 I.1-23 100 320 I.2-71 100 80 I.1-181 100 320 I.1-81 100 80 I.1-82 100 80 I.1-132 100 80 I.1-227 100 80 I.1-126 100 80 I.1-91 100 80 I.1-92 100 80

TABLE-US-00026 TABLE B5 Compound Amaranthus retroflexus Application rate Example No. (Efficacy in %) [g/ha] I.1-271 100 320 I.1-275 100 320 I.1-27 100 320 I.1-341 100 320 I.1-335 100 320 I.1-1 100 320 I.8-1 100 320 I.1-71 100 320 I.1-72 100 320 I.2-72 100 320 I.1-73 100 320 I.1-26 100 320 I.1-333 100 320 I.1-224 100 320 I.8-271 100 320 I.1-222 100 320 I.1-221 100 320 I.48-72 100 320 I.48-71 100 320 I.1-340 100 320 I.1-2 100 320 I.1-23 100 320 I.2-71 100 80 I.1-181 100 320 I.1-81 100 80 I.1-82 100 80 I.1-132 100 80 I.1-227 100 80 I.1-126 100 80 I.1-91 100 80 I.1-92 100 80

TABLE-US-00027 TABLE B6 Compound Matricaria inodora Application rate Example No. (Efficacy in %) [g/ha] I.1-271 100 320 I.1-275 100 320 I.1-27 100 320 I.1-341 100 320 I.1-335 100 320 I.1-1 100 320 I.8-1 100 320 I.1-71 100 320 I.1-72 100 320 I.2-72 100 320 I.1-73 100 320 I.1-26 100 320 I.1-333 100 320 I.1-224 100 320 I.8-271 100 320 I.1-222 100 320 I.1-221 100 320 I.48-72 100 320 I.48-71 100 320 I.1-340 100 320 I.1-2 100 320 I.1-23 100 320 I.2-71 100 80 I.1-181 100 320 I.1-81 80 80 I.1-82 100 80 I.1-132 100 80 I.1-227 90 80 I.1-126 100 80 I.1-91 100 80 I.1-92 100 80

TABLE-US-00028 TABLE B7 Compound Polygonum convolvulus Application rate Example No. (Efficacy in %) [g/ha] I.1-271 320 100 I.1-275 320 100 I.1-27 320 100 I.1-341 320 100 I.1-335 320 100 I.1-1 320 100 I.8-1 320 100 I.1-71 320 100 I.1-72 320 100 I.2-72 320 100 I.1-73 320 100 I.1-26 320 100 I.1-333 320 100 I.1-224 320 90 I.8-271 320 100 I.1-222 320 100 I.1-221 320 100 I.48-72 320 100 I.48-71 320 100 I.1-340 320 100 I.1-2 320 100 I.1-23 320 100 I.2-71 100 80 I.1-81 100 80

TABLE-US-00029 TABLE B8 Compound Stellaria media Application rate Example No. (Efficacy in %) [g/ha] I.1-271 100 320 I.1-275 100 320 I.1-27 100 320 I.1-341 100 320 I.1-335 100 320 I.1-1 100 320 I.8-1 100 320 I.1-71 100 320 I.1-72 100 320 I.2-72 100 320 I.1-73 100 320 I.1-26 100 320 I.1-333 100 320 I.1-224 100 320 I.8-271 90 320 I.1-222 100 320 I.1-221 100 320 I.48-72 100 320 I.48-71 100 320 I.1-340 100 320 I.1-2 100 320 I.2-71 100 80 I.1-181 100 320 I.1-82 100 80

TABLE-US-00030 TABLE B9 Compound Viola tricolor Application rate Example No. (Efficacy in %) [g/ha] I.1-271 100 320 I.1-275 100 320 I.1-27 100 320 I.1-341 100 320 I.1-335 100 320 I.1-1 100 320 I.8-1 100 320 I.1-71 100 320 I.1-72 100 320 I.2-72 100 320 I.1-73 100 320 I.1-26 100 320 I.1-333 100 320 I.1-224 100 320 I.8-271 100 320 I.1-222 100 320 I.1-221 100 320 I.48-72 100 320 I.48-71 100 320 I.1-340 100 320 I.1-2 100 320 I.1-23 100 320 I.2-71 100 80 I.1-181 100 320 I.1-81 100 80 I.1-82 100 80 I.1-132 90 80 I.1-227 80 80 I.1-91 100 80

TABLE-US-00031 TABLE B10 Compound Veronica persica Application rate Example No. (Efficacy in %) [g/ha] I.1-271 100 320 I.1-275 100 320 I.1-27 100 320 I.1-341 100 320 I.1-335 100 320 I.1-1 100 320 I.8-1 100 320 I.1-71 100 320 I.1-72 100 320 I.2-72 100 320 I.1-73 100 320 I.1-26 100 320 I.1-333 100 320 I.1-224 100 320 I.8-271 100 320 I.48-72 100 320 I.48-71 100 320 I.1-340 100 320 I.1-2 100 320 I.2-71 100 80 I.1-181 100 320 I.1-81 80 80 I.1-82 100 80 I.1-91 100 80

TABLE-US-00032 TABLE B11 Compound Pharbitis purpurea Application rate Example No. (Efficacy in %) [g/ha] I.1-271 100 320 I.1-275 100 320 I.1-27 100 320 I.1-341 100 320 I.1-335 100 320 I.1-1 100 320 I.8-1 100 320 I.1-71 100 320 I.1-72 100 320 I.2-72 100 320 I.1-73 100 320 I.1-26 100 320 I.1-333 100 320 I.1-224 100 320 I.8-271 100 320 I.1-222 100 320 I.1-221 100 320 I.48-72 100 320 I.48-71 100 320 I.1-340 100 320 I.1-2 100 320 I.1-23 100 320 I.2-71 100 80 I.1-181 100 320 I.1-82 100 80

TABLE-US-00033 TABLE B12 Compound Hordeum murinum Application rate Example No. (Efficacy in %) [g/ha] I.1-271 100 320 I.1-275 90 320 I.1-27 80 320 I.1-341 80 320 I.1-335 90 320 I.1-1 90 320 I.8-1 90 320 I.1-71 90 320 I.1-72 90 320 I.2-72 90 320 I.1-73 90 320 I.1-26 100 320 I.1-333 100 320 I.1-224 100 320 I.1-222 90 320 I.1-221 100 320 I.1-181 90 320

TABLE-US-00034 TABLE B13 Compound Avena fatua Application rate Example No. (Efficacy in %) [g/ha] I.1-271 100 320 I.8-271 90 320 I.1-222 100 320 I.1-221 100 320 I.1-335 100 320 I.1-1 90 320 I.8-1 80 320 I.1-71 90 320 I.1-72 100 320 I.2-72 80 320 I.48-72 80 320 I.48-71 80 320 I.1-333 100 320 I.1-224 100 320 I.1-275 100 320 I.1-340 80 320 I.1-341 90 320 I.1-2 90 320 I.1-26 80 320 I.1-73 90 320 I.1-181 100 320

TABLE-US-00035 TABLE B14 Compound Digitaria sanguinalis Application rate Example No. (Efficacy in %) [g/ha] I.1-26 100 80 I.1-27 100 80 I.2-72 100 80 I.48-72 100 80 I.48-71 100 80 I.1-73 100 80 I.1-2 100 80 I.2-71 100 80 I.1-82 80 80

TABLE-US-00036 TABLE B15 Compound Lolium rigidum Application rate Example No. (Efficacy in %) [g/ha] I.1-271 100 320 I.1-275 90 320 I.1-27 90 320 I.1-341 100 320 I.1-335 100 320 I.1-1 80 320 I.8-1 90 320 I.1-71 90 320 I.1-72 100 320 I.2-72 90 320 I.1-73 100 320 I.1-26 90 320 I.1-333 100 320 I.1-224 100 320 I.1-222 100 320 I.1-221 100 320 I.48-72 80 320 I.48-71 90 320 I.1-340 100 320 I.1-2 90 320 I.1-181 100 80

TABLE-US-00037 TABLE B16 Compound Cyperus esculentus Application rate Example No. (Efficacy in %) [g/ha] I.1-271 80 320 I.1-224 90 320 I.1-222 100 320 I.1-221 100 320 I.1-275 80 320 I.1-1 100 320 I.8-1 90 320 I.1-71 80 320 I.1-72 80 320 I.1-333 80 320

[0609] Tables B17 to B19 below show the crop compatibilities of selected compounds of the general formula (I) according to tables I.1 to I.60 at an application rate corresponding to 320 g/ha or lower that were observed in trials according to the aforementioned trial method. The effects observed are reported here on selected crop plants by comparison with the untreated controls (values in %).

TABLE-US-00038 TABLE B17 Compound Oryza sativa Application rate Example No. (Efficacy in %) [g/ha] I.1-271 20 20 I.8-271 0 80 I.2-71 0 20 I.1-181 0 20 I.1-224 0 20 I.1-126 20 80 I.1-92 10 80

TABLE-US-00039 TABLE B18 Compound Zea mays Application rate Example No. (Efficacy in %) [g/ha] I.1-271 0 20 I.8-271 20 80 I.1-222 20 20 I.1-221 0 20 I.1-335 20 20 I.1-1 20 20 I.1-71 0 80 I.1-72 20 80 I.2-71 10 80 I.2-72 10 80 I.48-72 0 320 I.48-71 20 320 I.1-333 20 80 I.1-181 0 20 I.1-224 0 20 I.1-340 0 80 I.1-341 0 80 I.1-81 0 80 I.1-82 0 80 I.1-227 0 80 I.1-132 0 80 I.1-126 0 80 I.1-91 0 80 I.1-92 0 80 I.1-2 0 20 I.1-26 10 80 I.1-27 0 80 I.1-23 10 80 I.1-73 0 80

TABLE-US-00040 TABLE B19 Compound Glycine max Application rate Example No. (Efficacy in %) [g/ha] I.1-271 10 20 I.1-222 10 20 I.1-71 0 80 I.1-72 20 80 I.2-71 0 80 I.2-72 20 20 I.48-72 10 320 I.48-71 0 20 I.1-333 0 80 I.1-181 20 80 I.1-224 0 20 I.1-340 20 80 I.1-81 0 80 I.1-132 20 80 I.1-126 10 80 I.1-91 20 80 I.1-26 0 20 I.1-27 20 80 I.1-23 0 80 I.1-73 0 80

[0610] As the results show, inventive compounds of the general formula (I) in the case of pre-emergence treatment exhibit good herbicidal efficacy against harmful plants, for example against harmful plants such as Abufilon theophrasti, Alopecurus myosuroides, Amaranthus retroflexus, Avena fatua, Cyperus esculentus, Digitaria sanguinalis, Echinocloa crus-galli, Hordeum murinum, Lolium rigidum, Matricaria inodora, Pharbitis purpurea, Polygonum convolvulus, Setaria viridis, Stellaria media, Veronica persica and Viola tricolor at an application rate of 0.32 kg of active substance per hectare. The tested crop plants Glycine max, Oryza sativa and Zea mays are impaired only to a minor degree, if at all, after application of inventive compounds of the general formula (I) at an application rate of 0.02 to 0.32 kg of active substance per hectare.